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ABSTRACT 
Lameness is a significant cause of wastage in equine athletes, with reportedly 66% 
days lost from training being contributed to musculoskeletal injuries. The use of 
regenerative cell therapies has been suggested as an alternative to current 
treatments which have low tissue restorative success. Although stem cell 
treatments are currently utilised, the optimal tissue source of equine 
mesenchymal stem cells (MSC) for treatment has not been determined. 
 
The aim of the project was to compare the recovery of MSCs from adipose tissue 
(AT), bone marrow (BM) and peripheral blood (pB). Stem cell characteristics 
including adherence, proliferation, multipotency, as well as gene expression for 
stemness and differentiation markers were investigated.  
 
Adipose tissue, bone marrow and peripheral blood samples were isolated from six 
mares and grown to confluence to investigate MSC yield and proliferation rate. 
The samples were cryopreserved in liquid nitrogen and then placed into a 
trilineage differentiation assay to assess tissue-dependent plasticity. Messenger 
RNA was isolated before and during differentiation to assess changes in gene 
expression.  
 
All three tissue sources yielded fibroblast MSC-like cells however, AT and BM were 
found to be superior source of MSCs compared to pB. Trilineage differentiation 
capacity was demonstrated in AT and BM derived MSCs while peripheral blood 
derived stem cells were not investigated for multipotency due to a low number of 
samples. The selected pluripotent ‘stemness’ markers were not widely expressed 
in any of the three cell types and may not be suitable for use with multipotent 
stem cells of equine origin. Bone marrow derived stem cells displayed superior 
expression of differentiation markers compared to adipose derived stem cells. 
 
Adipose tissue was found to be a rich reliable source of MSCs however, this cell 
source displayed lower efficiency for chondrogenic differentiation. Overall, bone 
marrow derived stem cells appeared to be a superior source of equine MSCs. An 
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in vivo investigation of treating musculoskeletal injuries with BM and AT derived 
MSCs is required to determine which source of MSCs offers the best therapeutic 
benefit for injured horses. 
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CHAPTER 1: LITERATURE REVIEW AND AIMS 
1.1 INTRODUCTION 
Mesenchymal stem cells (MSCs) have received a great deal of attention in recent 
years for their ability to self-renew and differentiate (Marfe et al., 2012). These 
adult-derived stem cells can be harvested from connective tissue found 
throughout the body, making it highly accessible for therapeutic use. 
Mesenchymal stem cells have been attributed with regenerative (Uccelli et al., 
2008) and immunomodulatory (Chen et al., 2008; Uccelli et al., 2008) properties 
and have been widely suggested as a candidate for regenerative therapy (Bunnell 
et al., 2010, Carrade et al., 2011; Chen et al., 2008). Musculoskeletal injuries are 
the leading cause of lameness in racehorses and are the single largest reason for 
horses to miss days from training (Dyson et al., 2008). A regenerative therapy, 
which restores tissue functionality, would contribute to a reduction of 
musculoskeletal associated wastage. Currently, there are a wide range of 
protocols used to isolate and culture equine MSCs from raw tissue. There are also 
considerable differences in the protocols used for the isolation of MSCs for 
therapeutic application in equines. Due to this variability in techniques and 
approaches, it becomes difficult to compare published studies on equine MSC 
culture. This project evaluated three sources of connective tissue, adipose tissue 
(AT), bone marrow (BM) and peripheral blood (pB), to determine which source is 
optimal for harvesting MSCs. Adipose derived stem cells (ADSC), bone marrow 
derived stem cells (BMSC) and peripheral blood derived stem cells (pBSC) were 
isolated from adult tissue to compare growth characteristics, cryopreservation 
ability, differentiation capacity and expression of stemness genes. Gene 
expression of selected markers of differentiation were also investigated before 
and after differentiation.  
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1.1.1 WHAT IS A STEM CELL? 
A mesenchymal stem cell is considered to be an archetypal cell which gives rise to 
identical daughter cells capable of differentiating into multiple cell types 
(Gattegno-Ho et al., 2012). Additional characteristics of MSCs are the ability to 
proliferate as adherent cells and exhibit fibroblast-like morphology (Verfaillie, 
2002, Uccelli et al., 2008, Lakshmipathy and Verfaillie, 2005).  
 
Stem cells sourced from the inner cell mass of a blastocyst are termed embryonic 
stem cells (ESC) and are capable of maturing into cells from all three germ layers 
(mesoderm, ectoderm and endoderm) (Gattegno-Ho et al., 2012). These 
pluripotent cells are considered to have particular significance in regenerative 
medicine, as they are capable of differentiating into any cell type. Adult stem cells 
(ASC) on the other hand are derived from fully developed adult tissues and have 
limited differentiation ability. 
 
The development potential of ASCs into specific cell lineages is thought to be 
restricted to the type of adult tissue from which they are derived. Stem cells 
derived from connective tissue are able to differentiate into adipocytes, 
chondrocytes and osteocytes, which are of mesodermal lineage. The term 
mesenchymal stem cell refers to the capacity of these cells to self-renew and 
differentiate into cells of the mesodermal lineage (Uccelli et al., 2008). Stem cells 
of mesodermal origin are also referred to as multipotent stromal cells or 
mesenchymal progenitor cells (Bourzac et al., 2010). In comparison with ESCs, 
ASCs have limited differentiation potential but they can be successfully harvested 
from multiple organs.  In addition, the use of ESCs for cell therapy has been 
associated with the development of tumours referred to as teratomas (Li et al., 
2010). These are encapsulated tumours containing tissues from more than one 
germ layer (Prokhorova et al., 2009). The use of ASCs not only avoids the risk of 
teratoma formation but also the ethical concerns connected with using embryonic 
tissue. Although it is generally thought that MSCs can only differentiate into cells 
of mesodermal lineage, there have also been reports of MSCs being able to 
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differentiate into cells of ectoderm and endoderm lineages such as neural and 
muscle cells (Uccelli et al., 2008) (Figure 1.1). 
 
 
Figure 1.1. Mesenchymal stem cell lineages. Diagram of bone marrow derived 
multipotent mesodermal differentiation capacity (straight solid arrows) and self-
replication ability (curved, solid arrow). The potential ability of mesenchymal stem 
cells to transdifferentiate into endoderm and ectoderm lineages is indicated by dashed 
arrows. (Uccelli et al., 2008). 
 
Currently, this transdifferentiation ability is tentatively explained by referring to 
the developmental origin of MSCs during embryogenesis. During early 
development, mesenchymal tissues develop in the neuroepithelium and neural 
crest. This early neural origin suggests a potential capability of adult MSCs to 
differentiate into cells of non-mesodermal lineage. However, transdifferentiation 
has not been consistently demonstrated due to the low number of circulating 
MSCs of non-mesodermal embryonic lineages (Uccelli et al., 2008). Potentially, 
MSCs are able to differentiate into cells of almost any lineage although consistent 
in-vitro demonstration of this ability is still required.   
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1.1.2 IN VIVO ROLE AND MECHANISMS 
Adult stem cells play a key role in homeostasis and regeneration within the body, 
however, the specific mechanisms of how MSCs carry out these functions are 
generally unknown, particularly in terms of in vivo differentiation (Chen et al., 
2008; Kang et al., 2012; Shi et al., 2012). In the BM specifically, it is generally 
accepted that MSCs contribute to the formation of a hematopoietic stem cell 
niche. Within this niche they regulate cellular self-renewal, proliferation and 
differentiation of hematopoietic progenitor cells (Caplan 2009; Chen et al., 2008). 
Adipose tissue acts as a reservoir for MSCs which are situated around the mature 
adipocytes in subcutaneous white fat (Oñate et al., 2012) and visceral fat 
(Girolamo et al., 2013). After the occurrence of an acute injury, MSCs migrate to 
the site of tissue damage, either from the surrounding tissue or from the BM (Shi 
et al., 2012). The injured tissue environment provides the necessary signals for the 
MSCs to behave as precursors of bone, cartilage and fat (Uccelli et al., 2008). Blood 
vessels act as the primary route for MSC transportation around the body (Kang et 
al., 2012).  
 
Although considerable emphasis has been placed on the differentiation capacity 
of MSCs, the ability of MSCs to ameliorate tissue damage may outweigh their role 
as cell precursors.  Through the secretion of special regulators, including cytokines 
and growth factors, MSCs assist in tissue repair following injury or disease by 
altering the tissue microenvironment surrounding the site of injury (Chen et al., 
2008). These molecules include hepatocyte growth factor (HGF), transforming 
growth factor-1 (TGF-1), various interleukin cytokines and stem cell factor (SCF) 
(Chen et al., 2008). Together, these soluble factors may improve the regeneration 
ability of injured tissues, stimulate proliferation and differentiation, as well as 
regulating inflammatory responses (Chen et al., 2008). Mesenchymal stem cells 
are also considered to elicit a poor immune response and specifically, may 
suppress the cellular functions of many T cells, B cells and natural killer cells (NK), 
as well as affecting dendritic cell activity (Chen et al., 2008; Uccelli et al., 2008).  
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1.1.3 CELL LIFE CYCLE 
Mesenchymal cells are somatic cells which undergo mitosis to divide into two 
identical cells. Mitotic division comprises two main phases, the interphase and the 
mitotic phase (Colville and Bassert, 2002). 
 
 
Figure 1.2. Somatic cell cycle - stages of interphase in human cells.  
(University of Leicester, 2013). 
 
The interphase is the duration of time between cellular divisions where the cell 
carries out normal metabolic functions. The interphase has been subdivided into 
three consecutive stages (Figure 1.2). First, the growth one (G1) phase is a period 
of intense growth and metabolic activity; second, the synthetic (S) phase is marked 
by deoxyribonucleic acid (DNA) synthesis and replication; and thirdly, the growth 
two (G2) phase is a very short phase involving the synthesis of enzymes and 
proteins for cell division and growth (Freshney, 2010).  
 
On completion of interphase the cell enters the mitotic phase. This is a time where 
the cell undergoes active division to produce two daughter cells with identical 
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copies of the original cell’s DNA. Mitotic division comprises of five phases, 
prophase, prometaphase, metaphase, anaphase and telophase (Figure 1.3).  
 
 
 
Figure 1.3. Somatic cell cycle - stages of Mitotic Phase.  
(University of Leicester, 2013). 
 
During prophase, the chromatin contracts and condenses and is associated with a 
cessation in metabolic function while the DNA strands are tightly bound. The 
nuclear envelope and the nucleoli disappear during prophase, and as the cell 
moves into prometaphase the centrioles divide and replicate prior to moving to 
either end of the cell for chromosome orientation in the metaphase stage. The 
metaphase stage is associated with the alignment of the chromosomes on the 
median plane of the cell located between the centrioles positioned at either end 
of the cell. Once the chromosomes are located correctly they begin to migrate 
away from each other to their respective centrioles at the far end of the cell. This 
movement characterises the anaphase stage of mitotic division. The telophase 
stage is marked with the reversion of the chromosomes back to being long-fibre 
chromatids. The nuclear envelope and nucleoli reappear and the separated 
Chapter 1  Literature Review and Aims 
7 
 
chromosomes are now located in two independent, identical daughter cells 
(Colville and Bassert, 2002). 
 
The number of times a cell can self-replicate is a genetically controlled event 
known as senescence, which is regulated by several different genes (Freshney, 
2010). Cells derived from adult tissue can only be expanded in culture for a limited 
number of times before the cells lose the ability to divide. With each cell division 
the DNA ends are not completely replicated due to the lack of telomerase 
expression in somatic cells (Mathon & Lloyd, 2001). Telomerase is a 
ribonucleoprotein required for the complete replication of DNA. Telomeres, 
repetitive DNA sequences located at the linear ends of the chromosomes, are 
therefore not fully replicated with each cell division and become progressively 
shorter (Mathon & Lloyd, 2001). Once the telomeres reach a critical length, the 
cell is signalled to undergo senescence and can no longer self-replicate (Freshney, 
2010).  
 
Cell senescence is also correlated to changes in differentiation capacity. With 
increasing passages, cultured MSC telomere integrity is reduced, with a 
corresponding decline in the efficiency of MSCs to develop into certain lineages. 
Significant decreases in differentiation capacity has been reported in murine 
BMSCs for adipogenic, chondrogenic and osteogenic lineages (Kretlow et al., 
2008).   
 
1.1.4 SOURCES OF STEM CELLS 
Mesenchymal stem cells were first discovered in the bone marrow by Friedenstein 
and colleagues in 1976 (Mafi et al., 2011). Since then, multiple sources of MSC-like 
cells have been identified (Barry and Murphy, 2004; Payushina, et al., 2006). 
Additional sources of cells displaying MSC-like properties include adipose tissue 
(de Mattos Carvalho et al., 2011; Ranera et al., 2012), periosteum (Payushina et 
al., 2006), vascular wall (Abedin et al., 2004), synovial membrane, skeletal muscle, 
dermis, dental pulp (Chen et al., 2008), umbilical cord blood (UCB) (Reed and 
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Johnson, 2012) and peripheral blood (Ahern et al., 2011; Koerner et al. 2006; 
Marfe et al., 2012). However, the density and viability of MSC-like cells from 
different tissues can vary considerably (Payushina et al, 2006). Additionally, cell 
phenotype, proliferation rates and differentiation capacity is tissue dependant, 
with some cell sources being superior to others (Chen et al., 2008).    
 
Adipose tissue isolation in the horse has received a significant amount of attention 
for its straightforward collection procedure, abundance of tissue and high yield of 
stem cells (de Mattos Carvalho et al., 2011, Ranera et al., 2012). Bone marrow 
aspiration has been investigated in a number of species (Payushina et al., 2006; 
Pittenger et al., 1999) including the horse (Vidal et al., 2008). Peripheral blood has 
received relatively recent attention, compared to AT and BM, as a source of MSCs. 
While highly accessible, with low collection costs, blood has a low concentration 
of MSCs, and there has been variable success in the isolation of adherent 
mononucleated cells from this source (Ahern et al., 2011; Koerner et al., 2006; 
Marfe et al., 2012). Adipose tissue, BM and pB all share the same characteristics 
of being retrievable from a live animal with relatively low levels of invasiveness. 
Indeed, the surgical manipulations performed on a horse to retrieve either AT or 
BM are considered to be minor manipulations which heal well with minimal 
complications. Due to ease of collection, and the ability to collect a large sample 
volume at any time from such a large animal, pB offers an exciting potential source 
of MSCs in equids.  
 
Traditionally, BM has been considered as the richest and most reliable source of 
MSCs (Chen et al., 2008). However AT has recently been considered to be a high 
yielding source of MSCs in the horse, even more so than BM (Kang et al., 2012). 
Although pB is a low yielding MSC source, isolated cells can be cultured to amplify 
cell numbers.   
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1.1.5 ADIPOSE TISSUE 
Adipose tissue is generally removed from the easily accessible dorsal gluteal 
region in the horse (Ahern et al., 2011; de Mattos Carvalho et al., 2011; Dhar et 
al., 2012; Ranera et al., 2012; Vidal et al., 2007). Adipose tissue appears to be a 
robust tissue source to harvest, as it is able to be kept at room temperature for up 
to 24 hours before significant tissue degeneration occurs (Bunnell et al., 2008). A 
single 10g collection of AT can be used to isolate stem cells for culture, expansion, 
differentiation and treatment (Ahern et al., 2011; Dhar et al., 2012). The minimum 
sample size reported in the literature was 5g from the dorsal gluteal region (de 
Mattos Carvalho et al., 2011), from which MSCs were able to be isolated and 
expanded in culture. The size of the surgical incision can be refined when 
harvesting a smaller volume of fat, resulting in reduced healing time and 
minimised scarring. The amount of fat deposited in the dorsal gluteal region will 
determine the size of the incision in order to collect a minimum of 5g of tissue. 
Athletic horses, such as Thoroughbreds, may have minimal deposits of fat 
available due to their lean build and, therefore, may require larger surgical 
incisions to collect the minimal amount of tissue required for processing. 
 
A number of authors (Ahern et al., 2011; Bunnell et al., 2008 & Dhar et al., 2012) 
use a series of phosphate buffered saline (PBS) washes followed by incubating the 
sample in collagenase to dissociate the tissue. There are variable types and 
concentrations of collagenase reported in the literature (de Mattos Carvalho et al., 
2011; Martinez- Lorenzo et al., 2009). Collagenase type 1 is predominately used 
for adipose tissue dissociation (Bunnell et al., 2008; Ranera et al., 2011; Vidal et 
al., 2008; Raabe et al., 2010; Raabe et al., 2011; Dhar et al., 2012) however, there 
are published protocols which utilise collagenase type 1A (Aguena et al., 2012) and 
collagenase type II (Braun et al., 2009). The collagen digestion unit (CDU) may vary 
from 125-250CDU/mg and significant lot to lot variation may require readjustment 
of collagenase concentrations to achieve tissue dissociation (Williams et al., 1995). 
The length of incubation time in collagenase also varies considerably ranging from 
a minimum of 30 minutes (Ranera et al., 2011) to 12 hours (de Mattos Carvalho et 
al., 2011).  
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1.1.6 BONE MARROW 
The collection site of BM is largely influenced by the species from which it is being 
isolated. In small species, such as rodents, complete segments of the femur and 
tibia are removed from euthanized animals and the marrow is then extracted from 
within the bone cavity (Ferreira et al., 2012). In human studies, BM is extracted 
from the posterior iliac crest as well as the femur and tibia (Kemp et al., 2005). The 
three regions have all provided reliable and adequate yields of MSCs. Equine 
BMSCs are either collected from the sternum or iliac crest with or without the use 
of diagnostic ultrasonography (Bourzac et al., 2010; Kasashima et al., 2011; 
Koerner et al., 2006; Ranera et al., 2012; Smith et al., 2003; Sutter, 2007). As an 
alternative to sternal bone marrow collection, aspiration of the tuber coxae, which 
is a specific anatomical point on the ilium, can be performed (Sutter, 2007).  This 
may be a preferable option to owners of valuable horses who do not want to risk 
the potential complication associated with sternal bone marrow collection. 
However, the yield of equine MSCs is comparatively lower from tuber coxae 
aspiration. Sternal aspiration provides a larger volume of bone marrow with a 
denser population of MSCs than currently obtainable from the tuber coxae in 
horses (Delling et al., 2012).  
 
Typically, bone marrow aspirate is processed using a density gradient to isolate 
stem cells suspended in the aspirate (Bourzac et al., 2010; Spaas et al., 2013). 
Three different gradients are used in the literature, Ficoll (density 1.077g/ml) 
(Bourzac et al., 2012), Percoll (density 1.07g/ml) (Bourzac et al., 2012) and 
Lymphoprep (1.077g/ml) (Ranera et al., 2011) for equine BM aspirate processing. 
The entire cell fraction isolated from raw BM aspirate can also be plated without 
using a density gradient however, the use of a gradient concentrates the MNC 
fraction and reportedly results in higher density of cells at confluence (Bourzac et 
al., 2012).  
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1.1.7 PERIPHERAL BLOOD 
The use of pB provides a minimally invasive collection technique when compared 
with BM or AT harvesting. However, the low concentration of stem cells in pB 
limits its use as a reliable source of MSCs. Blood can be collected from any 
accessible vein, however, veins in the lower leg or the jugular vein are 
predominately used in the horse (Dhar et al., 2012; Marfe et al., 2012; Spaas et al., 
2013). The volume of blood collected from a horse at one time ranges from 10ml 
(Spaas et al., 2013) to 4000ml (Ahern et al., 2011).  
 
The isolation of MNCs from raw pB utilises density gradient protocols similar to 
those used for isolating MNCs from BM. Percoll (Spaas et al., 2012), Ficoll 
(Giovannini et al., 2008; Koerner et al., 2006; Martinello et al., 2011) and 
Lymphoprep (Dhar et al., 2011) are all used to isolate equine blood MNCs. Isolation 
success of equine pBSCs ranges from 30.3% (Koerner et al., 2006, using Ficoll) to 
100% (Spaas et al., 2013, using Percoll). 
 
1.1.8 MESENCHYMAL STEM CELL CULTURE MEDIA AND SUPPLEMENTS 
Culture media types and supplements used for the culture of equine MSCs from 
AT, BM and pB were reviewed (Table 1.1). Dulbeccos Modified Eagle Medium 
(DMEM) is consistently used for equine MSC culture. The supplement of F12 to 
DMEM provides additional amino acids, and can be used when culturing ADSCs, 
BMSCs and pBSCs (Ahern et al., 2011; Dhar et al., 2012; Giovannini et al., 2008).  
Serum is added to media to promote cell proliferation and attachment. Protein is 
the major component of serum and acts as a carrier for minerals, fatty acids and 
hormones and as a source of growth factors. Protein also increases medium 
viscosity and may reduce damage to cell structure during pipetting and other 
physical manipulations (Freshney, 2010). Fetal bovine serum (FBS), also known as 
fetal calf serum (FCS), is the most widely used serum, although horse serum is 
preferred by some labs as it is considered to be more consistent batch to batch 
than FBS (Freshney, 2010).  
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Glutamine is required by all cells, and may be used as a source of energy and 
carbon. This amino acid was found to be used as a supplement by a number of 
researchers (Braun et al., 2009; Giovannini et al., 2008; Kemp et al., 2005; 
Martinello et al., 2010; Ranera et al., 2012; Spaas et al., 2013), however, it does 
not appear to be a standard additive.  
 
Medium buffering is an important aspect of cell culture to ensure the pH levels 
remain stable throughout culture. Bicarbonate buffer or hydroxyethyl 
piperazineethanesulfonic acid (HEPES) are used as effective buffering systems. 
HEPES is a much stronger buffer than bicarbonate, however, bicarbonate is used 
more frequently due to its low toxicity and low cost (Freshney, 2010). Bicarbonate 
also reportedly provides a nutritional benefit to the cells whereas HEPES does not 
(Freshney, 2010). The exact nutritional benefit of bicarbonate is not stated in cell 
culture literature (Freshney, 2010). An investigation on bicarbonate 
supplementation in human patients with chronic kidney disease reported an 
improvement in protein uptake with increased bicarbonate ingestion (de Brito-
Ashurst et al., 2009). This may or may not relate to cells in culture but potentially, 
bicarbonate may provide a nutritional benefit to culture cells by improving protein 
metabolism.  
 
Primary tissue culture is fraught with potential contamination from a number of 
sources. Contaminated equipment, media, work spaces, tissue samples and poor 
aseptic techniques can all lead to culture contamination resulting in the loss of 
samples. Bacteria, fungi, yeast and mycoplasma are all types of contamination 
which can potentially occur with cell culture (Freshney, 2010). The addition of 
antibiotics and antifungals can reduce the rate of contamination, although the low 
concentrations used in culture, to minimize detrimental effect on cell viability and 
proliferation, can allow for contaminations to occur. While bacteria, fungi and 
yeast infections are visible, mycoplasma contaminations require more powerful 
methods for detection (Freshney, 2010).  
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Mycoplasma contaminations are important to detect as they can alter the 
behaviour and metabolism of cells, and can significantly affect the findings of a 
research project without the researchers knowing the cause. Detection of 
mycoplasma infections requires fluorescent staining, PCR, enzyme-linked 
immunosorbent assay (ELISA), immunostaining, autoradiography or 
microbiological assay. The most commonly used technique for mycoplasma 
detection is fluorescent staining of DNA (Freshney, 2010).  
 
Antibiotics are added to reduce the chance of bacterial contamination, particularly 
when working with primary tissue cultures. It appears that equine stem cell culture 
relies on the addition of penicillin/streptomycin (P/S) to prevent bacterial 
contamination, although this combination of antibacterials target an ever 
narrowing range of bacteria, with resistant strains continuing to emerge. 
Gentamicin (G) is used for human stem cell culture with minimal detrimental 
effect on the viability and proliferation rates in culture being reported when used 
at low concentrations (Chang et al., 2006), however, it is not widely used for 
equine stem cell culture. Out of the range of literature reviewed only Spaas et al. 
(2013) used G (50µg/ml) for culturing equine pBSCs.  
 
Fungal contaminations are particularly common during the warmer months when 
the air is filled with fungal spores. Amphotericin B is a commonly used antibiotic 
due to its activity against fungi and yeast (Freshney, 2010).  
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Table 1.1. Medium, additives and antibiotics used for equine adipose, bone marrow 
and peripheral blood derived stem cells. 
Adipose derived stem cells 
Author Culture medium Additives Antibiotics 
De Mattos 
Carvalho et al., 
2011 
DMEM 10% FBS Not reported 
Ranera et al 2012 DMEM LG 10% FBS, 1% glutamine 1% P/S 
Ahern et al. 2011 DMEM, 10% FBS 1% P/S 
Dhar et al, 2012 DMEM-F12, 10% FBS 1% P/S 
Braun et al., 2009 DMEM LG 10% FBS, 1% 
glutamine, 25mM 
HEPES  
1% P/S  
Bone marrow derived stem cells 
Author Culture medium Additives Antibiotics 
Ranera et al., 
2012 
DMEM LG 10% FBS, 1% glutamine 1% P/S 
Kasashima et al., 
2011 
DMEM LG 10% FBS 2% P/S 
Giovannini et al., 
2008 
DMEM-F12 10% FBS 1% P/S 
Bourzac et al, 
2010 
DMEM LG 10% FBS, pyruvate 1% P/S amphotericin 
B, 
Peripheral blood derived stem cells 
Author Culture medium Additives Antibiotics 
Spaas et al., 2013 DMEM LG 30% FBS, 1% 
ultraglutamine, 10-11 
dexamethasone 
50µg/ml gentamicin 
Koerner et al., 
2006 
DMEM 20% FCS, 1% P/S 
Ahern et al., 2011 DMEM-F12 20% FBS 1% P/S 
Martinello et al., 
2010 
DMEM 20% FBS glutamine. P/S (percentage not 
stated) 
Giovannini et al., 
2008 
DMEM, 20% FBS l-glutamine & 
15mM HEPES, , 
1% P/S 
DMEM – Dulbecco’s modified eagle medium, FBS – fetal bovine serum, FCS – fetal calf 
serum,  HEPES - hydroxyethyl piperazineethanesulfonic acid, LG – low glucose, P/S - 
Penicillin/streptomycin 
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1.1.9 CELL CULTURE 
Cell culture can be divided into two stages, primary culture and secondary culture. 
Primary culture is the stage of culture after cell isolation from raw tissue but 
before the first subculture (Freshney, 2010). Following the first subculture the cells 
are referred to as secondary culture. Passaging is used to increase the number of 
cells in culture and maintain the population’s self-replication ability. The first 
passage occurs once the primary culture has covered the available surface of a 
culture vessel. Cells are then replated into new culture vessels at low densities to 
allow for cell expansion during secondary culture (Freshney, 2010).  
 
As with any non-immortalized somatic cell, MSCs have a limited lifespan in culture. 
For this reason, cells are cryopreserved during early passages to preserve the 
expansion ability for future culturing. There are variable reports for the number of 
passages a particular cell line can undergo before senescence occurs. Adult 
derived MSCs can reportedly be expanded for 20-50 passages before self-
replication is lost (Lakshimpathy & Verfaillie, 2005). Adipose tissue derived stem 
cells have been found to reach senescence at later passages than BMSCs. Samples 
of ADSC could be passaged nine times while BMSC samples could only be passaged 
six times (Braun et al., 2010) although conflicting reports have been found in the 
literature.  
 
Although MSCs are usually cultured in heterogeneous populations, there has been 
a more recent push to culture clonal populations to validate the stemness of 
isolated cells. Indeed, Bianco et al. (2013) is of the opinion that adherent cells 
derived from adult tissue cannot be termed MSCs unless they have been amplified 
from a single colony derived from a single stem cell and proven to have trilineage 
capability. Clonal growth is not widely used in MSC research; indeed, all of the 
papers reviewed for this project used heterogeneous cell populations which were 
referred to as MSCs.   
 
Chapter 1  Literature Review and Aims 
16 
 
1.1.10 CRYOPRESERVATION 
The cryopreservation allows cells to be retained for future use, reducing the need 
for repeated tissue sampling. As MSCs undergo a limited number of passages 
before senescence, preservation of early passage cells is particularly important.  
The freezing process causes significant stress to the cells and as such, precautions 
need to be made to protect against cell damage during freezing and thawing 
(Haack-Sorensen & Kastrup, 2011). During the cryopreservation process, 
intracellular and extracellular water transforms into ice crystals, and cellular 
metabolism functions cease. Cryoprotectants are used to prevent the formation 
of ice crystals within the cells during freezing, maintaining the integrity of the 
cellular membrane which is particularly vulnerable to rupture during freezing and 
thawing (Berz et al., 2007). Dimethyl sulfoxide (DMSO) (Seo et al., 2011), 
hydroxytheyl starch (HES), trehelose and polyvinal (Naaldijk et al., 2012) have all 
been used successfully as cryoprotectants.  
 
Dimethyl sulfoxide (DMSO) is a hygroscopic polar compound commonly used in 
cryopreservation due to its ability to attract and hold on to water molecules from 
the surrounding environment (Seo et al., 2011). This ability makes it particularly 
applicable to stem cell cryopreservation as it prevents cells from drying out (Seo 
et al., 2011). Although this compound works effectively as a cryoprotectant it can 
be toxic to cells at room temperature, as it is highly permeable. As a precautionary 
measure, it is recommended to use DMSO at temperatures less than 4°C to 
prevent additional damage to cells (Hunt, 2011). However, it has been reported 
that, when using low concentrations of DMSO with high concentrations of serum, 
the adverse effects are greatly reduced even when working at ambient 
temperatures as long as slow freezing and rapid thawing protocols are used (Hunt, 
2011).  
 
Serum is added to the cryogenic medium to further protect the cell walls from 
damage due to ice crystal formation (Haack-Sorensen & Kastrup, 2011).  Fetal 
bovine serum is commonly used as a source of protein in cell culture and in 
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cryopreservation. There is a range of FBS concentrations used for freezing, from 
10% (M. Green, personal communication, November, 2012) to 90% (Hunt, 2011).  
 
The rate at which cells or tissues are frozen can significantly impact on their ability 
to recover post thaw (Seo et al., 2011; Vajti & Kuwayama, 2006). The traditional 
slow rate freezing has been used in cell culture and reproductive technology for 
many years (Vajti & Kuwayama, 2006). A slow, controlled rate of freezing reduces 
the quantity of intracellular ice build-up and prevents the rupture of cellular 
membranes. A slow rate of freezing is achieved through the use of an alcohol 
based freezing container, commonly marketed as a Mr Frosty™ freezing container. 
This container holds a number of cryovials which can be slowly frozen at a 
controlled rate of -1°C per minute when placed in a -80°C freezer. 
 
When cryopreserved cells are required for further research or treatment 
applications, a fast thawing process should be used to prevent morphological 
damage to the cells (Berz et al., 2007). Cells are generally thawed rapidly in a 37ºC 
water bath followed by dilution with culture medium (Berg et al., 2009). Following 
thawing, it is important to remove the DMSO quickly by immediately diluting the 
cell suspension in culture medium and washing the cells thoroughly to remove 
traces of DMSO (Bunnell et al., 2008; Naaldijk et al., 2012; Wu et al., 2012). This is 
of particular importance if the sample is to be administered directly or plated out 
for culture. Indeed, samples containing traces of DMSO at the time of patient 
treatment can result in adverse reactions (Berz et al., 2007; Hunt, 2011).  
 
Cryopreservation can also be used to store intact tissue samples for later 
processing for MSC isolation. Human AT is able to be frozen intact, stored in liquid 
nitrogen, thawed and then processed for MSC isolation. The cells from frozen 
tissue samples were compared to cells from fresh tissue samples, with no 
significant difference found in proliferation capacity, morphology, differentiation 
capacity, and gene expression (Choudhery, 2013).  
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1.1.11 DIFFERENTIATION 
Differentiation is a diagnostic method applied to MSCs to assess plasticity and 
confirm them as MSCs (Lakshmipathy et al., 2005). Plasticity is the capacity of a 
cell to give rise to one or more lineages. Unipotent cells give rise to only one 
lineage, multipotent cells give rise to more than two lineages, pluripotent cells 
may give rise to several lineages and totipotent cells are able to give rise to all 
known cell types (Freshney, 2010). Mesenchymal stem cells are considered 
multipotent due to their ability to differentiate into more than two lineages.  
 
Adipogenic, chondrogenic and osteogenic lineages are the most commonly 
differentiated cell types for confirmation of MSC plasticity, although tenogenic 
(tendon) and myogenic (muscle) differentiation has been confirmed for equine 
MSCs (Ahern et al., 2011, Kasashima et al, 2011, Ranera et al., 2012) (Table 1.2). 
Equine ADSCs, BMSCs and pBSCs all have proven trilineage differentiation capacity 
although variability in differentiation efficiency has been reported between the 
three cell sources (Table 1.2).  
 
Table 1.2. Differentiation success of equine adipose, bone marrow and peripheral 
blood derived stem cells for adipogenic, chondrogenic, osteogenic, tenogenic and 
myogenic lineages. 
Adipose derived stem cells 
Author Adipogenic Chondrogenic Osteogenic Tenogenic Myogenic 
Burk et al., 
2013 
Yes Yes Yes N/D N/D 
Colleoni et 
al., 2009 
N/D Yes Yes N/D N/D 
Vidal et al., 
2007 
Yes N/D Yes N/D N/D 
Braun et 
al., 2010 
Yes Yes Yes N/D N/D 
Bone marrow derived stem cells 
Author Adipogenic Chondrogenic Osteogenic Tenogenic Myogenic 
Burk et al., 
2013 
Yes Yes Yes N/D N/D 
Colleoni et 
al., 2009 
N/D Yes Yes N/D N/D 
Violini et 
al., 2009 
N/D N/D Yes Yes N/D 
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Bourzac et 
al., 2010 
Yes Yes Yes N/D N/D 
Peripheral blood derived stem cells 
Author Adipogenic Chondrogenic Osteogenic Tenogenic Myogenic 
Dhar et al., 
2012 
Yes Yes Yes N/D N/D 
Spaas et 
al., 2013 
Yes Yes Yes N/D N/D 
Martinello 
et al., 2010 
Yes N/D Yes N/D Yes 
 
The differentiation potential of MSCs is not guaranteed within a specific 
population of cells. Colonies of MSCs grown from a single precursor cell have 
reportedly formed a population of cells with varied multilineage differentiation 
potential (Baksh et al., 2004). Additionally, Muraglia et al. (2000) found that only 
30% of cells derived from nonimmortalised cell clones expressed trilineage 
differentiation capacity, while the remaining cells expressed bi-lineage or uni-
lineage potential. 
 
1.1.11.1 ADIPOGENIC DIFFERENTIATION 
Adipogenic differentiation requires a combination of specific medium, serum and 
additional reagents (Table 1.3). The basal medium DMEM, either containing low 
glucose (LG), or with F12 combined with FBS or rabbit serum (RS) or a combination 
of both, has been shown to induce adipogenic differentiation. Rabbit serum is 
widely used due to it containing specific fatty acids which are responsible for 
strong adipogenic differentiation (Diascro et al., 1998). The supplements used for 
adipogenesis and their associated actions are listed in Table 1.6. 
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Table 1.3. Media, serum and additives used for adipogenic differentiation of equine 
mesenchymal stem cells. 
Author DMEM/ SERA Dexamethasone IBMX Indomethacin Insulin 
Schwarz et 
al., 2012 
DMEM, 10% 
autologous 
serum 
1µM 1mM 0.2mM 1.6µM 
Ranera et 
al., 2012      
DMEM LG10% 
FBS, 15% RS 
1µM 0.5mM 0.2mM - 
Burk et al., 
2013 
DMEM F12 15% 
RS 
1µM 0.5mM 0.1mM 0.7µM 
Vidal et al., 
20071 
DMEM Hams 
F12 3% FBS, 5% 
RS 
1µM 0.5mM - 0.1µM 
Braun et 
al., 20102 
DMEM LG 10% 
FBS, 5% RS 
1µM 0.5mM 0.1mM 0.1µM 
Raabe et 
al., 2011 
DMEM, 10% FCS 1µM 0.5mM 0.1mM 10µM 
Giovannini 
et al., 2007 
DMEM F12 5% 
RS 
1µM 0.5mM 0.1mM 1.7µM 
Spaas et 
al., 2013 
DMEM LG 15% 
RS 
1µM 0.5mM 0.2mM 0.1µM 
1 Biotin - 33µmol/L, Pantothenate - 17µmol/L, Rosiglitazol - 5µmol/L also added 
2 D-glucose - 4.5g/L also added 
 
The detection of adipogenic differentiation is achieved through determination of 
morphological characteristics, the use of specific stains and evaluating gene 
expression in differentiated cells. For adipogenic fate, oil red O is typically used to 
stain lipid vesicles deposited within adipocyte cells. While the use of BODIPY was 
not reported in any of the equine adipogenic differentiation papers, this 
fluorescent stain has been used with human ADSCs and BMSCs to confirm 
intercellular accumulation of lipid droplets (Bunnell et al., 2008; Fink et al., 2004).  
 
Gene expression of specific adipogenic markers have been used in a number of 
papers to complement histological findings (Poloni et al., 2013; Raabe et al., 2011; 
Ranera et al., 2012). Peroxisome proliferator-activated receptor gamma (PPARγ2) 
is one of the key positive transcriptional regulators of adipogenesis (Payushina et 
al., 2006; Poloni et al., 2013). The activation of PPARγ2 triggers the expression of 
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additional adipogenic genes required for lipid accumulation. Dexamethasone is 
considered to be a trigger of the transcription factor CCAAT-enhancer-binding-
protein delta (C/EBPδ). This factor binds to the promoter of PPARγ2, leading to its 
activation (Payushima et al. 2006). Although PPARγ2 is considered to be the 
highest expression towards the end of differentiation (Ranera et al., 2012), 
upregulation of this gene has been reported after six and seven days in adipogenic 
medium (Braun et al., 2010, Bracegirdle et al, submitted). 
 
1.1.11.2 CHONDROGENIC DIFFERENTIATION 
Chondrogenic differentiation requires DMEM, generally with high glucose (HG), 
although LG has also been used (Table 1.4). Varying amounts of FBS are used, 
ranging from 0% to 10%. The supplements used for chondrogenesis and their 
associated actions are listed in Table 1.6.  
 
In addition to the specific supplements required for differentiation, the cell culture 
system used has a significant impact on whether chondrogenic differentiation can 
occur. By plating the cells at high densities in 96 well plates or equivalent, a three 
dimensional cell aggregate is able to form (Berg et al., 2009; Pilz et al., 2011). A 
tertiary structure is vital to chondrocyte formation and care must be taken during 
medium changes to prevent disturbing the cell pellet (Berg et al., 2009; Payushina 
et al., 2006). If the pellet is disrupted, the aggregate collapses and cell to cell 
communication is lost. The close association of cells with one another mimics the 
cell-cell interactions which occur during embryonic cartilage formation and is 
important for chondrogenic differentiation to occur (Giovannini et al., 2008).   
 
 
 
 
 
 
Chapter 1  Literature Review and Aims 
22 
 
Table 1.4. Media, serum and additives used for chondrogenic differentiation of 
equine mesenchymal stem cells. 
Author DMEM TGF-β 
*ITS+ 
premix 
Proline 
Ascorbate-2-
phosphate 
Dexamethasone 
Ranera et 
al., 2012      
DMEM HG, 
10% FBS 
TGF-β3 
10ng/ml 
Yes  40µg/ml 0.05mM 0.1µM 
Colleoni et 
al., 2009 
Not stated TGF-β1 
5ng/ml 
Yes - 0.25mM 0.1µM 
Burk et al., 
2013 
DMEM HG TGF-β1 
10ng/ml 
1% 400µM 0.1mM 0.1µM 
Vidal et al., 
20081 
DMEM HG TGF-β3 
10ng/ml 
Yes - 0.05mM 0.1µM 
Braun et 
al., 20102 
DMEM LG, 
10% FBS 
TGF-β3 
10ng/ml 
- 350µM - 0.1µM 
Ahern et 
al., 2011 
DMEM, 
serum not 
stated 
TGF-β3 
5ng/ml 
1% - 0.1mM 0.1µM 
Giovannini 
et al., 2007 
DMEM HG TGF-β3 
5ng/ml 
1% - 0.1mM 0.1µM 
1 BMP-6  - 10ng/ml also added 
2 D-glucose – 4.5g/L also added 
*ITS+premix: culture supplement containing insulin, transferrin, and selenium  
 
The detection of chondrogenic differentiation is achieved through determination 
of morphological characteristics, such as the shape and density of a tertiary 
structure, the use of specific stains and evaluating gene expression in 
differentiated cell pellets. Chondrogenic differentiation is detected by a variety of 
stains including Alcian Blue (Ahern et al., 2011), toluidine blue (Bunnell et al., 2008) 
and Safranin O for glycosaminoglycan (GAG) deposits (Burk et al., 2013), 
hematoxylin and eosin (H&E) for cell structure (Vidal et al., 2008) and Massons 
Trichrome (Burk et al., 2013) for collagen fibre formation.  
 
In conjunction with histological stains, gene expression is used to confirm that 
chondrogenic differentiation has occurred. Chondrogenic-specific lineage markers 
include collagen type 2, collagen type 1, Aggrecan, SOX9 and cartilage-derived 
retinoic acid-sensitive protein (CD-RAP) (Berg et al., 2009). The marker SOX9 is a 
cartilage-specific transcription factor used by a number of authors for analysis of 
chondrogenic differentiation in MSCs in a range of species including dogs (Csaki et 
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al. 2007), horses (Berg et al., 2009) and humans (Ullah et al., 2012). This gene has 
an essential role in the commitment of cells towards chondrogenic fate. 
Upregulation of SOX9 stimulates the reduction of intercellular spaces within cell 
aggregates (Tacchetti et al., 1992), expression remains high during differentiation 
and is then ‘turned off’ at the end of differentiation, as the cells begin to undergo 
prehypertrophy (Lefebvre et al., 2005).   
 
1.1.11.3 OSTEOGENIC DIFFERENTIATION 
Osteogenic differentiation medium appears to be relatively consistent across the 
literature (Table 1.5). Basal medium (DMEM), either with LG or with F12 is used 
with a combination of dexamethasone, β-glycerophosphate and ascorbate 2-
phosphate. Only one reviewed article (Ahern et al., 2011) did not use or did not 
report the use of dexamethasone, however osteogenic differentiation was still 
achieved. The supplements used for osteogenesis and their associated actions are 
listed in Table 1.6. 
Table 1.5. Media, serum and additives used for osteogenic differentiation of equine 
mesenchymal stem cells. 
Author DMEM Dexamethasone β-glycerophosphate Ascorbate 2-
phosphate 
Ranera et al., 
2012 
DMEM 10% FBS 0.1µM 10mM 0.05mM 
Colleoni et 
al., 2009 
DMEM/TCM199 
10% FBS 
0.1µM 10mM 0.25mM 
Burk et al., 
2013 
DMEM F12,10% FBS 0.1µM 10mM 0.1mM 
Vidal et al., 
2007 
DMEM Hams F12, 
10% FBS 
0.2µM 10mM 0.05mM 
Braun et al., 
2010 
DMEM LG, 10% FBS 1µM 10mM 0.1mM 
Ahern et al., 
2011 
DMEM – serum not 
specified 
- 5mM 0.1mM 
Raabe et al., 
2011 
DMEM 10% FCS 0.1µM 10mM 0.05mM 
Schwarz et 
al., 2012 
DMEM, 10% 
autologous serum 
0.1µM 10mM 0.05mM 
Giovannini 
et al., 2007 
DMEM F12 10% FBS 0.1µM 10mM 0.1mM 
Spaas et al., 
2013 
DMEM LG, 10% FCS 0.1µM 10mM 0.2mM 
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The detection of osteogenic differentiation is achieved through determination of 
morphological characteristics, the use of specific stains which target mineral 
deposits in the cells and evaluating gene expression in differentiated cells. 
Osteogenic differentiation can be detected with Alizarin Red stain which highlights 
calcium mineral content (Vidal et al., 2007).  
 
A range of osteogenic differentiation markers have been investigated in equine 
MSCs. The expression of osteogenic lineage specific markers includes alkaline 
phosphatase (ALP), osteocalcin (BGLAP), collagen type I (COL1A1), runt-related 
transcription factor 2 (RUNX2) and secreted phosphoprotein 1 (SPP1) (Ranera et 
al., 2012). The early expression of RUNX2 and SPP1 markers leads to a cascade of 
gene expression resulting in osteogenic differentiation (Eyckman et al., 2012; 
Ranera et al., 2011). The expression of RUNX2 in particular is correlated to the 
expression of other osteogenic markers indicating closely linked upregulation. The 
markers RUNX2 and SPP1 are reportedly expressed at similar stages of 
differentiation.  However, RUNX2 appears to precede SPP1 expression by three 
days in equine BMSCs undergoing osteogenic differentiation (Ranera et al., 2011).  
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Table 1.6. Differentiation medium supplements and corresponding actions 
Name of reagent Action Reference 
Dexamethasone  Growth factor. A synthetic 
hydrocortisone commonly added 
to media to increase the 
attachment capacity of cells 
Baker et al., 1978 
IBMX Nonspecific inhibitor of 
phosphodiesterases which 
possess adenosine agonist activity 
IBMX - Life 
technologies, 2013 
Indomethacin Non-steroidal anti-inflammatory 
which increases PPARy2 protein 
levels 
Styner et al., 2010; 
Dhar et al., 2012. 
Insulin Hormone that triggers induction 
transcription factors which assist 
in differentiating pre-adipocytes 
into mature adipocytes 
Klemm et al., 2001 
TGF-β Family of cytokines which regulate 
cell differentiation and 
proliferation 
Clark and Coker, 
1998 
ITS+premix Culture supplement containing 
insulin, human transferrin, and 
selenous acid which stimulates 
cell proliferation 
ITS+premix - BD 
Sciences, 2013  
Proline Αn amino acid which induces 
differentiation. Important for 
maintenance of pluripotency in 
ESC 
Washington et al., 
2010 
Ascorbate 2-
phosphate 
Vitamin supplement capable of 
stimulating cell differentiation, 
specifically collagen synthesis and 
alkaline phosphatase activity 
Takamizawa et al., 
2004 
β-
glycerophosphate 
Serine-threonine phosphatase 
inhibitor. Functions as an organic 
phosphate donor for osteogenic 
differentiation 
β-glycerophosphate 
–Sigma, 2013 
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1.1.11.4 DIFFERENTIATION EFFICIENCIES OF EQUINE MESENCHYMAL STEM CELLS 
There are varying reports for adipogenic differentiation efficiency between 
different sources of equine MSCs. Adipocyte potential is reportedly similar for 
equine ADSCs and BMSCs but poor adipogenic differentiation capacity has been 
observed in umbilical cord blood and tendon derived stem cells (Burk et al., 2013). 
Ahern et al. (2011) however, found that ADSCs stained strongly for adipogenic 
differentiation while no detectable difference in staining intensity was seen for 
BMSCs following exposure to adipogenic medium and control cells. There have 
also been varied results for pBSC differentiation into adipocytes. Koerner et al. 
(2006) reported weak staining for lipid vesicles following adipogenic 
differentiation, while Dhar et al. (2012) reported strong positive staining of lipids 
for pBSCs. Dhar et al. (2012) also compared two combinations of adipogenic media 
and found that ADSCs demonstrated lipid vesicle development in both 
combinations of media, while pBSCs were only able to achieve adipogenic 
differentiation in medium supplemented with indomethacin. Overall, it appears 
that ADSCs have superior adipogenic differentiation efficiency compared to other 
sources of equine MSCs. 
 
Previous studies looking at chondrogenic differentiation in ADSCs and BMSCs have 
produced conflicting results. Burk et al. (2013) found that BMSCs demonstrated 
the weakest chondrogenic potential compared to cells isolated from UCB, UCT, AT 
and tendon tissue. However, in a study by Giovannini et al. (2008), BMSCs 
displayed intense chondrogenic differentiation, and Vidal et al. (2008) reported 
that BMSC chondrogenic potential was greater than ADSC chondrogenic potential. 
Furthermore, expression of collagen type II (COL1A2) was found to be higher for 
BMSC chondrocytes than ADSC chondrocytes (Vidal et al., 2008). Positive staining 
for GAG deposits could also be seen as early as day three after activation in BMSC 
chondrocytes, while GAG deposits in ADSC chondrocytes could only be seen from 
day 14 (Vidal et al., 2008).    
 
Bone marrow derived stem cells reportedly have superior osteogenic potential 
compared to ADSCs (Vidal et al., 2008). Vidal et al. (2008) also reported that a 
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longer duration of exposure to osteogenic medium is required for ADSC 
differentiation to occur. Additionally, ADSCs expressed lower levels of alkaline 
phosphatase (ALP) than BMSCs. Alkaline phosphatase is an important component 
in the formation of hard tissue and is strongly expressed in mineralised tissue cells 
(Golub & Boesze-Bottaglia, 2007). The expression levels of ALP reported by Vidal 
et al. (2008) contradicts the results found by Ranera et al. (2012). When comparing 
ADSC expression with BMSC expression Ranera et al, (2012) found that ALP 
expression was significantly higher in ADSCs. Colleoni et al. (2009) reported that 
the levels of osteonectin, a stimulant of cell division and differentiation, in 
osteogenic differentiated ADSCs and BMSCs were similar when the cells were 
treated with basic fibroblast growth factor (bFGF). Osteonectin levels were 
increased to similar levels for both cell types following exposure to this treatment 
(Freshney, 2010). 
 
1.1.12 IDENTIFICATION OF IN VITRO EQUINE MSCS 
Although a great deal of research has been carried out on equine MSCs, a uniform 
approach to characterising these cells is yet to be established (De Schauwer et al., 
2011).  
 
In human medicine, only cells which express or lack specific surface markers can 
be labelled as MSCs (De Schauwer et al., 2011). This specific list in human medicine 
uses a panel of antigens that unequivocally identifies MSCs. Such a list or even a 
standard approach to identification is lacking in equine stem cell culture. 
Currently, researchers rely on cell attachment and differentiation into fat, 
cartilage and bone as proof of stemness. As a third approach to confirm stemness, 
it has been proposed that a panel of cell surface antigens be established for use 
with equine MSCs (De Schauwer et al., 2011).  
 
Cell surface marker expression and messenger RNA (mRNA) gene expression have 
both been used for evaluating stemness in equine MSCs. Although gene 
expression at the mRNA level does not necessarily translate to protein level (Guest 
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et al., 2008), mRNA analysis is still a valuable characterisation tool when suitable 
antibodies are not available (De Schauwer et al., 2011). Cell surface marker 
analysis is reliant on the availability of species-specific or cross-reacting antibodies 
for proper immunophenotyping. Many equine studies use anti-human antibodies 
for the determination of equine cluster of differentiation (CD) markers, but 
difficulties arise due to the small reactivity of available human antibodies with 
equine epitopes (Ranera et al., 2012). Currently, this is the greatest limiting factor 
to the establishment of cell marker analysis in veterinary medicine (De Schauwer 
et al., 2011). 
 
A range of different cell surface markers and gene markers have been evaluated 
in equine MSCs isolated from AT, BM and pB (Table 1.7). Recently, De Schauwer 
et al., (2012) published a list of suggested cell surface markers which may be used 
for positively identifying equine umbilical cord tissue stem cells (UTSC). However, 
this is yet to be incorporated into research to determine whether these markers 
are expressed in additional sources of equine MSCs. Although a range of markers 
have been investigated, there is still no proven selection of markers for routine 
stem cell identification. 
 
The pluripotent markers octamer-binding transcription factor 4 (Oct4) and Nanog 
are reportedly positive in ADSCs (Raabe et al., 2010) and BMSCs (Violini et al., 
2009) and, although expression at protein level is variable (Guest et al., 2008), they 
have been suggested as markers of MSCs (Raabe et al., 2010; Violini et al., 2009). 
Oct4, and Nanog are also reportedly expressed in MSCs derived from equine 
umbilical cord blood (Mohanty et al., 2014). Both of these markers are involved in 
maintaining self-replication and pluripotency in embryonic stem cells (Poloni et 
al., 2013). As the expression of Oct4 and Nanog in adult derived stem cells has 
been established in a number of studies (Poloni et al., 2013; Raabe et al., 2010; 
Raabe et al., 2011; Violini et al., 2009) it has been suggested that the distinction 
between adult and embryonic stem cell markers is not as clear cut as originally 
thought (Violini et al., 2009). Further research into the expression of additional 
embryonic markers has been recommended (Violini et al., 2009).  
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Bone marrow derived stem cells have been found to positively express CD105 
(Ranera et al., 2012), CD29, CD44, CD90, CD11a/CD18 and CD45RB (Radcliffe et 
al., 2010) while CD45, CD79α and major histocompatibility complex II (MHC II) are 
not expressed (De Schauwer et al., 2012). Adipose derived stem cells are also 
reportedly negative for the expression of CD45 (Dhar et al., 2012) but positive for 
CD29 (Ranera et al., 2012), CD51, CD90 and CD105 (Raabe et al., 2011). Peripheral 
blood derived stem cells are positive for CD45, CD34, CD51, CD90 and CD105 (Dhar 
et al., 2012).  
 
There appears to be minimal overlap in the expression of tested markers for 
equine MSCs. CD29 appears to be expressed in ADSCs and BMSCs (Radcliffe et al., 
2010; Ranera et al., 2011) but not in pBSCs. Similarly, CD51 is expressed in ADSCs 
and pBSCs but not in BMSCs. The marker CD90 was found to be expressed in ADSCs 
(Raabe et al., 2011), BMSCs (Radcliffe et al., 2010) and pBSCs (Dhar et al., 2012). 
The only other marker that appears to be expressed in all three MSC types is 
CD105 however, a study by De Schauwer et al., (2012) reported variable 
expression of CD105 when umbilical cord tissue was used. 
 
Table 1.7. Overview of different cell surface markers and gene markers evaluated in 
equine mesenchymal stem cells from adipose tissue (AT), bone marrow (BM) and 
peripheral blood (pB). 
Tissue 
type 
Author Cell surface marker Gene marker 
BM Guest et 
al., 2008 
CD14, CD29, 
CD44,CD79α, CD90, 
MHC-I, MHC-II 
ND 
Radcliffe et 
al., 2010 
CD11a/CD18, CD29, 
CD44, CD45RB, CD90 
CD11a, CD13, CD29, CD44, CD45, 
CD90 
Ranera et 
al., 2012  
ND CD31, CD34, CD45, CD73, CD90, 
CD105, CD166, ALP, BGLAP, 
COL1A1, RUNX2, SPP1, LPL, PPARγ,  
Ranera et 
al., 2011 
CD13, CD29, CD31, 
CD34, CD44, CD45, 
CD45d, CD73, CD90, 
CD105, CD106, CD146, 
CD166 
CD13, CD29, CD31, CD34, CD44, 
CD45, CD45d, CD73, CD90, CD105, 
CD106, CD146, CD166 
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Violini et 
al., 2009 
ND CD34, Oct4, Nanog, Sox2 
Berg et al., 
2009 
ND COL1A1, COL1A2, Aggrecan, SOX9, 
CD-RAP 
AT Ranera et 
al., 2012  
ND CD31, CD34, CD45, CD73, CD90, 
CD105, CD166, ALP, BGLAP, 
COL1A1, RUNX2, SPP1, LPL, PPARγ,  
 Ranera et 
al., 2011 
CD13, CD29, CD31, 
CD34, CD44, CD45, 
CD45d, CD73, CD90, 
CD105, CD106, CD146, 
CD166 
CD13, CD29, CD31, CD34, CD44, 
CD45, CD45d, CD73, CD90, CD105, 
CD106, CD146, CD166 
 Raabe et 
al., 2011 
ND Oct4, Nanog, CD90, CD105, 
PPARγ2, AR, PP, Runx2, OC 
 Dhar et  al., 
2012 
CD34, CD45, CD51, 
CD90, CD105 
ND 
pB Dhar et  al., 
2012 
CD34, CD45, CD51, 
CD90, CD105 
ND 
 Giovanni et 
al, 2008 
ND COL1A1, COL1A2, Aggrecan, 
Versican 
 Martinello 
et al., 2009 
CD13, CD44, CD45, 
CD90, CD117, CD140a. 
ND 
 
1.1.13 THERAPEUTIC APPLICATION OF MESENCHYMAL STEM CELLS IN HORSES 
The equine industry is associated with a high percentage of wastage, a large 
proportion of which is attributed to musculoskeletal injury (Ramzan & Palmer, 
2011). An Australian study of wastage in two-year-old Thoroughbreds, stated that 
66% of lost training days are due to musculoskeletal injuries (Bailey et al., 1997). 
Additionally, Dyson et al. (2008) reported that in the UK, lameness remained the 
major cause of days lost from training. A further review of UK equine industry 
wastage determined that joint problems account for 15 – 25% of horses lost from 
training, and tendon and ligament injuries account for up to 46% of limb injuries 
(Paris and Stout, 2010). There is also a high incidence of re-injury once a 
rehabilitated horse has returned to training. A case controlled study of 400 horses 
in the UK revealed that the re-injury rate of tendon and ligament injuries was 53% 
(O’Meara et al. 2010).  
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Current treatments focus on restoring functionality, however, they do not appear 
to demonstrate a significant improvement in tendon structure (Schnabel et al., 
2009). Furthermore orthopaedic injuries, such as subchondral bone cysts, bone 
fractures, cartilage defects and tendon damage, significantly contribute to 
wastage of otherwise healthy horses (Richardson et al., 2007).  
 
The most common musculoskeletal injury in racehorses is superficial digital flexor 
tendonitis of the forelimb (O’Meara et al., 2010). A number of risk factors 
contribute to superficial digital flexor tendon (SDFT) injuries including age, sex, 
race distance, frequency of high speed work, heavier bodyweight, track surface 
and longer racing careers. During maximal exercise the SDFT is at its highest 
likelihood of over-strain injury, as the tendon is pushed to its maximal potential 
(O’Meara et al., 2010; Richardson et al., 2007). Tendon over-strain injuries present 
a situation where the tendon tissue heals naturally but the resultant scar tissue is 
considerably weaker than uninjured tendon tissue, resulting in reduced 
performance and increased risk of re-injury (Richardson et al., 2007).  
 
Over the past few years, an intense interest in stem cell therapy has developed 
due to the potential benefits of these self-renewing, multi-lineage cells (Lopez and 
Daigle, 2013; Richardson et al., 2007; Undale et al., 2009).  An increasing amount 
of research is being carried out on whether the perceived benefits of MSC 
treatment can be proven through equine in vivo studies. However, there are 
relatively few reports which demonstrate long term benefits from these 
treatments (Schnabel et al., 2013) (Table 1.8).  
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Table 1.8. In vivo mesenchymal stem cell research in equine cell therapy. 
Site of treatment Results Reference 
Adipose derived stem cells 
Superficial digital flexor 
(chemical lesion) 
Treated limbs had increased 
organisation and uniformity of 
tendon tissue 
de Mattos Carvalho 
et al., 2011 
Middle carpal joint (bilateral 
arthroscopic surgery) 
No statistically measurable effect  Frisbie et al., 2009 
Superficial digital flexor 
(chemical lesion) 
Histological improvement compared 
with control (PBS) 
Nixon et al. 2008 
Bone marrow derived stem cells 
Superficial digital flexor 
(clinical cases) 
Reinjury rate 27.4% (lower than 
published controls circa 55%) 
Godwin et al. 2012 
Superficial digital flexor 
(surgical lesion) 
No difference to control 
(supernatant) 
Canigala et al. 2011 
Suspensory ligament and 
superficial flexor (clinical cases) 
11 / 13 (85%) horses returned to 
competition 
Torricelli et al. 2011 
Superficial digital flexor Improved healing Crovace et al. 2010 
Stifle joint Improved healing of cartilage Fortier et al. 2010 
Middle carpal joint (bilateral 
arthroscopic surgery) 
Reduction in PGE2 concentration, 
minimal overall effect on injury 
Frisbie et al., 2009 
Superficial digital flexor 
(chemical lesion) 
Histological improvement compared 
to control (PBS) 
Schnabel LV et al. 
2009 
Superficial digital flexor 
(surgical lesion) – autologous 
vs allogeneic transfer 
No cell mediated response to 
allogeneic transfer 
Guest et al. 2008 
Stifle joint Improved early healing Wilke et al. 2007 
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Superficial flexor tendon 
(clinical cases) 
Minimal change in lesion size. 5% 
reduction at 6 weeks post 
implantation. 
Smith et al., 2003 
Peripheral blood derived stem cells 
Superficial digital flexor 
(clinical cases) 
Improved healing - regenerated 
tendon tissue 
Marfe et al. 2012 
Embryonic stem cell and mesenchymal stem cell comparison 
Superficial digital flexor ESC survival was better than MSC in 
the host. Neither cell source initiated 
a host immune response or tumour 
formation 
Guest et al. 2010 
Foetal derived embryonic stem cells (feES) 
Superficial digital flexor 
(chemical lesion) 
Improved histological markers of 
healing. 
Watts et al. 2011 
 
1.1.14 AIMS OF RESEARCH AND HYPOTHESIS 
The aim of this research was to compare the recovery of stem cells from AT, BM 
and pB. The three tissues were collected from six adult horses to compare cell yield 
and viability at isolation, and cell proliferation differences during culture. All three 
tissue types were investigated for stemness markers in undifferentiated and 
differentiated cells. Adipose tissue and BM were also evaluated for multipotent 
differentiation capacity.  
 
In addition to the main aims of the project, several questions were investigated 
through the course of the project. Due to contamination issues during AT isolation 
an antibiotic trial was carried out to compare two combinations of antibiotics for 
minimising bacterial contamination. Two combinations of cryopreservation 
medium were also compared for cellular viability after thawing.  
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Through the use of validated techniques, the aim was to determine which of the 
three selected tissue sources should be used for routine harvest of equine MSCs. 
Determining the optimal source of equine MSCs would be greatly beneficial for 
veterinary practitioners wishing to utilise stem cell therapies to treat lameness in 
horses. 
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CHAPTER 2: MATERIALS AND METHODS 
Ethics approval was gained from the University of Waikato School of Science and 
Engineering Animal ethics committee prior to the commencement of this study. 
Ethics approval was also received from the AgResearch Ltd Animal Ethics 
Committee prior to the study commencing. 
2.1 PILOT TRIAL 
A pilot trial, in association with AgResearch Ltd, was carried out using post-mortem 
samples to enable training in the necessary skills and techniques required to 
complete the project’s laboratory work. The pilot trial was also used to ensure the 
protocols were successful before the live samples were collected.  
2.1.1 ANIMALS 
AC Petfoods Ltd very generously allowed the collection of AT, BM and pB from 
horses they had purchased for meat processing. Samples were collected from 13 
horses of various breed and age. Mares (11) and geldings (2) were included. The 
individuals are identified in Table 2.1. Post-mortem (PM) samples were used for 
training and verifying isolation, cryopreservation and differentiation protocols.  
Table 2.1. Post-mortem horse information, age, sex, breed and tissue type collected 
from each individual. Thoroughbred (TB), Warmblood (WB), Standardbred (SB). 
Gelded male (GM), Female (F). 
Sample name Tissue 
collected 
Breed Sex Age 
PM1 AT TB GM 6 
PM2 AT, pB TB F 7 
PM3  BM TB F 7 
PM4 AT, BM WB F 12 
PM5 AT, pB TB F 23 
PM6 AT, pB TB GM 10 
PM7 AT, pB TB F 7 
PM8 AT TB F 9 
PM9 AT TB F 7 
PM10 AT TB F 6 
PM11 AT, pB SB F 7 
PM12 AT TB F 6 
PM13 AT TB F 11 
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2.1.2 TISSUE COLLECTION 
Adipose tissue and BM samples were collected within 30min after the horses were 
euthanized. Adipose tissue was collected after the horses had been skinned. Using 
a sterile scalpel holder (Appendix 2) and blade (Appendix 2) a 10g section of tissue 
was sliced away from the subcutaneous fat deposits and transferred to a sterile 
collection container (Appendix 2) using sterile forceps. The sample was covered 
with PBS 2% P/S (Appendix 1) and sealed with a lid. A total of 10g each was 
collected from 12 horses. Bone marrow was collected using the same technique 
described in section 2.2.1.2 without the use of local anaesthetic and a total of 
20ml was collected from two horses. Peripheral blood was collected from the 
jugular vein immediately after the horse was euthanized. A 20ml syringe 
(Appendix 2) and an 18g needle (Appendix 2) was used to collect blood. The blood 
was then injected into sterile EDTA blood tubes (Appendix 2) a mean of 27ml +/- 
6.6ml of blood was collected from five horses.   
 
2.1.3 TISSUE PROCESSING, CULTURE AND DIFFERENTIATION 
Adipose tissue was processed using the protocol described in section 2.3.1, BM 
and pB were processed using two different protocols. The initial protocol used 
Percoll density gradient (1.08g/ml) but this did not appear to suit the composition 
of equine BM or pB. An alternative method using Lymphoprep (1.077g/ml) 
resulted in a well-defined interface containing mononucleated cells and minimal 
erythrocytes. This protocol was used for the live BM and pB samples and is 
detailed in section 2.3.2 and section 2.3.3 respectively. 
 
Two different media were used for pB culture, DMEM F12, 20% FBS, 1% P/S, 0.1% 
fungizone and DMEM High Glucose, 20% FBS, 1% P/S, 0.1% fungizone.  
 
To establish differentiation techniques, ADSCs and BMSCs from two individual 
horses were activated into adipocytes, osteocytes and chondrocytes using the 
protocols set out in sections 2.7.1 (adipogenic), 2.7.2 (chondrogenic) and 0 
(osteogenic). The adipogenic protocol was refined by altering plating densities and 
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comparing two different matrixes. Laminin was determined to be superior to 
Matrigel for adipogenic seeding as more cells adhered to Laminin than to Matrigel. 
Myogenic differentiation was carried out for one BMSC sample using the protocol 
set out in section 2.1.4.  Peripheral blood was not placed in a differentiation assay 
due to the low number of pBSC samples (2) reaching confluence.  
 
2.1.4 MYOGENIC DIFFERENTIATION 
The materials and methods for differentiating equine MSCs into myogenic linages 
are based on the protocol used at AgResearch Ltd.  A single BMSC sample was 
plated in three wells at a density of 1x104 cells in a 24 well plate. Coverslips were 
placed on the surface of the three wells (Appendix 2). The cells were cultured in 
myogenic media (Appendix 3) for 21 days. The cells were then fixed using the 
protocol set out in section 2.7.4.1. Staining was carried out using an ICC protocol 
to identify myosin heavy chain proteins which may have formed during 
differentiation. The fixed coverslips were permeabilized with 0.1% triton X-100 in 
PBS for 10 min at room temperature. The coverslips were then washed with 1 x 
Tris buffered saline with 0.2% tween (TBS-T) wash. The cells were then blocked 
with the polysaccharide carrageenan lambda (Cג) in PBS with 10% normal sheep 
serum (NSS) for 30-60min at room temperature. Mouse anti-MHC (myosin heavy 
chain) antibody (1:200) in 0.35% Cג in PBS + 5% NSS was added to the wells 
containing the coverslips and left overnight at 4°C wrapped in parafilm. The 
following day the coverslips were washed three times in 1 x TBS-T for 5mins for 
each wash. Biotinylated Sheep anti-Mouse (1:300) in 0.35% Cג + 5% NSS was 
aliquoted into each well and incubated for one hr at room temperature. 
Streptavidin Alexa Fluor 488 was then added at 1:400 in 0.35% Cג and incubated 
for one hr at room temperature. Streptavidin is a biotin binding protein which 
covalently attaches to the fluorescent label Alexa Fluor. The coverslips were 
washed twice in TBS-T for 5min each. A DAPI counter stain (1:1000) in PBS was 
added and incubated for 5min followed by two PBS washes. The cells were then 
mounted using the protocol set out in section 2.7.4.2. The coverslips were then 
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viewed under the fluorescent microscope (Appendix 2) at 20x magnification using 
SPOT software. 
2.2 MAIN PROJECT 
Adipose tissue, BM and pB samples were collected from six adult female horses 
(mean age 10.5 +/- SEM 2.04) (Table 2.2). The horses were located at Equibreed 
NZ Ltd for the duration of the project. All surgical procedures were carried out at 
this location which has purpose built facilities for safely restraining horses. 
Following the surgical procedures the mares were monitored twice daily for seven 
days until the sutures were removed from the AT harvesting site.  
 
Table 2.2. Tissue collected from live horses, adipose tissue (AT), bone marrow (BM), 
and peripheral blood (pB). Sexually mature female (F) Thoroughbred (TB) and 
Standardbred (SB) horses were of various age (7-20 years old). 
Sample name 
Tissue 
collected 
Breed Sex Age 
Live horse 1 
(LH1) 
AT, BM, pB 
SB F 11 
Live horse 2 
(LH2) 
AT, BM, pB 
TB F 9 
Live horse 3 
(LH3) 
BM, pB 
TB F 7 
Live horse 4 
(LH4) 
AT, BM, pB 
TB F 20 
Live horse 5 
(LH5) 
AT, BM, pB 
TB F 6 
Live horse 6 
(LH6) 
AT, BM, pB 
SB F 10 
 
2.2.1 TISSUE COLLECTION 
The number of samples collected is displayed in Table 2.3. Multiple sampling was 
carried out for AT as a number of samples were lost due to bacterial contamination 
at isolation. Bone marrow was collected twice from three horses due to 
contaminated medium. Peripheral blood was collected three times from each 
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horse, six samples were lost due to fungal contamination and the remaining 
samples did not reach confluence. 
 
Table 2.3. Total number of adipose tissue (AT), bone marrow (BM) and peripheral 
blood (pB) samples collected from live horses. 
Tissue type AT BM pB 
Number of 
samples collected 
9 9 18 
 
2.2.1.1 ADIPOSE TISSUE COLLECTION 
The horses were handled by experienced handlers and were adequately restrained 
in stocks for pre-analgesic administration. The sterile surgical site was clipped and 
prepared aseptically with chlorhexidine scrub (Appendix 2) and ethanol (Appendix 
2). The horses were then sedated with Dormosedan and Torbugesic (1mg/kg, i.v.) 
(Appendix 2), followed by infiltration of the skin and subcutaneous tissues with 
Bomacaine (Appendix 2) using an inverted L-block. Ultrasound was used to identify 
a deposit of adipose tissue before an incision was made. 
 
Adipose tissue collection procedure was based on previously published methods 
for equine AT harvesting (Ahern et al., 2011; Ranera et al., 2011). An incision of 
approximately 10cm in length was made parallel to and approximately 15cm 
below the spinal column, permitting visualization of a layer of AT between the skin 
and musculature. An average of 12g of tissue was collected from each horse into 
a sterile collection container. A sterile penrose drain (Appendix 2) was 
incorporated into the surgical site to aid the healing process. The surgical site was 
then sutured closed with Supramid Braun suture material (Appendix 2) using a 
single uninterrupted suture pattern (Figure 2.1).  
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Figure 2.1. Adipose tissue collection site with incorporated penrose drain. 
 
2.2.1.2 BONE MARROW COLLECTION 
Following sedation with Dormosedan and Torbugesic (1mg/kg, i.v.) the sternal 
region was clipped with electronic clippers then scanned with an ultrasound 
(Appendix 2) to identify an intersternebral space shown as an inverted V shape on 
the ultrasound screen. Two of these images were marked on the horse’s skin with 
a marker pen (on light-coloured horses) or white correction pen (on dark-coloured 
horses). These V shapes indicated the 5th- 6th intersternebral space and the caudal 
end of the 7th intersternebral (Figure 2.2). Bone marrow aspiration methodology 
was based on the protocols published by Kasashima et al. (2011). 
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Figure 2.2. Location of intersternebral spaces to determine insertion point of 
Jamshidi® needle. 
 
The sternal area was then prepared aseptically with chlorhexidine scrub and 70% 
ethanol. Six millilitres of Bomacaine was injected into the tissue surrounding the 
predicted insertion point to desensitise the skin. At this point two 20ml luer slip 
(Appendix 2) syringes were preloaded with 0.5ml of 5000 iu/ml of heparin 
(Appendix 2) to give a final concentration of 125 iu/ml when 20ml of BM was 
aspirated. The predicted insertion points were checked a second time via 
ultrasound to ensure the correct entry point was identified. The area was scrubbed 
a final time with the chlorhexidine scrub and ethanol. The horses were also 
thoroughly assessed at this point to ensure adequate sedation. If required, 
additional sedative was administered by the veterinarian. After the final aseptic 
preparation of the insertion site, a sterile 11 gauge scalpel blade was used to make 
a small stab incision through the skin. A sterile 11 gauge Jamshidi® needle 
(Appendix 2) was inserted through the skin opening and advanced slowly until the 
needle point made contact with the ventral surface of the sternebrae. The needle 
was gradually advanced through the ventral cortex into the medullary cavity using 
a rotating movement until the handle end of the Jamshidi® needle was no more 
than 5cm away from the skin surface. A 20ml syringe preloaded with heparin was 
          7th      5th-6th  
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attached and the BM was slowly aspirated (Figure 2.3). This process was repeated 
with an additional syringe to collect a total of 40ml of BM aspirate from each 
horse. Upon collection, the samples were gently inverted to ensure even 
distribution of heparin to prevent clotting.  
 
 
Figure 2.3. Bone marrow aspiration using a Jamshidi® needle. 
 
2.2.1.3 PERIPHERAL BLOOD COLLECTION 
Forty millilitres of pB was collected from the jugular vein in four 10ml EDTA 
vacutainers with an 18 gauge needle. During pB collection the horses were 
restrained in a stock and an experienced technician collected the blood. The 
vacutainers were inverted immediately after collection to ensure adequate mixing 
of EDTA and blood to prevent clotting.   
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2.3 TISSUE PROCESSING 
Samples were processed to yield a mononucleated cell (MNC) fraction which 
contains MSCs, additional MNCs and RBCs.  
 
2.3.1 ADIPOSE TISSUE 
Mononucleated cells from AT were isolated using enzymatic digestion and washes 
to produce a cell pellet. Briefly, MNCs were isolated from the tissue samples using 
the following methods and materials set out in Table 2.4. The procedure was in 
accordance with an established preadipocyte isolation protocol for bovine ADSCs 
at AgResearch Ltd (M. Senna Salerno, personal communication, November, 1, 
2012) and is similar to other published ADSC isolation protocols although specific 
details were not provided in the published papers (Ahern et al., 2011; Ranera et 
al., 2011). 
 
Table 2.4. Isolation protocol for adipose tissue. 
Step Process 
1 Mechanical separation of tissue, wash with PBS 
2 PBS wash and spin 
3 Retrieve fat layer, resuspend and spin 
4 Digest in 0.2% Type 1A collagenase 
5 Neutralise, spin, remove supernatant 
6 Resuspend in medium 
7 Filter (70µm strainer) and spin 
8 Resuspend, lysis 
9 Wash in PBS and spin 
10 Resuspend cells in DMEM 10% FBS, 1% P/S, 0.1% 
fungizone 
11 Count, record viability and plate 
 
The cell pellet was resuspended in DMEM, 10% FBS, 1% P/S, 0.1% fungizone 
(Appendix 1) for counting and viability assessment. The mononucleated cells were 
seeded at a density of 2 x105 cells per cm2 in 75cm2 flasks (Appendix 2) and placed 
in the CO2 incubator (Appendix 2).  
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2.3.2 BONE MARROW  
Bone marrow aspirate was isolated using a lymphocyte gradient technique 
established at Equibreed NZ Ltd (Table 2.5) and was based on a lymphocyte 
density gradient protocol published by Ranera et al., (2011) with some minor 
modifications. 
Table 2.5. Isolation protocol for bone marrow. 
Step Process 
1 Strain BM through a 70um cell strainer 
2 Dilute 1:3 with PBS 
3 Dispense 10ml of aspirate over 5ml of Lymphoprep 
4 Centrifuge at 1400rpm for 15min 
5 Collect interface and dilute with 30ml of PBS 
6 Centrifuge at 2000rpm for 5min 
7 Discard supernatant, add 5ml RBC lysis and leave 
for 10min 
8 Add 30ml of PBS, mix and centrifuge at 2000rpm for 
5min 
9 Discard supernatant 
10 Resuspend cells in DMEM/F12, 10% FBS, 1% P/S, 
0.1% fungizone 
11 Count, check viability and plate 
 
Briefly, the sample was diluted 1:3 in PBS (Appendix 1) and filtered through a 70µm 
cell strainer (Appendix 2). Ten millilitres of diluted aspirate was layered over 5ml 
of Lymphoprep (Appendix 2) in 15ml falcon tubes using sterile disposable pipettes 
(Appendix 2). The falcon tubes were centrifuged for 15min at 1400rpm without a 
brake. The samples separated into a red blood cell fraction, a Lymphoprep fraction 
and a PBS fraction. An interface containing MNCs was isolated between the 
Lymphoprep fraction and the PBS fraction (Figure 2.4).  
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Figure 2.4. Bone marrow aspirate separation using Lymphoprep. A - PBS fraction, B - 
interface, C - Lymphoprep fraction, D – red blood cell fraction. 
 
Using sterile 3ml disposable pipettes, the interface was isolated and transferred 
to a 50ml falcon tube. The interface from each density gradient was combined in 
a single 50ml falcon tube which was then diluted with 30ml of PBS and centrifuged 
for 5min at 2000rpm to remove traces of Lymphoprep. The MNCs formed a pellet 
at the base of the falcon tube and the supernatant was tipped off into a waste 
collection bottle. The pellet was loosened by flicking the base of the tube and 
resuspended in 5ml of RBC lysis for 10min to reduce red blood cell contamination. 
The resuspended sample was diluted a final time in 30ml of PBS to remove traces 
of RBC lysis. The pellet formed from this wash was resuspended in 20ml of 
DMEM/F12, 10% FBS, 1% P/S, 0.1% fungizone (Appendix 1) and underwent 
counting and viability assessment. The mononucleated cells were seeded at a 
density of 2 x105 cells per cm2 in 75cm2 flasks (Appendix 2) and placed in the CO2 
incubator. 
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2.3.3 PERIPHERAL BLOOD  
Peripheral blood samples were processed using a combined protocol adapted 
from Spaas et al. (2013) and Dhar et al. (2011) with some minor modifications.  
 
Table 2.6. Isolation protocol for peripheral blood. 
Step Process 
1 Centrifugation 2200rpm, 20min 
2 Remove buffy coat, dilute 1:2 with PBS 
3 Buffy coat layered on 3ml of Lymphoprep 
4 Centrifuge at 1400rpm for 15min 
5 Collect interface 
6 Add 30ml of PBS 
7 Centrifuge at 2000rpm for 15min 
8 Discard interface resuspend pellet in 30ml of PBS 
9 Centrifuge at 2000rpm for 15min 
10 Discard interface and resuspend cells in DMEM F12, 
20% FBS, 1% P/S, 0.1% fungizone 
11 Count, check viability and plate 
 
Briefly, 40ml of peripheral blood was centrifuged (Appendix 2) for 20min at 
2200rpm before being processed using a Lymphoprep density gradient protocol 
established at Equibreed NZ Ltd (Table 2.6). The initial centrifugation resulted in a 
buffy layer forming on the surface of a dense layer of red blood cells with a large 
fraction of plasma located above the buffy layer. The buffy layer and the plasma 
was then collected from each of the four EDTA tubes using sterile 3ml disposable 
pipettes and combined into a single sample in a 50ml falcon tube. The buffy layer 
was then diluted 1:3 in PBS and 5ml was layered on 3ml of Lymphoprep density 
gradient. The samples were then centrifuged for 15min at 1400rpm to form the 
four fractions of density separation (Figure 2.5). 
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Figure 2.5. Peripheral blood separation using Lymphoprep. A - PBS fraction, B - 
interface, C - Lymphoprep fraction, D – red blood cell fraction. 
 
The MNC interface from each tube was combined in a single 50ml falcon tube, 
diluted with 30ml of PBS and centrifuged for 5min at 2000rpm to remove traces 
of Lymphoprep. The MNCs formed a pellet at the base of the falcon tube and the 
supernatant was tipped off into a waste collection bottle. The pellet was loosened 
by flicking the base of the tube and resuspended in 30ml of PBS followed by 
another centrifugation for 5min at 2000rpm. The pellet formed from the final 
wash was resuspended in 10ml of DMEM/F12, 20% FBS, 1% P/S, 0.1% fungizone 
(Appendix 1) and underwent counting and viability assessment. The cells were 
seeded at a density of 2 x105 cells per cm2 in 25cm2 flasks (Appendix 2) and placed 
in the CO2 incubator (Table 2.6).  
 
2.3.4 COUNTING AND VIABILITY ASSESSMENT 
A Neubauer counting chamber (Appendix 2) (Figure 2.6) was used to determine 
the concentration and viability of cells at isolation, replating and freezing. 
Methodology was based on techniques used at AgResearch Ltd and published cell 
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counting protocols by Freshney (2010). The specialised coverslip was adhered to 
the surface of the counting chamber by moistening the sides of the chamber with 
70% ethanol and sliding the cover slip on top until Newton’s rings were visible. 
This method ensured the coverslip would stay firmly attached during counting and 
prevented the cells from moving around the grid and being miscounted.  A 20µl 
sample of cell suspension was aliquoted into an eppendorf tube and resuspended 
with 10µl of trypan blue exclusion dye (Appendix 1). A 20µl sample was evenly 
distributed under the cover slip, ensuring the counting chamber was covered with 
the cellular suspension.  
 
 
Figure 2.6. Neubauer improved counting chamber with gridlines shown. 
 
The sample was immediately viewed under the microscope (Appendix 2) and 
methodically counted using either a five square count if there was a high density 
of cells or a 25 square count if there was a low density of cells. The gridlines in the 
centre of Figure 2.6 show the central 25 square grid on which the cells are 
counted. Viability was determined by visually identifying dead cells stained with 
trypan blue dye. The formula used for determining cell count is shown below. 
 
Cell count = (n x 104) x (Dilution volume of trypan blue) x (dilution volume of total 
cell suspension) 
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2.4 CELL CULTURE 
Mononucleated cell samples were plated and incubated until confluence was 
reached. During pBSC culture, the samples were incubated for 21 days before 
discarding the flasks if no cell colonies had appeared.  
 
All of the cells isolated from each tissue type were plated as a single population of 
cells with no clonal growth protocol. The cell populations grown are heterologous 
with a mixture of cell types and a range of cell growth stages are represented in 
each flask of cells. As no live pB samples reached confluence, cell culture data was 
collected from live ADSCs and BMSCs only. Peripheral blood derived stem cell 
growth and culture behaviour data was recorded from the two post-mortem pB 
samples which reached confluence. For evaluation of isolation counts, data from 
tissue collected on the same day or within the same week were used for 
comparison to reduce day effect on cell yield.   
 
2.4.1 PASSAGES AND CONFLUENCE 
The primary stem cells collected directly from raw tissue were labelled as passage 
– (P-) as they had not yet been plated. Passage zero (P0) cells had been plated but 
had not yet been removed, divided and replated. Passage one (P1) cells had 
undergone one removal, division and replating and passage two (P2) cells had 
undergone two removals, divisions and replatings (Figure 2.7). Cells at P2 were 
frozen for future use from all samples that reached this passage stage.  
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Figure 2.7. Passage stages during culture, passage minus (P-), passage zero (P0), 
passage one (P1) and passage 2 (P2). Grey passages are primary cell from raw tissue. 
White passages are secondary cells which had been replated. 
 
The cells were removed from the flasks when they reached 80% confluence, 
determined by evaluating the entire surface of the flask to gauge overall cell 
density. 
 
Adipose derived stem cells, BMSCs and pBSCs from P0 were plated at a density of 
5000 cells/cm2 in 75cm2 nunclon flasks in medium prescribed for each tissue type. 
The interval of time from point of plating to day of confluence was recorded. This 
plating density was repeated for an additional passage until the cells reached P2. 
The length of culture time until confluence was recorded for each passage, as was 
the number of cells and cell viability. Adipose derived stem cells from LH4 and LH6 
were passaged to P2 and then cryopreserved.  Bone marrow derived stem cells 
from LH2, LH3, LH4, LH5 and LH6 were passaged to P2 then cryopreserved. For use 
in the differentiation assays, ADSCs and BMSCs were thawed and passaged until 
the required number of cells were available. The maximum passage reached was 
passage 6 (P6) and the cells used for differentiation range from P4 to P6 cells.  
 
P-
•Unplated cells collected directly from body tissue
P0
•Cells plated immediately after tissue processing
•Medium changed until cells multipled and reached confluence
•When confluence reached cells are trypsinised and replated at 5000cells/cm2
P1
•Replated cells from P0
•Medium changed until confluence reached
•When confluence reached cells are trypsinised and replated at 5000cells/cm2
P2
•Replated cells from P1
•Medium change until confluence reached
•When confluence reached cells are trypsinised and frozen
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2.4.2 MEDIUM CHANGES 
Every three days the flasks were removed from the CO2 incubator, evaluated 
under a light microscope (Appendix 2) and placed in the laminar flow hood. 
Medium changes were carried out following the protocol published by Freshney 
(2010). Briefly, the medium stock bottle was prewarmed in a 37°C water bath to 
ensure the cells remained at a stable temperature. The lids of the flasks were 
removed and the medium was removed using a sterile 10ml pipette (Appendix 2). 
The medium was then discarded into a waste bottle. The replacement medium 
was added via a sterile 10ml pipette by releasing the liquid along the side of the 
flask to minimise disturbing the attached cells. The cells were then placed back 
into the CO2 incubator. At each medium change the cells were assessed for 
morphology, attachment and proliferation. The medium was examined for 
changes in pH and clarity which can be an indication of cell growth and 
contamination. At day one in culture, the ADSCs and BMSCs were examined under 
the microscope to assess cell attachment. The flasks were then left to attach 
before changing the medium at day three. Medium changes were carried out 
every three days until confluence. The pBSC flasks were examined at day one in 
culture and the medium was replaced in each flask to remove the red blood cells 
which were contained in the isolated cell fraction. On day five, the pBSC medium 
was replaced and changed every three days until the cells were either confluent 
or the flasks were discarded due to lack of cell adherence. Flasks containing the 
mononucleated cell fraction from pB were maintained in culture for a maximum 
of 20 days to allow time for cell attachment. This generous allowance in time was 
seen in previously published papers on equine pBSC culture (Dhar et al., 2011; 
Giovannini et al., 2008).  
 
2.4.3 SUBCULTURING 
When the adherent cell layer approached late log phase, demonstrated by 
reaching 80% confluence, the cells were removed from the flask using a subculture 
protocol published by Freshney (2010). Briefly, the flasks were removed from the 
CO2 incubator and washed with sterile PBS to remove traces of medium prior to 
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the cells being trypsinised. Two ml of Trypsin/EDTA (Appendix 2) was added to the 
washed flasks, swirled around the entire surface and the excess solution was 
tipped out of the flask into a waste bottle to leave a residual film on the flask 
surface. The flasks were incubated at 37°C for 2min until the cells become rounded 
and detached from the flask surface. The trypsin was neutralised by adding DMEM 
10% FBS and the cells were collected in a 50ml falcon tube. A cell count was 
determined following the protocol set out in section 2.4.4. The cells were then 
replated at 5000cells/cm2. Cell plating density was based on published papers 
using culture flasks for cell proliferation analysis (Ranera et al., 2011; Vidal et al., 
2008). Cell counts, viability and duration to confluence was recorded at each 
passage.  
 
The method used for estimating confluence involved assessing the concentration 
of cells throughout the plate and estimating a percentage of the flask surface that 
was covered with cells. Accurately assessing cell confluence requires experience 
with cell behaviour in culture which was gained during the course of the project.  
 
2.4.4 CELL CALCULATIONS  
The proportion of MSCs contained in raw tissue was calculated based on the 
number of MNCs per ml of raw tissue at isolation (P-) and the number of MSCs per 
ml that reached initial confluence (P0). 
2.5 ANTIBIOTIC TRIAL 
Five AT primary cell samples were plated at 5000cells/cm2 and cultured in two 
separate combinations of antibiotics in 25cm2 flasks. Standard culture medium for 
ADSC was used with the addition of either penicillin/streptomycin (P/S) 
(100U/100µg) or gentamicin/vancomycin (G/V) (40µg/ml). Once the cells reached 
confluence the number of cells per flask and viability percentage was measured 
and compared. 
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2.6 CRYOPRESERVATION 
2.6.1 FREEZING 
Cryopreservation of cell populations followed the freezing protocols used by 
AgResearch Ltd with some minor differences in cryopreservation medium 
composition. The minor changes were made based on the results of a summer 
project carried out at EquiBreed NZ Ltd. The project compared cell viability after 
freezing in 5% DMSO, 20% FBS and 75% DMEM to cell viability after freezing in 5% 
DMSO, 90% FBS and 5% DMEM. As no significant difference was found in cell 
viability after freezing 5% DMSO, 20% FBS and 75% DMEM was suggested as a 
potential cryopreservation medium for routine freezing and storage of equine 
MSCs.   
 
The methodology for MSC cryopreservation is based on the protocols used by 
AgResearch Ltd and the protocols published by Freshney (2010). The flasks were 
trypsinised (see section 2.4.3), counted and washed to remove trypsin and pellet 
the cells. The cell pellet was resuspended in cryopreservation medium consisting 
of 5% DMSO, 20% FBS and 75% DMEM medium. The cells were diluted in enough 
cryopreservation medium to produce a final concentration of approximately 1 x 
106 cells per ml and 1ml of cell suspension was aliquoted into 2ml cryovials 
(Appendix 2). The vials were placed into a Mr Frosty™ freezing container (Figure 
2.8) and stored in a -80°C freezer for 24 hours before being transferred into a liquid 
nitrogen tank.  
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Figure 2.8. Mr Frosty™ freezing container. 
 
2.6.2 THAWING 
The cryovials were retrieved from the liquid nitrogen tank and placed in a 37°C 
waterbath for 2min until the ice crystals had disappeared as described by Naaldjik 
et al. (2012). Cell samples were then diluted in the standard medium for each cell 
type (Appendix 1) and cultured in a CO2 incubator at 37°C. A 20µl aliquot of thawed 
cells were counted and assessed for viability after cryopreservation.  
 
2.6.3 CRYOPRESERVATION MEDIUM COMPARISON 
Five post-mortem ADSC samples (PM4, PM5, PM7, PM8 and PM9) were used to 
compare the effect of two different concentrations of FBS (20% and 90%) on cell 
viability and number after cryopreservation. The cells were trypsinised and 
counted using the protocols set out in sections 2.4.3 and 2.3.4. The samples were 
then frozen in cryopreservation media comprising of either 20% FBS, 5% DMSO 
and 75% DMEM or 90% FBS, 5% DMSO and 5% DMEM. After approximately three 
weeks after freezing, the cells were thawed, counted and assessed for viability 
using trypan blue stain. The cell count and viability results, before and after 
freezing, was compared to obtain a percentage of cell survival post-thaw.   
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2.7 DIFFERENTIATION 
Differentiation was carried out in triplicate design which was duplicated to provide 
one plate for determining differentiation morphology changes and another for 
determining changes in gene expression during differentiation. The differentiation 
assay for ADSC included the two live horse samples (LH4 and LH6) and two of the 
post-mortem samples to increase the number of samples in the assay (Table 2.7). 
The samples used for differentiation had been previously stored in liquid nitrogen 
before being thawed, plated and amplified.  
 
Table 2.7. Adipose derived stem cell (ADSC) and bone marrow derived stem cell 
(BMSC) samples used for trilineage differentiation assay. 
Cell type Adipogenic Chondrogenic Osteogenic 
ADSC (4) LH4, LH6, PM1, 
PM13 
LH4, LH6, PM1, 
PM13 
LH4, LH6, PM1, 
PM13 
BMSC (5) LH2, LH3, LH4, 
LH5, LH6 
LH2, LH3, LH4, 
LH5, LH6 
LH2, LH3, LH4, 
LH5, LH6 
 
2.7.1 ADIPOGENIC DIFFERENTIATION 
The methodology for adipogenic differentiation was a combination of two 
published protocols (Raabe et al., 2011; Spaas et al., 2013) with some minor 
adjustments for insulin concentration during adipogenic maintenance. The use of 
a matrix or coverslips was not published in the literature but were added to the 
protocol to facilitate cell surface adherence and ease of staining.  
 
Adipogenic differentiation was carried out in 24 well plates (Appendix 2) with the 
addition of 13mm cover slips (Appendix 2) and a laminin matrix (Appendix 2) (1:20 
dilution). The coverslips were placed in the well plates and coated with 200µl of 
laminin and incubated for two hours before use. The laminin was removed and 
the wells were washed three times with PBS. Undifferentiated ADSC and BMSC 
samples were trypsinised, counted and resuspended in DMEM, F12, 10% FBS, 1% 
P/S, 0.1% fungizone at a density of 1.5 x 105 cells per well. The cells were cultured 
until confluence which took approximately 24-48 hours from seeding. Once 
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confluence was reached, the medium was replaced with adipogenic induction 
medium (Appendix 3). The cells were incubated for three days then cultured in 
adipogenic maintenance medium (Appendix 3).  
 
The adipogenic assay was incubated for a total of 14 days from the day of exposure 
with adipogenic induction medium. Medium changes were carried out every three 
days and the cells were assessed regularly for cellular development and 
morphology. A semi-quantitative scoring system was developed for assessing the 
percentage of differentiated cells and the size and arrangement of lipid droplets 
within the cells (Table 2.8). 
 
Table 2.8. Semi-quantitative scoring system used to evaluate adipogenic 
differentiation of mesenchymal stem cells under fluorescent microscopy after staining 
with BODIPY and DAPI. 
% of differentiated 
cells  
Lipid vesicle size Number and orientation of 
lipid vesicles 
0 >0-25 0 No vesicles 0 No vesicles 
1 >25-50 1 Small, < 1/3 
nucleus 
1 Few individual vesicles 
throughout cell 
2 >50-75 2 Medium 
sized 1/3 of 
nucleus 
2 Few individual vesicles 
surrounding nucleus 
3 >75-100 3 Large > 1/3 
of nucleus 
3 Many vesicles 
surrounding nucleus 
     
2.7.2 CHONDROGENIC DIFFERENTIATION 
The protocol used for chondrogenic differentiation was based on a protocol 
published by Pilz et al. (2011). Chondrogenic differentiation was carried out in 96 
well round-bottomed plates (Appendix 2). The wells were seeded with 4 x 105 cells 
in 20µl of incomplete chondrogenic medium (Appendix 3). After an incubation 
period of two hours 180µl of complete chondrogenic medium (Appendix 3) was 
pipetted into the treated pellet wells. For each horse, ADSCs and BMSCs were 
seeded in two control wells and three treatment wells. The control pellets were 
exposed to incomplete chondrogenic medium throughout the length of 
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incubation. Medium changes were carried out every three days. The chondrogenic 
assay was incubated for 21 days from seeding. A semi-quantitative scoring system 
was developed to assess structural changes to the pelleted cells and the intensity 
of Alcian Blue staining (Table 2.9).  
 
Table 2.9. Semi-quantitative scoring system used to evaluate chondrogenic 
differentiation of mesenchymal stem cells after staining with Alcian Blue. 
Pellet shape Pellet structure Lacunae formation Staining intensity 
of pellet 
0 No distinct 
shape 
0 No tertiary 
structure 
0 No gaps 0 No colour 
change 
1 Variable 
rounded 
shape  
1 Soft 1 < 10% gaps 
throughout 
section 
1 Light blue 
2 Irregular 
spherical 
shape 
2 Medium 
hardness 
2  10-50% gaps 
throughout 
section 
2 Medium 
blue 
3 Symmetric
al sphere 
3 Hard pellet 3 >50 % gaps 
throughout 
section 
3 Intense 
blue 
 
2.7.3 OSTEOGENIC DIFFERENTIATION 
Osteogenic differentiation was carried out in 24 well plates (Appendix 2) in a 
triplicate design. The cells were directly seeded onto the surface of the wells 
without the addition of cover slips or a matrix. Following trypsinisation and 
counting, the cells were resuspended in medium consisting of DMEM, F12, 10% 
FBS, P/S and fungizone at a density of 3 x 105 per well with a total of 9 x 105 cells 
used for osteogenic differentiation per horse. The first medium change was 
carried out when the cells reached confluence, the medium was removed and 
changed to osteogenic induction medium (Appendix 3).  
 
The osteogenic assay was incubated for 10 days from the point of exposure to 
osteogenic medium. Medium changes were carried out every three days. 
Differentiated cells were assessed using a semi-quantitative scoring system to 
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measure the percentage of differentiated cells and the formation and staining 
intensity of cell clusters (Table 2.10). 
 
Table 2.10. Semi-quantitative scoring system used to evaluate osteogenic 
differentiation of mesenchymal stem cells after staining with Alizarin Red. 
Size of cell clusters Region of staining Staining intensity of 
cells 
0 No 
clusters 
  0 Small areas     0-25 0 No stained 
cells 
1 Small 1 Small/medium areas 
25-50 
1 Light red 
2 Medium 2 Medium 50-75 2 Red 
3 Large 3 Large 75-100 3 Bright red 
 
2.7.4 DIFFERENTIATION ANALYSIS 
2.7.4.1 FIXING CELLS  
The differentiation plates were removed from the CO2 incubator and washed 
three times in 1ml of prewarmed PBS to remove medium. Care was taken with the 
adipogenic well to ensure the cover slip remained in the same position. 
Prewarmed fixative (Appendix 3) was pipetted into each well and incubated for 
20sec at room temperature. Fixative was discarded into a designated formalin 
collection container. The wells were then washed three times with PBS. The 
osteogenic and chondrogenic plates were stained immediately after fixing, the 
adipogenic plate had 1ml of PBS added to each well, was wrapped in parafilm 
(Appendix 2) then stored at 4°C.  
 
2.7.4.2 ADIPOGENIC STAINING 
The fluorescent stains BODIPY and DAPI were used to determine adipogenic 
differentiation. This procedure took place in a darkened room due to the 
fluorescent nature of the stains. The PBS was aspirated out of the wells. The 
BODIPY/DAPI stain (Appendix 1) was added, 1ml per well, and incubated in a dark 
place at room temperature for 20min. The stain was removed using a 1ml pipette 
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(Appendix 1) and washed three times with PBS. The first and second wash was left 
for 3min, the third wash was removed straight away. The cover slips were then 
mounted on a Polysine slide (Appendix 2) using Dako mounting medium (Appendix 
2) and were covered with a 22 x 60mm cover slip (Appendix 3). Each Polysine slide 
was placed in a separate slide holder, wrapped in tin foil and stored at 4°C 
overnight. The cover slips were viewed using a fluorescent microscope (Appendix 
2) at 20x magnification using SPOT software.  
 
2.7.4.3 CHONDROGENIC STAINING 
Alcian Blue stain, 1% pH 1.0 (Appendix 1) was used to visualise glycosaminoglycan 
(GAG) deposits within the chondrogenic pellets. The pellets were washed three 
times with MQ water, 100µl of Alcian Blue (Appendix 1) was added to each well 
and incubated for 10min at room temperature. This method did not appear to 
result in efficient staining so an alternative incubation method, 24hrs at 37°C in 
100µl of Alcian Blue was used.  
 
Chondrocyte pellets were prepared for embedding in tissue freezing medium by 
washing three times in 30% sucrose solution (Appendix 1). The pellets were 
incubated overnight at 4°C on a rocking platform. The pellets were then incubated 
in 100µl of 30% sucrose mixed with two drops of tissue freezing medium 
(Appendix 2) over night at 4°C on a rocking platform. One cryomold per pellet was 
filled with tissue freezing medium and the pellet was placed in the centre of the 
mold and covered with more tissue freezing medium. The molds were snap frozen 
with freezing spray (Appendix 2) and sectioned on a cryostat (Appendix 2) in 6µm 
sections. The sections were placed on Apex slides (Appendix 2) and air dried 
overnight. 
 
The sections of pellets were placed in a 3% Acetic acid wash (Appendix 1) for 3min. 
The slides were then placed in 1% Alcian Blue stain for 30min and rinsed in distilled 
water for 1min. After being dipped briefly in alcohol to dehydrate the sections the 
slides were allowed to air dry.  Using mounting medium (Appendix 2) and 
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coverslips (Appendix 2), the slides were covered and viewed under phase contrast 
microscopy (Appendix 2). Staining of GAGs and the formation of lacunae were 
then assessed under phase contrast microscopy.  
 
2.7.4.4 OSTEOGENIC STAINING 
Alizarin Red stain pH 4.1 (Appendix 1) was used to stain the calcium deposits which 
develop during osteogenic differentiation. The fixed cells were washed three times 
in MQ water to remove PBS. One ml of Alizarin Red was added to each well and 
incubated for 3min at room temperature. The stain was removed and the wells 
were washed three times with MQ water. One ml of MQ water was left in each 
well to facilitate visualization under the Leica microscope (Appendix 2). 
 
2.8 RT-PCR ANALYSIS 
Cell RNA was extracted from the ADSCs and BMSCs before differentiation and 
during differentiation for all three tissue lineages. Due to the high number of cells 
detaching during the assay, RNA was extracted on day six for adipogenic cells and 
day seven for osteogenic cells. Extraction of RNA for chondrogenic cells occurred 
at day eight. An RNA sample was extracted from one post-mortem 
undifferentiated pBSC sample. Undifferentiated cells were collected from the 
samples of cells used for the differentiation assays to enable comparison of the 
same population of cells before and during differentiation. A selection of primers 
were made and purchased from Sigma Aldrich (Table 2.11). The samples used for 
mRNA extraction are displayed in Table 2.12. 
 
 
 
 
 
Chapter 2  Materials and Methods 
61 
 
Table 2.11. RT-PCR Primers. 
Gene NCBI sequence # Forward Primer 5’ – 3’ 
Reverse Primer 5’ – 3’  
Product 
size (bp) 
Annealing 
Temp (°C) 
GAPDH 
(HK) 
NM_00116385
6 
GGCAAGTTCCATGGCACAGT 
CACAACATATTCAGCACCAGCAT 
128 66 
B2M  
(HK) 
NM_00108250
2 
TCGTCCTGCTCGGGCTACT 
ATTCTCTGCTGGGTGACGTGA 
81 67 
NANOG 
(P, DP) 
XM_00149880
8.1 
TACCTCAGCCTCCAGCAGAT 
CAGTTGTTTTTCTGCCACCT 
118 62 
OCT4  
(P, DP) 
XM_00149010
8.3 
CGAGAAGGACGTGGTACGAG 
GTGGTGACAGACACAGAGGG 
248 64 
CD34 
(HM) 
XM_00149159
6 
CACTAAACCCTCTACATCATTTTCTCC
TA 
GGCAGATACCTTGAGTCAATTTCA 
100 65 
PPARγ2 
(AD) 
XM_00149241
1 
TGCAAGGGTTTCTTCCGGA 
GCAAGGCATTTCTGAAACCG 
124 67 
RUNX2 
(OD) 
XM_00150251
9 
GAACCCAGAAGGCACAGACA 
GGCTCAGGTAGGAGGGGTAA 
249 64 
SPP1  
(OD) 
XM_00149615
2 
CTCACATCACCTGTGGAAAGCA 
CACGGCTGTCCCAATCAGA 
96 67 
SOX9 
(CD) 
XM_00149842
4.3 
ATGAAGATGACCGACGAGCA 
GTTCAGCAGTCTCCAGAGCTT 
419 64 
HK – Housekeeping, P – Proliferation, DP – Differentiation potential, HM – Hematopoietic marker, AD 
– Adipogenic differentiation, OD – Osteogenic differentiation, CD – Chondrogenic differentiation.  
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Table 2.12. Adipose derived stem cell (ADSC), bone marrow derived stem cell (BMSC) 
and peripheral blood derived stem cell (pBSC) samples used for mRNA extraction. 
Samples derived from undifferentiated or differentiated states. 
Cell type Undifferentiated Adipogenic Chondrogenic Osteogenic 
ADSC LH4, LH6, PM1, 
PM13 
LH4, LH6, 
PM1, PM13 
LH4, LH6, 
PM1, PM13 
LH4, LH6, 
PM1, PM13 
BMSC LH2, LH3, LH4, 
LH5, LH6 
LH2, LH3, 
LH4, LH5, 
LH6 
LH2, LH3, 
LH4, LH5, LH6 
LH2, LH3, 
LH4, LH5, LH6 
pBSC PM13 - - - 
 
2.8.1 RNA EXTRACTION 
Undifferentiated cells were pelleted in 2ml eppendorf tubes by centrifuging for 
5min at 2000rpm. The supernatant was tipped off into a waste container and 
300ul of TRIzol® reagent (Appendix 3) was added via a pipette. The contents were 
resuspended by pipetting six times and frozen in a -80°C freezer until required.  
 
The RNA from differentiated cells was collected from each well by firstly removing 
the medium and adding 100µl of TRIzol® in each well. The TRIzol® was pipetted 
over the surface of the wells then removed and collected in a single 2ml eppendorf 
tube to form a total of approximately 300µl. Samples were pooled from the 
triplicate differentiation assay due to the high number of cells lifting from the well 
surfaces and the low number of cells available for RNA extraction. The 
chondrogenic pellets were collected intact as they proved too solid to break up via 
pipetting. A total of three pellets were collected in approximately 300µl of TRIzol®. 
The RNA from the differentiated samples was then placed in a -80°c freezer until 
required. 
 
2.8.2 RNA PROCESSING, PCR AMPLIFICATION AND GEL ELECTROPHORESIS 
Undifferentiated cells, adipogenic cells and osteogenic cells were thawed and 
resuspended with additional TRIzol® so that all tubes contained 500µl of 
TRIzol®/RNA mix. Chondrogenic pellets were processed with a BeadBeater 
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(Appendix 3) to break up the three pellets in each eppendorf tube. The pellets 
were broken up by adding glass and silica beads (Appendix 3) to the RNA and 
mixing twice at 4800rpm for 30sec on the BeadBeater. All samples were then 
processed using the protocol set out in Table 2.13.  
Table 2.13. Steps for RNA processing from TriZol® extraction. 
Step Process 
1 Add 50µl of 1-Brom-3-chloropan (BCP) 
2 Mix thoroughly by hand for 15s 
3 Place on emulsifier table 10min at room temp. 
4 Centrifuge for 10min, 13 rcf, 4°C 
5 Remove supernatant and place in eppendorf 
6 Add NaAc (2M, pH 4.0), acid phenol, BCP, emulsify for 15 sec 
7 Centrifuge for 10min, 13 rcf, 4°C 
8 Collect supernatant, add equal volume of isopropanol 
9 Centrifuge for 10min, 13 rcf, 4°C 
10 Add 1ml 70% ethanol 
11 Centrifuge, 10sec at 6 rcf 
12 Remove supernatant and add 20µl of TrisMn 
 
Processed RNA was then measured using a Nanodrop spectrophotometer 
(Appendix 2). One ml of RNA sample was loaded on to the Nanodrop pedestal and 
the sample absorbance at 260 and 280 nm was determined. The RNA samples 
were then treated with DNase (Appendix 2) by adding 1µl of DNase per 10µl of 
samples. The mixture was vortexed and centrifuged briefly before being incubated 
for 30min at 37°C. Two microlitres of DNase stop was added and the samples were 
incubated for 10min at 65°C then placed on ice.  
 
RNA was then converted to cDNA with BioRad Kit iScript™ (Appendix 2) following 
the manufacturer’s instructions (Appendix 4). Complementary DNA was evaluated 
using conventional PCR, performed with GAPDH and B2M primers as house-
keeping genes. These two endogenous controls are widely used in equine MSC 
research (Raabe et al., 2011; Ranera et al., 2011). A master mix (2M MgCl2) was 
mixed with Taq (Appendix 2) and forward and reverse primers. For 125µl of master 
mix 0.65µl of Taq and 2.5µl of primer mix was added. The mixture was vortexed 
and aliquoted to make 24µl per tube. One microlitre of cDNA was then added to 
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each tube and the samples were amplified in a thermal cycler (Appendix 2) using 
the stages set out in Table 2.14. 
 
Table 2.14. Stages of thermal cycling for PCR amplification. 
Stage number Temp Duration # of reps 
1 95c 15 Single 
2 95c 20  
X 10  65c 20 
 -1c 1 cycle 
 72C 30 
3 95c 20 X 35 
 55c 20 
 72c 30 
Finish 68c 5min single 
 
The amplified PCR products were run on a 1% gel (Appendix 2) containing 3µl of 
ethidium bromide (Appendix 2). Ten microlitres of PCR product was mixed with 
2µl of loading dye buffer and dispensed into the gel wells covered with 1% TAE 
(Appendix 2). The gels were run for 30min at 90V using an electrophoresis unit 
(Appendix 2). Gels were viewed on a UV illuminator (Appendix 2) using Scion 
Image software.  
 
2.8.3 RT-PCR AMPLIFICATION AND ANALYSIS 
Real-Time PCR amplifications were carried out for nine genes including two 
housekeeping genes for each of the 36 samples using SYTO®82 Orange fluorescent 
Nucleic Acid Stain (Appendix 2). Each RT-PCR run comprised of 27 cDNA samples 
and nine negative control samples (Table 2.15).  
Table 2.15. RT-PCR run sample set up example. 
Replicate GAPDH B2M CD34 NANOG OCT4 PPARy2 RUNX2 SPP1 SOX9 
1 cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA 
2 cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA 
3 cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA cDNA 
-ve 
control 
-ve -ve -ve -ve -ve -ve -ve -ve -ve 
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Each RT-PCR run used a reaction mix containing of 750µl of 4M MgCl2, 0.3µl Syto 
82 and 5µl of Taq. An aliquot of 450µl of reaction mix was divided into nine tubes 
and combined with 1µl of forward and reverse primers for each gene. The 
remaining 300µl of reaction mix was divided into three 100µl aliquots and 
combined with 9µl of cDNA. A 10µl aliquot of diluted cDNA was added to each of 
the nine primer tubes. Each cDNA sample was run in a cycle profile optimised for 
SYTO®82 using a RT-PCR machine (Appendix 2) (Table 2.16).  
 
Table 2.16. Steps for RT-PCR amplification using SYTO®82 optimised cycling. 
Cycle stage (40 
repeats) 
Temperature Time 
Hold 95°C 15 min 
Step 1 95°C Hold 20sec 
Step 2 55°C Hold 20sec 
Step 3 68°C Hold 30sec 
Step 4 80°C Hold 10sec 
 
Relative quantification was determined by using the comparative CT method. 
Expression of target genes NANOG, OCT4, CD34, PPARγ2, RUNX2, SPP1 and SOX9 
relative to the reference genes GAPDH and B2M were calculated using 2∆∆CT. The 
efficiencies of the target gene amplification and the efficiencies of the reference 
gene amplification were calculated to ensure they were equal. Comparative 
quantification analysis was performed using Corbett software (Appendix 2). Gene 
expression as normalised to the housekeeping gene B2M and calculated using the 
following equation by Pfaffl et al. (2002).  
 
Ratio = (Etarget)∆CPtarget(control - sample)/(Eref)∆CPref(control - sample) 
 
2.8.4 PRIMER SEQUENCING 
Primers used for RT PCR were sequenced at the Waikato University sequencing 
unit. Twenty-five microlitres of amplified primer product was combined with 1.0µl 
of Exo Nucl 1, 3.0µl SAP and 7.6µl of water (Appendix 2). The samples were 
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amplified in a thermal cycler (Appendix 2) for 30min at 37°C and for 5min at 95°C 
before being sent for sequencing. 
 
2.9 STATISTICAL ANALYSIS 
Statistical analysis was limited due to the low number of samples available across 
the different tissue types. A post-hoc Tukey’s multiple comparison test was used 
following ANOVA analysis of P- cell counts and viability for AT, BM and pB MNCs. 
An ANOVA was also used for analysis of ADSC and BMSC proliferation in culture. 
Differentiation analysis was carried out using students two sample T-Test, 
assuming unequal variance.  A two sample paired T-Test was also used to analyse 
paired observations for the antibiotic trial. Cryopreservation medium effect was 
analysed using a two sample paired T-Test. Data was calculated using the mean 
and standard error of the mean (SEM). Comparison of differentiation gene 
expression between ADSCs and BMSCs was carried out using a two sample paired 
T-Test.  
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CHAPTER 3: RESULTS 
3.1 PILOT TRIAL 
The pilot trial was carried out using post-mortem sampling to refine cell isolation, 
culture and differentiation protocols. Isolated cells from all three raw tissue types, 
adipose tissue (AT), bone marrow, (BM) and peripheral blood (pB) were plated and 
cultured until confluence was reached. Cells directly isolated from raw tissue for 
primary culture were referred to as P- mononucleated cells (MNC) before plating, 
and as P0 mesenchymal stem cells (MSC) once they had been plated. The P- cells 
were a heterologous mixture of MNCs while the P0 cell population contained a 
mixture of fibroblast-like cells. Once in culture, adherent cells were then referred 
to as MSCs from their tissues of origin, namely ADSCs, BMSCs and pBSCs from 
adipose tissue, bone marrow and peripheral blood respectively. Although this 
appears to be a complicated nomenclature, it is important to distinguish the two 
different populations of cells as they contain different proportions of cell types. 
 
3.1.1 POST-MORTEM STEM CELL ISOLATION AND CULTURE 
Of the 12 post-mortem AT samples collected, nine samples reached confluence 
and three were discarded due to bacterial contamination. One sample was 
isolated from behind the point of the elbow as no adipose tissue deposits were 
available in the typical dorsal gluteal region. The sample isolated from this 
alternative region was not included in the data due to the unusual morphology of 
the tissue sample and the low number of MNCs isolated. Therefore, a total of eight 
samples were available for analysis. Two post-mortem BM samples were obtained 
and both reached confluence. Five post-mortem pB samples were collected, two 
of which reached confluence (Table 3.1). Post-mortem pBSCs grown in DMEM F12 
(see section 2.1.3) reached confluence at day 20 while the pBSCs cultured in high 
glucose (HG) DMEM (see section 2.1.3) reached confluence at day 33. 
Chapter 3  Results 
68 
 
Table 3.1. Number of post-mortem samples from adipose tissue (AT), bone marrow 
(BM) and peripheral blood (pB) collected and the number of samples which reached 
confluence. 
Tissue type Number of samples 
collected 
Number of samples which 
reached confluence 
AT 12 9* 
BM 2 2 
pB 5 2 
*Three samples were discarded due to bacterial contamination. 
 
Minimal differences in MNC yield at isolation were seen for AT and pB however, 
BM yielded approximately half the number of cells per 10ml of raw tissue (Table 
3.2). Mononucleated cell viability was found to be significantly higher for pB and 
BM cell samples (P<0.05) before plating (99% and 98% respectively) compared to 
AT MNC viability which was 91% at isolation.  
 
Table 3.2. Post-mortem viability and yield of mononucleated cells per 10 ml of raw 
adipose tissue (AT), (11 samples), bone marrow (BM), (2 samples) and peripheral 
blood (pB), (5 samples). Data shown as mean (SEM). One AT sample was not included 
as the sample was collected from a different anatomical location. 
Tissue type  Viability Cells/10ml of raw tissue 
AT (11) 91 (1.7) 94.45 x 105 (19.22 x 105) 
BM (2) 98 (1.5) 52.61 x 105 (3.88 x 105) 
pB (5) 99 (0) 92.71 x 105 (29.82 x 105) 
 
The eight post-mortem samples of MNCs isolated from raw AT reached confluence 
in an average of 4.88 days (+/-0.52) after plating. Mononucleated cells isolated 
from the two raw BM aspirate samples reached confluence in an average of 27 
days (+/-1) after plating. Mononucleated cells from two of the five raw pB samples 
reached confluence in an average of 26.5 (+/-6.5) days after plating (Table 3.3). 
However, these two samples had been cultured in two different culture media. 
The cells that reached confluence were then referred to as mesenchymal stem 
cells (MSC) as they demonstrated the ability to adhere to the surface of the culture 
flask and proliferate as well as display fibroblast-like morphology. No statistical 
Chapter 3  Results 
69 
 
comparison was made between the three tissue types due to the low number of 
BM and pB samples.  
 
Table 3.3. Post-mortem culture of primary cells from adipose tissue (AT) (8), bone 
marrow (BM) (2) and peripheral blood (pB) (2) which reached confluence. Days of 
confluence, viability % and number of cells at confluence x 105 shown as mean (SEM). 
One AT sample was not included as the fat sample was collected from a different 
anatomical location. 
Tissue type  Days to 
confluence 
Viability at 
confluence % 
Number of cells at 
confluence X 105 
AT (8) 4.88 (0.52) 97.13 (0.77) 36.56 (7.59) 
BM (2) 27 (1) 92.5 (2.5) 49.50 (7.5) 
pB (2) 26.5 (6.5) 89 (9) 111.25 (64.75) 
 
The initial cell population isolated from raw tissue contains a range of MNCs. 
After plating, the varied nature of the cell population becomes refined to cells 
capable of plastic adherence, which is a characteristic associated with MSCs. By 
comparing the number of cells displaying the ability to adhere, to the number of 
MNCs obtained from the original cell fraction, an indication of the proportion of 
MSC contained in a MNC fraction can be inferred (Table 3.4). Eight AT samples 
from post-mortem horses (PM2, PM4, PM5, PM6, PM7, PM8, PM9 and P13) were 
used for this calculation (see materials and methods section 2.4.4). From an 
average of 6.91 x 105 (+/-1.52 x 105) MNCs at P- and an average of 3.65 x 105 (+/- 
.75 x 105) MSCs at P0, MSCs made up 52% of MNCs in 1ml of raw AT. This implies 
that equine derived AT may contain a dense population of MSCs. As the protocols 
used for isolating cells from BM and pB were modified with progressive sampling, 
the cell counts were not compared. 
 
Table 3.4. Percentage of mesenchymal stem cells (MSCs) in 1ml of raw AT from eight 
post-mortem horses. One AT sample was not included as the sample was collected 
from a different anatomical location. 
Cell type Cells/ml of raw 
tissue x 105 
Cells/ml x 105 at 
confluence 
Percentage of MSCs 
per ml of raw tissue 
AT (8) 6.91 (1.52) 3.65 (.75) 52% 
Chapter 3  Results 
70 
 
Once the cells from P- reached confluence (P0) they were then termed ADSCs, 
BMSCs or pBSCs as the populations contained adherent MSCs capable of 
proliferation. In addition to analysing MSC proportions in each sample, two post-
mortem samples, one BMSC sample and one ADSC sample were used for trialling 
four differentiation protocols, adipogenic, chondrogenic, osteogenic and 
myogenic lineages (see materials and methods sections 2.7.1-0). Differentiation 
was confirmed for adipogenic and osteogenic lineages using the appropriate 
stains, while the chondrogenic lineage was not confirmed with staining due to 
time and resource constraints. Myogenic differentiation was evaluated in the 
BMSC sample only but positive differentiation was not observed using 
immunocytochemistry with anti-myosin heavy chain antibodies (see materials 
and methods section 2.1.4).  
 
3.2 MAIN PROJECT 
Following the completion of the pilot trial, AT, BM and pB samples were collected 
from six live horses. The same nomenclature previously used in section 3.1 for 
post-mortem tissue culture was used for live tissue culture.  
 
The samples collected from each horse and the identification of each horse is 
outlined in Table 2.2. Due to bacterial contamination of some of the samples, 
repeated sampling was carried out from some of the horses. Nine AT samples were 
collected from LH1, LH2, LH4, LH5 and LH6, of which, seven samples were lost due 
to bacterial contamination and the two remaining samples reached confluence.  
One horse (LH3) did not have available AT in the dorsal gluteal region and no 
sample was collected from this animal.  Of the nine BM samples, three samples 
were discarded due to media contamination and six samples were cultured to 
confluence. One BM sample (LH1) reached initial confluence (P0) but when 
replated, the cells did not attach and proliferate. Of the 18 pB samples collected 
from live horses, no samples reached confluence (Table 3.5).  
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Table 3.5. Number of live adipose tissue (AT), bone marrow (BM) and peripheral blood 
(pB) samples collected and the number of samples which reached confluence. 
Tissue type Number of samples 
collected  
Number of samples 
reaching confluence 
AT 9 2 
BM 9 6 
pB 18 0 
 
3.2.1 COMPARISON OF ISOLATION COUNTS AND VIABILITY  
The MNC fractions isolated from the live raw tissue samples were counted to 
determine cell number per ml of raw tissue. The three sources of stem cells did 
not demonstrate significant differences in MNC yield per ml of raw tissue (Table 
3.6). Five horses were used for isolation comparison as no AT could be collected 
from one horse (LH3). Although multiple samples were collected from some of the 
individuals, only the samples collected on the same day or in close proximity of 
each other were used, in an attempt to reduce variability due to date of collection.  
 
Table 3.6. Live horse sample viability % and yield of mononucleated cells x 105 per 10 
ml of raw adipose tissue (AT), bone marrow (BM) and peripheral blood (pB) from five 
horses* collected on the same day or within the same week. Data shown as mean 
(SEM). Data from horses with tissue samples sourced from all three tissue types.  
Tissue type Viability 
% 
Cells/10 ml of  raw tissue x 105 
AT (5) 93 (1.81) 134.00 (19.90) 
BM (5) 99 (0.21) 169.17 (31.20) 
pB (5) 100 (0.24) 111.13 (39.36) 
*Data from one horse (LH3) was excluded as adipose tissue could not be collected and compared 
to bone marrow or peripheral blood. 
The count carried out on freshly isolated cells demonstrated some minor tissue-
specific differences. Bone marrow had the highest number of MNCs per 10ml of 
raw tissue (mean - 169.17 x 105 (SEM - 31.20)) with AT and pB being the second 
lowest and lowest respectively (mean AT - 134.00 x 105 (SEM 19.90), mean pB - 
111.13 x 105 (SEM 39.36)). However, no statistically significant differences were 
found between the three tissue sources (P < 0.05). Viability was highest for MNCs 
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isolated from live pB and BM, at 100% and 99% respectively. Mononucleated cells 
from live AT had an average of 93% viability at isolation and were found to be 
significantly lower than the viability of MNCs isolated from BM and pB (P < 0.05). 
No statistically significant difference was found between the viability of BM and 
pB (P > 0.05).  A post-hoc Tukey’s multiple comparison test was used for statistical 
analysis of MNC counts and viability. In summary, the data showed no significant 
difference in the number of MNCs isolated from the same volume of raw AT, BM 
and pB tissues, while cell viability was significantly higher for MNCs from BM and 
pB (P<0.05). Mononucleated cells from AT demonstrated significantly lower 
viability, perhaps due to the more extensive processing required to isolate the cells 
(see section 2.3.1).  
 
The cell samples were cultured until the first confluence was reached (P0).  Two 
AT samples (LH4 and LH6) reached confluence and six BM samples reached 
confluence (LH1, LH2, LH3, LH4, LH5 and LH6). The two matched pairs of samples 
were from LH4 and LH6 both of which had one AT sample and one BM sample 
reaching confluence. These paired samples were used for initial confluence 
analysis.  
 
The duration of time required for initial confluence to be reached for LH4 and LH6 
ADSC samples was 5.5 days (SEM-0.5) while BMSCs from LH4 and LH6 reached 
confluence after 15 days (SEM-0) (Table 3.7). The mean day of P0 confluence for 
all six of the BMSC samples was 15.83 (SEM-1.27) (Data not shown). From the AT 
and BM samples isolated from LH4 and LH6, it appears that ADSCs reach 
confluence faster than BMSCs when harvested directly from raw tissue, confirming 
the results obtained from post-mortem derived stem cells.  
Table 3.7. Day of confluence for adipose derived stem cells (ADSCs) and bone marrow 
derived stem cells (BMSCs) isolated from LH4 and LH6. Data shown as mean (SEM). 
Cell type Day of confluence  
ADSCs (2) 5.5 (.5) 
BMSCs (2) 15 (0) 
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The proportion of MSCs contained in the freshly isolated MNC fraction was 
calculated using the methods set out in section 2.4.4. One ml of raw AT contained 
a higher percentage of MSCs than 1ml of raw BM (53% vs 11%). (Table 3.8). The 
higher proportion of MSCs contained in the MNC fraction from AT may account 
for the reduced number of days required for MNCs from AT to reach confluence. 
 
Table 3.8. Percentage of mesenchymal stem cells (MSCs) per ml of raw adipose tissue 
(AT) and bone marrow (BM) from two horses (LH4 and LH6). Data shown as mean 
(SEM). 
Tissue type Cells/ml of raw 
tissue x 105 
Cells/ml x 105 at 
confluence 
Percentage of MSCs 
per ml of raw tissue 
AT (2) 9.8 (0.3) 5.15 (0.85) 53% 
BM (2) 16.00 (9.5) 1.77 (0.13) 11% 
 
In summary, AT appears to be a better source of MSCs compared to BM aspirate 
as the higher proportion of MSCs per ml of raw AT resulted in reduced time to 
achieve confluence.  
 
3.2.2 COMPARISON OF CELL PROLIFERATION RATES AND CELL YIELD IN 
CULTURE 
Secondary culture counts and proliferation rate assessment was carried out using 
live ADSCs and BMSCs only. No pBSCs were included as no live samples reached 
confluence.  The two ADSC samples from LH4 and LH6 and the five BMSC samples 
from LH2, LH3, LH4, LH5 and LH6 were used for assessment. The ADSC and BMSC 
samples from LH4 and LH6 were used for statistical analysis. The ADSCs and BMSCs 
that reached initial confluence (P0) were plated at 5000 cells per cm2 and passaged 
twice to provide confluence counts. Passage one count is referred to as P1 and the 
passage two count is referred to as P2. The comparison of growth rates from both 
cell sources, AT and BM, provides an indication of any difference in proliferation 
rate due to cell tissue type origin. A subjective assessment of confluence was used 
to determine whether the cell population had covered 80% of the culture flask 
surface. Both of the ADSC samples were cultured to P2 however, only five of the 
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BMSC samples could be cultured to P2 as the BMSC sample from LH1 failed to 
attach and proliferate after passaging (Table 3.9). 
 
Table 3.9. The number of adipose derived stem cell (ADSC) and bone marrow derived 
stem cell (BMSC) samples reaching confluence at passage one (P1) and passage two 
(P2)  
Cell type (number of 
samples) 
P1 P2 
ADSC (2) 2 2 
BMSC (6) 5 5 
 
The passage data generated from the ADSC and BMSC samples from LH4 and LH6 
were analysed to determine if there were any differences in cell yield and time to 
confluence. An ANOVA test found that ADSCs yielded a significantly higher number 
of cells than BMSCs (P = 0.014) from the same seeding concentration for both 
passages. Adipose derived stem cells yielded 4.5 x 105 cells/ml while BMSCs 
yielded 2.04 x 105 cells/ml in the same number of days to confluence. Interestingly, 
there was no significant difference in the day cells reached confluence for ADSCs 
and BMSCs once the samples were established in culture.  
 
Cell morphology and behaviour was evaluated during culture (Figure 3.1). All three 
tissue types contained cells which attached to the flask surface and displayed 
fibroblast-like morphology. Adipose derived stem cells grew in a monolayer and 
developed distinctive swirl patterns throughout the culture flask when reaching 
near confluence. Bone marrow derived stem cells also demonstrated a monolayer 
in culture with distinctive swirl patterns although there were also areas of densely 
clustered cells. The two pBSC samples available for analysis from post-mortem 
origin grew in clusters which eventually spread out to a monolayer although the 
areas of densely packed cells remained. These clusters were visible even without 
the use of a microscope. Adipose derived stem cells and BMSCs from live horses 
and pBSCs from post-mortem horses were able to be passaged to P2 and 
cryopreserved.  
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A B C 
Figure 3.1. Comparison of cell morphology in culture at P2, A – adipose derived stem 
cells, B – bone marrow derived stem cells, C – peripheral blood derived stem cells 
(from post-mortem sample). Phase contrast microscopy. (10 x magnification). 
 
Cell culture summary 
All three tissue sources yielded fibroblast-like cells capable of adherence and 
proliferation. However, AT and BM appeared to be considerably more reliable 
sources of MSCs than pB. Based on the percentage of MSCs per ml of raw tissue, 
AT appeared to be a better source of equine MSCs compared to BM and pB. 
Adipose tissue reached initial confluence faster than BM or pB derived cells. 
Interestingly, ADSCs and BMSCs reach confluence at similar rates once the 
populations have been established in culture, however, the density of the cell 
population at confluence was significantly higher for ADSCs (P=0.014). Overall, the 
cell culture phase of the project suggests that ADSCs outperform BMSCs and pBSCs 
during initial cell culture. However, once in culture, rate of ADSC and BMSC 
confluence is not significantly different although the number of cells at confluence 
was significantly higher for ADSC samples.   
 
3.3 CRYOPRESERVATION 
The cryopreservation phase of the project investigated the capacity of all three 
tissue types to withstand freezing in liquid nitrogen. The two ADSC samples from 
LH4 and LH6 and the five bone marrow derived stem cell samples from LH2, LH3, 
LH4, LH5 and LH6 were cryopreserved. As no live pBSCs were obtained, the two 
post-mortem pBSC samples were cryopreserved. Cultured cells from all three 
sources were placed in a cryopreservation medium to preserve cell integrity and 
were slowly cooled to -80°C. The samples were then stored in liquid nitrogen for 
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a minimum of four weeks before being fast-thawed and plated to observe any 
changes in cell behaviour.  
 
All of the samples that were thawed and plated reached confluence, 
demonstrating the retention of growth characteristics after controlled exposure 
to the extremely cold temperatures required for long-term storage. 
 
In addition to investigating the effect of cryopreservation on ADSCs, BMSCs and 
pBSCs, two different combinations of cryopreservation media were compared 
using post-mortem ADSC samples (PM4, PM5, PM7, PM8 and PM9) 
(Methodology: 2.6.1).  A two-sample paired T-Test analysis found no significant 
differences between the number and viability of ADSCs before and after 
cryopreservation (P value = 0.218) (Figure 3.2). As there was no statistically 
significant difference between the two different combinations of media, the use 
of a low-serum medium, containing 20% FBS, may be a more cost-effective 
approach for cryopreserving equine MSCs. 
 
 
Figure 3.2. Survival percentages of post-mortem adipose derived mesenchymal stem 
cell samples following cryopreservation in DMSO with two different fetal bovine 
serum concentrations.  
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Overall, it appears that equine MSCs can be stored using a low-serum 
cryopreservation medium in liquid nitrogen, without detrimental effect on cell 
attachment and proliferation ability.  
 
3.4 ANTIBIOTIC TRIAL 
Due to the loss of samples early in the project, an antibiotic trial was carried out 
to determine if a combination of wide spectrum antibiotics would provide greater 
protection from bacterial contaminations. Two combinations of antibiotics were 
trialled using post-mortem ADSC samples. The cells from the same horse were 
plated at the same densities in P/S medium and G/S to compare cell attachment 
and proliferation. One sample placed in G/V culture medium did not reach 
confluence while all of the samples placed in P/S culture medium reached 
confluence. However, no significant difference in proliferation rate between the 
two antibiotic combinations could be seen (P>0.05). It appears that as all of the 
five samples cultured in P/S reached confluence, this combination of antibiotics 
has less detrimental effect on cell attachment and growth than G/V. However, as 
four of the five samples cultured in G/V reached confluence at a similar rate to P/S 
cultured cells this combination of antibiotics is a viable option for equine ADSC 
culture, particularly in conditions where contaminations are more likely to occur.  
 
3.5 POST-MORTEM AND LIVE HORSE SAMPLE 
COMPARISON 
During the pilot trial, post-mortem samples were collected for training purposes. 
After observing the live surgical procedures, I began to question the use of live 
samples for culture research purposes. If post-mortem samples could be used for 
isolating MSCs from various tissue sources, there would be no need to put 
research horses through surgery to collect samples.  
 
Live and post-mortem samples at isolation were compared to see if there were 
differences in cell yield and viability. Due to the low number of samples, statistical 
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analysis could not be performed however, the means and standard error of the 
means were compared. There appeared to be a slightly higher yield of MNCs from 
live tissue for all three tissue sources compared to post-mortem tissue.  Cellular 
viability did not appear to be affected by live or post-mortem collection. The 
number of MNCs isolated from live horse BM was higher than the number of MNCs 
isolated from post-mortem BM, however, this may be due to the different 
isolation techniques used and the smaller volume of post-mortem BM collected. 
Mononucleated cell yield from pB was also higher for live samples (Table 3.10).  
 
Table 3.10. Live and post-mortem comparison of adipose tissue (AT), bone marrow 
(BM) and peripheral blood (pB), viability and cells/ml of tissue. Data shown as mean 
(SEM). 
Tissue type Viability % Cells/ml of tissue x 105 
Live AT (5) 92 (1.81) 13.4 (1.99) 
PM AT (11) 91 (1.7) 9.57 (1.90) 
Live BM (5) 99 (0.21) 16.9  (3.12) 
PM BM (2) 98 (1.5) 5.26 (0.38) 
Live pB (5) 99 (0.16) 11.11 (3.93) 
PM pB (5) 99 (0) 9.21 (1.75) 
 
Although cell counts from live horse samples appear to be higher than for post-
mortem samples, this comparison shows that MSCs can be isolated from both live 
and post-mortem tissues without any effect on cell viability. 
 
3.6 HISTOLOGICAL ANALYSIS OF TRILINEAGE 
DIFFERENTIATION  
Multipotency of ADSCs and BMSCs was assessed through trilineage differentiation 
into adipogenic, chondrogenic and osteogenic lineages. The samples used for 
differentiation are displayed in Table 2.7.  Adipose derived stem cell samples 
included two live horse samples (LH4, LH6) and two post-mortem samples (PM1, 
PM13). Bone marrow derived stem cell samples were from five live horse samples 
(LH2, LH3, LH4, LH5 and LH6). Adipogenic, chondrogenic and osteogenic 
differentiation assays were carried out over 14, 21 and 10 days respectively. At the 
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end of each assay, histological stains were used to assess the morphological 
degree of differentiation in each sample.  
 
3.6.1 ADIPOGENIC DIFFERENTIATION 
Adipogenic differentiation was carried out over 14 days using ADSC and BMSC 
samples. Adipose derived stem cell samples were from two live samples (LH4 and 
LH6) and two post-mortem samples (PM1 and PM13). Bone marrow derived stem 
cell samples were from five live samples (LH2, LH3, LH4, LH5, and LH6). The cells 
were incubated in adipogenic induction medium for three days and then cultured 
in adipogenic maintenance medium for the remaining duration of the assay. 
Changes in cell morphology and behaviour were assessed during medium changes 
which occurred every three days. On the final day of differentiation, the samples 
were fixed and stained with BODIPY and DAPI to observe morphological changes 
within the cells (Methodology: 2.7.4.2). 
 
3.6.1.1 EFFICIENCY OF ADIPOSE DERIVED STEM CELLS 
Changes in cell morphology were evident from day three after exposure to 
adipogenic induction medium (Figure 3.3). Some of the cells began to lift from the 
well surface while the attached cells began to convert from a fibroblast-like to a 
spherical shape. By day six, the attached cells displayed spherical morphology and 
cell detachment continued to occur. By day nine, small droplets had formed within 
the cells. At this stage there were cells with rounded morphology, mostly due to 
resettlement of floating, detached cells, and some which had retained fibroblast-
like morphology. The adipogenic differentiation staining was performed at day 14.  
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 A  B 
 C  D 
 
 
Figure 3.3. Stages of adipogenic differentiation in adipose derived stem cell samples. A 
- Day 0, pre-exposure, arrow indicates near-confluent fibroblast-like cells, B - Day 3 
after exposure, arrow indicates development of spherical morphology, C - Day 6 after 
exposure, arrow indicates increase in cell width, D - Day 9 after exposure, black arrow 
indicates increase in cell width, white arrow indicates attached fibroblast-like cell, E - 
Day 14 after exposure, black arrow indicates areas of attached cells. Phase contrast 
microscopy. (10 x magnification). 
 
Adipose derived stem cells were evaluated using BODIPY fluorescent stain to 
determine the degree of lipid accumulation within the cells as well as the size of 
the lipid containing vesicles. The lipid vesicles were stained green with BODIPY 
giving an indication of lipid vesicle size and density.  The nuclei of the cells were 
stained blue with DAPI, providing an estimate of how many cells were attached 
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and how the lipid droplets were orientated around the nuclei of each cell (Figure 
3.4).  
 
A B 
C D 
Figure 3.4. Adipose derived stem cells from four different horses following adipogenic 
differentiation, stained with BODIPY (green) and DAPI (blue), A – LH4, B – LH6, C – 
PM1, D – PM13. Fluorescent microscopy. (20 x magnification). Dashed white arrow 
indicates a cell nucleus stained with DAPI, white arrow indicates lipid vesicles stained 
green with BODIPY surrounding the nucleus. 
 
Adipogenic differentiation was obtained in the four ADSC samples, all of which 
displayed strong staining for differentiation. There was a range of lipid droplet 
sizes across the samples, LH6 displayed strong BODIPY staining due to the high 
number of large lipid droplets present (Table 3.11). The sample from PM1 
appeared to have the most intense level of staining however, the size of the lipid 
droplets were smaller than for LH6. Live horse four (LH4) and PM13 displayed 
strong staining with BODIPY, although the lipid vesicle size was smaller than seen 
for LH6 and PM1. (For scoring system see methodology section: Table 2.8). 
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Table 3.11. Differentiation and lipid grades for adipogenic differentiated adipose 
derived stem cells from live horse four (LH4), live horse six (LH6), post-mortem horse 
one (PM1) and post-mortem horse 13 (PM13). 
Horse Differentiation 
grade 
Lipid size Lipid number and 
orientation 
LH4 3 2 3 
LH6 3 3 3 
PM1 3 2 3 
PM13 3 2 3 
 
3.6.1.2 EFFICIENCY OF BONE MARROW DERIVED STEM CELLS 
The activated BMSCs developed a more spherical morphology by day three and 
only a small number of floating detached cells were visible (Figure 3.5). Changes 
in morphology continued to be seen at day six with the centre of the cells 
increasing in width. Detached cells were also evident at this stage. Cells at day nine 
retained the same morphology seen at day six and there appeared to be a range 
of cell morphology throughout the plate. Some cells retained the distinctive 
fibroblast-like shape whereas other attached cells had a spherical shape. Attached 
cells at day 14 in culture also showed a range of morphologies and the cells were 
stained at this point with BODIPY and DAPI (see staining methodology: 2.7.4.2).  
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A B 
 C  D 
 E  
Figure 3.5. Stages of adipogenic differentiation in bone marrow derived stem cells. A - 
Day 0, pre-exposure, arrow indicates near-confluent fibroblast-like cells, B - Day 3 
after exposure, arrow indicates development of spherical morphology, C - Day 6 after 
activation, black arrow indicates cell increasing in width, D - Day 9 after exposure, 
black arrow indicates cell increasing in width, white arrow indicates attached 
fibroblast-like cell, E - Day 14 after exposure, black arrow indicates cell with enlarged 
centre. Phase contrast microscopy. (10 x magnification). 
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Adipogenic differentiation was obtained in all of the five BMSC samples used in 
the assay (Figure 3.6) although the differentiation grade and lipid vesicle size 
varied between samples (Table 3.12). Three of the samples differentiated well 
with lipid deposits surrounding the nuclei of the cells. Two of the samples 
differentiated weakly and demonstrated a low number of attached cells which 
were surrounded by few, small lipid deposits, particularly in LH6. 
 
A B 
C D 
E 
   
Figure 3.6. Bone marrow derived stem cells from five different horses following 
adipogenic differentiation stained with BODIPY (green) and DAPI (blue), A – LH2, B – 
LH3, C – LH4, D – LH5, E – LH6. Fluorescent microscopy. (20 x magnification). Dashed 
white arrow indicate a cell nucleus stained with DAPI, white arrow indicates lipid 
vesicles stained green with BODIPY surrounding the nucleus. 
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Bone marrow derived stem cells displayed weak staining with BODIPY due to the 
low density of lipid vesicles within the cells (Table 3.12). The sample from LH2 
displayed the highest grade of differentiated cells with many small lipid vesicles. 
Live horse three (LH3) and LH4 had a lower grade of differentiation with many 
small lipid vesicles. Live horse five (LH5) showed an even lower grade of 
differentiation with very few small lipid vesicles surrounding the cells. Live horse 
six (LH6) displayed poor differentiation with a low number of attached cells 
surrounded by few, small lipid vesicles. 
 
Table 3.12. Differentiation and lipid grades for adipogenic differentiated bone marrow 
derived stem cells from five horses. 
Horse Differentiation grade Lipid size Lipid number 
and orientation 
LH2 2 1 3 
LH3 2 1 3 
LH4 2 1 3 
LH5 1 1 2 
LH6 0 1 1 
 
In summary, adipogenic differentiation efficiency appeared to be greater for 
ADSCs. All of the four ADSC samples displayed similar levels of differentiation 
efficiency while BMSC samples displayed a range of efficiencies and overall, 
exhibited lower staining scores for lipid vesicle development. Although ADSCs 
appear to be superior to BMSCs for adipogenic differentiation, both sources of 
cells were able to be pushed into the adipogenic lineage.  
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3.6.2 CHONDROGENIC DIFFERENTIATION 
Chondrogenic differentiation was carried out over 21 days. Adipose derived stem 
cell pellets were from two live samples (LH4 and LH6) and two post-mortem 
samples (PM1 and PM13). Bone marrow derived stem cell pellets were from five 
live samples (LH2, LH3, LH4, LH5, and LH6). Control pellets were exposed to 
incomplete chondrogenic medium for the duration of the assay. Control and 
treated pellets from LH4 and LH6 were sectioned to compare chondrogenic 
differentiation efficiency in ADSCs and BMSCs. The sectioned pellets were stained 
with Alcian Blue after being fixed to a slide and dehydrated. The Alcian Blue stain 
is an indicator of chondrogenic differentiation as it highlights deposits of 
glycosaminoglycans (GAG) strongly associated with the formation of chondrocyte 
cells. Pellet shape and structure was also assessed as an indicator of chondrogenic 
differentiation.  
 
3.6.2.1 EFFICIENCY OF ADIPOSE DERIVED STEM CELLS 
All four ADSC samples formed spherical aggregation of cells which developed into 
solid, hard pellets after 21 days in chondrogenic culture medium. Two of the ADSC 
chondrogenic pellets, LH4 and PM1, showed staining around the peripheral edge 
of the pellet and the remaining two pellets, LH6 and PM13 did not appear to be 
visually different following staining.  When compared to the differentiated pellets, 
the control pellets appeared smaller, less dense and did not have tidy, spheroid 
formations. Alcian Blue staining was also more intense with the treated pellets 
compared to the control pellets (Figure 3.7). 
 
Control pellets Treated pellets 
Figure 3.7. Control and treated chondrocyte pellets from adipose derived stem cells 
stained with Alcian Blue after 21 days in culture. 
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A B 
C D 
E  
Figure 3.8. Adipose derived stem cells from four different horses following 
chondrogenic differentiation and stained with Alcian Blue. A – LH4, B – LH6, C – PM1, 
D – PM13, E – control pellet. Phase contrast microscopy. (10 x magnification). Black 
arrow indicates Alcian Blue staining. 
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Sectioned ADSC pellets from LH4 and LH6 stained with Alcian Blue displayed light 
staining indicating low level GAG deposits in the extracellular matrix (Figure 3.9). 
Chondrocyte-specific lacunae formation could be seen throughout the pellet for 
LH6, however LH4 did not appear to form lacunae. 
 
 A  B 
 C  D 
Figure 3.9. Sectioned adipose derived stem cell chondrocyte pellets from LH4 and LH6 
stained with Alcian Blue for GAG deposits. A- LH4 control pellet, (10 x magnification), B 
– LH6 control pellet (10 x magnification), C- LH4 treated pellet (20 x magnification), D – 
LH6 treated pellet (20 x magnification). Phase contrast microscopy. White arrow 
indicates lacunae. 
 
Pellet shape, structure, GAG staining intensity and lacunae formation was 
assessed in LH4 and LH6 sectioned ADSC pellets (Table 3.13) (see scoring 
methodology Table 2.9). Pellet shape, structure and staining intensity was similar 
for both samples however lacunae formation could be seen in only one sample. 
The sectioned pellet from LH4 appeared to be poorly structured, however, 
chondrogenic differentiation was confirmed by the development of GAGs which 
stained medium blue. 
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Table 3.13. Pellet shape, structure, glycosaminoglycan staining intensity and lacunae 
formation grade for chondrogenic differentiation in sectioned adipose derived stem 
cell pellets from LH4 and LH6. Pellet shape and structure grade is from intact pellets 
before sectioning. Lacunae and staining intensity is from sectioned pellets. 
Horse Pellet 
shape 
Structure Lacunae 
formation 
Staining 
intensity 
LH4 2 3 0 2 
LH6 2 3 1 2 
 
3.6.2.2 EFFICIENCY OF BONE MARROW DERIVED STEM CELLS 
All of the five BMSC samples formed defined spherical pellets and four (LH2, 3, 4, 
5) were visibly blue after being stained although the extent of the stain could not 
be visualised in the intact pellets (Figure 3.11). Without the use of a microscope, 
all of the differentiated pellets appeared blue however, the treated pellets 
appeared to be more intense blue that the control pellets (Figure 3.10). All of the 
pellets were densely formed and although the control pellets also had distinctly 
spherical shapes, the cell density were visibly lower than that of the TGF-β1 
treated pellets. 
 
 
Control pellets Treated pellets 
Figure 3.10. Control and treated chondrocyte pellets from bone marrow derived stem 
cells stained with Alcian Blue after 21 days in culture. 
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A B 
C D 
 E F 
Figure 3.11. Bone marrow stem cells from five different horses following chondrogenic 
differentiation and stained with Alcian Blue, A – LH2, B – LH3, C – LH4, D – LH5, E – 
LH6, F – control pellet. Phase contrast microscopy. 10 x microscopy). White arrow 
indicates Alcian Blue stain. 
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Sectioned BMSC pellets from LH3, LH4 and LH6 were compared for lacunae 
formation and staining intensity (see scoring methodology: Table 2.9). The control 
pellets from all three horses displayed light blue staining, indicating GAG deposits. 
Treated pellets showed more intense staining than the control pellets indicating 
higher levels of GAG deposits. Lacunae formation was evident in the treated 
pellets from all three horses (Figure 3.12). 
 
A  B 
C D 
 E  
Figure 3.12. Sectioned bone marrow stem cell chondrocyte pellets stained with Alcian 
Blue for GAG deposits. A- control pellet – LH3, B – control pellet – LH4, C – control  
pellet – LH6, D – treated pellet – LH3, E – treated pellet – LH4, F – treated pellet, LH6. 
Phase contrast microscopy (20 x magnification). Black arrows indicate lacunae. 
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Pellet shape, structure, GAG staining intensity and lacunae formation was 
assessed in LH3, LH4 and LH6 sectioned BMSC pellets (Table 3.14) (see scoring 
methodology Table 2.9). The treated pellets from all three horses displayed 
irregular spherical shapes with hard pellet structures. When the pellet from LH3 
was sectioned, lacunae formation was evident throughout the pellet and Alcian 
Blue staining could be seen around the edges and in some places within the pellet. 
Sectioning of the LH4 pellet displayed lacunae formation across 10-50% of the 
pellet and intense blue staining was seen around the edge and in places within the 
pellet. The treated pellet from LH6 displayed the highest score for chondrogenic 
differentiation. Lacunae formation was evident throughout the pellet and deposits 
of GAGs, as determined by the uptake of Alcian Blue stain, were seen around and 
throughout the pellet section. 
 
Table 3.14. Pellet shape and staining intensity score for bone marrow derived stem cell 
chondrogenic differentiation 
Horse Pellet shape Pellet 
structure 
Lacunae 
formation 
Staining 
intensity 
LH3 2 3 3 2 
LH4 2 3 2 3 
LH6 2 3 3 3 
 
In summary, BMSCs appear to be more efficient in differentiating into 
chondrocytes than their ADSC counterparts. The control pellets for BMSCs 
displayed light staining with Alcian Blue, suggesting that chondrogenic 
differentiation may occur in BMSCs, even without the necessary differentiation 
supplements, namely, TGF-β1. 
 
3.6.3 OSTEOGENIC DIFFERENTIATION 
Osteogenic differentiation was evaluated at day 10 by staining with Alizarin Red 
for the presence of calcium deposits. Adipose derived stem cell samples were from 
two live sample (LH4 and LH6) and two post-mortem samples (PM1 and PM13) 
and bone marrow derived stem cell samples were from five live samples (LH2, LH3, 
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LH4, LH5, and LH6). Morphological changes in the samples were documented 
every three days prior to the medium change.  
 
3.6.3.1 EFFICIENCY OF ADIPOSE DERIVED STEM CELLS  
Morphological changes in ADSCs could be seen from day three following the start 
of differentiation (Figure 3.13). The cells began to contract and individual cells 
began to group together, developing dense clusters of cells in various regions 
throughout the plate. By day six the clusters became quite distinct and individual 
cells were no longer visible within the clusters. At day nine the cells had developed 
into defined clusters of densely layered cells.  
 
 A B 
C D 
Figure 3.13. Stages of osteogenic differentiation in adipose derived stem cell samples. 
A - Day 0, pre-exposure, white arrow indicates fibroblast-like morphology of confluent 
cells. B - Day 3 after exposure, white arrow indicates cell contraction. C - Day 6 after 
exposure, white arrow indicates formation of cell cluster. D - Day 9 after exposure, 
white arrow indicates formation of dense cell cluster. Phase contrast microscopy. (10 x 
magnification). 
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All of the four ADSC samples demonstrated the formation of cell clusters which 
stained positively for calcium deposits, indicative of osteogenic differentiation 
(Figure 3.14). The clusters were large and distinct with dark red centres indicating 
dense deposits of calcium. Surrounding cells which had not undergone 
differentiation could be clearly seen with visually distinct fibroblast-like 
morphology and no uptake of Alizarin Red (Figure 3.14).  
 
A B 
C D 
E  
Figure 3.14. Adipose derived stem cells from four horses following osteogenic 
differentiation stained with Alizarin Red, A – LH4, B – LH6, C – PM1, D – PM13, E – 
control, Phase contrast microscopy. (10 x magnification). White arrows indicate 
Alizarin Red staining, black arrows indicate non-stained fibroblast-like cells. 
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All four ADSC samples appeared to have similar efficiencies for osteogenic 
differentiation as similar cell cluster formation, region of staining and staining 
intensity were observed (Table 3.15) (see scoring methodology Table 2.10).  
 
Table 3.15. Stain and cluster grade for osteogenic differentiated adipose derived stem 
cells from two live horses (LH4 and LH6) and two post-mortem horses (PM1 and 
PM13). 
Horse Cluster size Region of 
staining 
Staining intensity 
LH4 3 2 2 
LH6 3 2 2 
PM1 3 2 2 
PM13 3 2 1 
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3.6.3.2 EFFICIENCY OF BONE MARROW DERIVED STEM CELLS 
Morphological changes in five BMSC samples were seen as early as day three after 
exposure to osteogenic differentiation medium. The BMSCs had the tendency to 
pull away from a monolayer distribution into clusters of cells (Figure 3.15). By day 
six a high proportion of cells had detached from the well surface and clusters of 
fibroblast-like cells could be seen throughout the well. Dense clusters of cells had 
formed by day nine and areas of single fibroblast-like cells could also be seen 
throughout the well.   
 
A B 
 C D 
Figure 3.15. Stages of osteogenic differentiation (BMSC) A - Day 0, pre-activation, black 
arrow indicates near-confluent fibroblast-like cells, B - Day 3 after activation, black 
arrow indicates cells pulling away from a monolayer, C - Day 6 after activation, black 
arrow indicates detached cells resettled on well surface, dashed black arrow indicates 
formation of cell clusters, D - Day 9 after activation, black arrow indicates dense 
cluster of cells, white arrow indicates single fibroblast-like cells. Phase contrast 
microscopy. (10 x magnification). 
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A B 
C D 
E  
Figure 3.16. Bone marrow derived stem cells from five horses following osteogenic 
differentiation stained with Alizarin Red. A – LH2, B – LH3, C – LH4, D – LH5, E – LH6. 
Phase contrast microscopy. (10 x magnification). White arrows indicate Alizarin Red 
staining, black arrows indicate non-stained fibroblast-like cells. 
 
Bone marrow derived stem cells demonstrated variable degrees of osteogenic 
differentiation (Figure 3.16). Although all five samples stained positively for 
calcium deposits, the intensity of the staining was variable and the formation of 
distinct osteogenic clusters was also variable (Table 3.16). Live horse two (LH2), 
LH4 and LH5 received higher grades compared to the two remaining samples (LH6 
and LH3) due to the formation of medium sized but distinct clusters which stained 
positively for calcium deposits (Figure 3.16). Live horse six (LH6) demonstrated 
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small cell clusters which stained positively, while LH3 had no distinct clusters. 
Interestingly, the LH3 sample stained a pale pink, indicating deposits of calcium in 
the monolayer of cells. 
 
Table 3.16. Stain and cluster grade for osteogenic differentiated bone marrow derived 
stem cells. Live horse two (LH2), live horse three (LH3), live horse four (LH4), live horse 
five (LH5) and live horse six (LH6). 
Horse Cluster size Region of 
staining 
Staining intensity 
LH2 2 2 3 
LH3 1 2 1 
LH4 2 2 1 
LH5 1 2 3 
LH6 2 2 1 
 
Osteogenic efficiency appeared to be similar for ADSC and BMSC samples. The 
uptake of Alizarin Red stain displayed similar distribution within the wells, and 
although the formation of cell clusters was more distinct in the four ADSC samples, 
two of the BMSC samples (LH2 and LH5) displayed intense staining with Alizarin 
Red for calcium deposits.  
 
3.6.4 DIFFERENTIATION EFFICIENCY SUMMARY 
The differentiation assays were carried out to compare the capacity of ADSCs and 
BMSCs to differentiation into three cell lineages. The results described in sections 
3.6.1, 3.6.2 and 3.6.3, obtained through the use of semi-quantitative scoring 
systems, were analysed using a two sampled unpaired T-Test with unequal 
variance. It appears that ADSCs differentiate more efficiently than BMSCs into 
adipogenic lineage (P=0.026) and BMSCs differentiate more efficiently into 
chondrocyte lineage than ADSCs (P=0.042). No significant difference was found 
between ADSC and BMSC osteogenic differentiation (Table 3.17).  
 
 
Chapter 3  Results 
99 
 
Table 3.17. Comparison of adipose derived stem cells (ADSC) and bone marrow 
derived stem cells (BMSC) total differentiation grade. Data: mean (SEM). Adipogenic 
and osteogenic data is from all ADSC samples and three BMSC samples (LH2, LH3 and 
LH5). Chondrogenic data from LH3, LH4 and LH6.  
Cell type  Adipogenic 
grade average 
 
Chondrogenic 
grade average 
Osteogenic grade 
average 
ADSC  8.25 (0.25) 7.50 (.5) 6.75 (0.25) 
BMSC  5.33 (0.52) 10.33 (.3) 5.66 (2.33) 
P value = 0.026 =0.042 = 0.358 
 
In summary, there were significant tissue dependent differences in differentiation 
efficiencies for adipogenic and chondrogenic lineages between the two sources of 
MSCs. No significant difference in osteogenic differentiation efficiency was found. 
The ability of BMSCs to differentiate efficiently into osteocytes and chondrocytes, 
suggests that this source of MSCs may have potentially higher therapeutic benefit 
for treating lameness in horses than ADSCs.   
 
3.7 GENE EXPRESSION 
Gene expression was carried out using mRNA extracted from samples that were 
undifferentiated and from samples undergoing differentiation into adipogenic, 
chondrogenic and osteogenic lineages as displayed in Table 2.12. Undifferentiated 
samples served as controls for measuring upregulation of differentiation markers 
as well as to investigate the levels of expression of stemness markers. The 
housekeeping gene B2M was used as an endogenous control. Due to the high 
number of cells detaching during adipogenic and osteogenic differentiation, 
mRNA was extracted on day six for adipogenic cells and day seven for osteogenic 
cells. Extraction of mRNA from chondrogenic cells occurred at day eight. Stemness 
in equine MSCs was investigated using Oct4 and Nanog as positive markers of 
stemness while CD34 was used as a negative marker of stemness. The expression 
of four tissue specific differentiation markers, PPARγ2 for adipogenesis, SOX9 for 
chondrogenesis and RUNX2 and SPP1 for osteogenesis, was investigated to 
determine whether these genes were upregulated during differentiation.  
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The fold increase in gene expression during differentiation for ADSCs is displayed 
in Table 3.18 and in Table 3.19 for BMSCs. Gene expression is relative to the house 
keeping gene B2M for each sample.    
 
Table 3.18. Fold increase in gene expression for trilineage differentiation in adipose 
derived stem cells from four different horses relative to the housekeeper B2M. 
Gene Fold increase in gene expression relative to B2M for each sample 
 LH4 LH6 PM1 PM13 
PPARγ2 0.000 2.431* 0.094 0.000 
RUNX2 0.404 0.492 0.261 1.701 
SPP1 0.140 1.155 0.633 3.732* 
SOX9 0 0 0.072 0.118 
PPARγ: adipogenic differentiation, RUNX2, SPP1: osteogenic markers, SOX9: chondrogenic 
marker. 
*Fold increase over 2 demonstrated upregulation of a gene 
 
Table 3.19. Fold increase in gene expression for trilineage differentiation in BMSCs 
relative to the housekeeper B2M 
Gene Fold increase in gene expression relative to B2M for each sample 
 LH2 LH3 LH4 LH5 LH6 
PPARγ2 0 0 0 0 0 
RUNX2 4.523* 11.417* 3.498* 10.229* 4.731* 
SPP1 0.323 28.341* 3.220* 1.273 6.987* 
SOX9 0 28.828* 3.272* 0 0 
PPARγ: adipogenic differentiation, RUNX2, SPP1: osteogenic markers, SOX9: chondrogenic 
marker. 
*Fold increase over 2 demonstrated upregulation of a gene 
 
3.7.1 OCT4 EXPRESSION 
Oct4 is a pluripotent marker required for self-replication and pluripotent 
differentiation. The positive expression of Oct4 has been found in some studies of 
equine MSCs, however, there have been conflicting results as to whether this 
marker is a reliable indicator of stemness in multipotent cells. In the present study, 
no relative expression of Oct4 could be detected using RT-PCR in any of the ADSC, 
BMSC or pBSC samples. The results found in the present study imply that this 
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pluripotent marker may not be suitable for identifying stemness in equine 
multipotent stem cells from AT, BM, or pB.  
 
3.7.2 NANOG EXPRESSION 
Nanog is a pluripotent marker required for self-replication and multilineage 
differentiation. Similarly to Oct4, Nanog expression has been found in equine 
MSCs although variable expression of this marker has been reported. In the 
present study, Nanog was found to be expressed by an undifferentiated ADSC 
sample (LH4). This expression disappeared when the cells underwent 
differentiation in the trilineage assay. As with Oct4, the results of the present study 
imply that this pluripotent marker may not be suitable for identifying stemness in 
equine multipotent stem cells from AT, BM, or pB. 
 
3.7.3 CD34 EXPRESSION 
The hematopoietic marker CD34 is positively expressed in hematopoietic stem 
cells but is thought to be negatively expressed in equine MSCs. Due the negative 
expression of this marker, it is widely used as a negative marker of stemness. In 
the present study, all of the BMSCs were found to be negative for CD34 expression, 
this was an encouraging finding as the BM contains a well characterised 
population of CD34+ hematopoietic cells. The negative expression of CD34 in the 
BMSCs in the present study indicates that the samples used were free of 
hematopoietic precursor cells. However, one undifferentiated ADSC sample 
(PM13) had positive expression of CD34. 
 
3.7.4 PPARγ2 EXPRESSION 
Peroxisome proliferator-activated receptor gamma 2 is an adipogenic 
differentiation marker upregulated as early as day six after adipogenic induction 
although expression is highest towards the end of differentiation. This marker is a 
key positive transcriptional regulator of adipogenesis and triggers the expression 
of additional adipogenic genes required for lipid accumulation.  Although mRNA 
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from adipogenic samples was collected on day six after adipogenic induction, 
PPARγ2 was not found to be widely expressed. Indeed, only one ADSC sample 
(LH6) expressed for PPARγ2 (Table 3.18) and no expression of PPARγ2 was found 
in any of the BMSC samples (Table 3.19). The day of mRNA collection may have 
preceded the upregulation of PPARγ2, particularly in the BMSC samples which did 
not appear to differentiate efficiently into adipocytes and may be associated with 
delayed upregulation of adipogenic transcription factors. The extensive lipid 
accumulation displayed in the ADSC sample from LH6 (Figure 3.4) may therefore 
be due to the earlier upregulation of PPARγ2 found in this sample.  
 
3.7.5 SOX9 EXPRESSION 
The primary transcription factor involved with chondrogenic differentiation is 
thought to be SOX9. This marker is responsible for early activation of cells into 
chondrocytes and maintaining the commitment of cells towards the chondrogenic 
lineage. In spite of the essential role SOX9 plays throughout chondrogenic 
differentiation, expression of this marker was only seen in two BMSC samples (LH3, 
LH4) following chondrogenic differentiation (Table 3.19) while no expression was 
seen in any of the ADSC samples (Table 3.18).  
  
3.7.6 RUNX2 EXPRESSION 
Runt-related transcription factor two is expressed during early osteogenic 
differentiation and precedes the expression of additional transcription factors, 
necessary for osteogenic differentiation to occur. The present study found that 
while RUNX2 was expressed in all of the BMSC samples on day seven after 
osteogenic induction (Table 3.19), no expression of RUNX2 in ADSC samples was 
detected (Table 3.18). The expression of this early osteogenic marker in all of the 
BMSC samples indicates that BMSCs differentiate into osteocytes at a lower rate 
than ADSCs. Indeed, the day of mRNA collection may have been after the peak of 
RUNX2 had occurred in the ADSC samples.  
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3.7.7 SPP1 EXPRESSION 
Secreted phosphoprotein 1 (SPP1) is an additional early osteogenic marker widely 
used for analysing osteogenic differentiation. The expression of this marker was 
found in three of the BMSC samples (Table 3.19) and in one of the ADSC samples 
(Table 3.18). This marker is preceded by RUNX2 and the expression of SPP1 in the 
single ADSC sample, compared to the expression seen in the three BMSC samples, 
indicates that osteogenic differentiation may occur at different rates for the two 
cell sources. 
 
3.7.8 COMPARISON OF MATCHED ADIPOSE DERIVED AND BONE MARROW 
DERIVED STEM CELL SAMPLES 
The ADSC and BMSC samples from the same horse were compared to see if any 
differences could be observed (LH4: Figure 3.17, LH6: Figure 3.18). It appears that 
BMSCs have a higher relative expression of markers for osteogenic differentiation 
(RUNX2 and SPP1) than ADSCs. Relative expression of SOX9 was increased in LH4 
BMSC chondrocytes but not in LH4 ADSCs. There was no expression of SOX9 in LH6 
ADSC or LH6 BMSC chondrocytes. An increase in PPARγ2 relative expression was 
seen for LH6 ADSC (2.431), however, this was the only MSC sample to show a fold 
increase in PPARγ2 expression following adipogenic differentiation.  
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Figure 3.17. Gene expression. Comparison of adipose derived stem cells (ADSC) and 
bone marrow derive stem cells (BMSC) from LH4 during differentiation into 
adipocytes, chondrocytes and osteocytes. 
 
 
Figure 3.18. Gene expression. Comparison of adipose derived stem cells (ADSC) and 
bone marrow derived stem cells (BMSC) from LH6 during differentiation into 
adipocytes, chondrocytes and osteocytes. 
 
In summary, the pluripotent markers Oct4 and Nanog were not consistently 
expressed in ADSC and BMSC samples. Oct4 was not expressed in any samples 
while Nanog was expressed in only one undifferentiated ADSC sample. This implies 
that pluripotent markers are not widely expressed by equine MSCs. The 
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hematopoietic marker CD34 was expressed in one ADSC sample but was not 
expressed in any of the BMSC samples. Despite displaying better morphological 
differentiation when compared to BMSCs, only one ADSC sample expressed 
PPARγ2 during adipogenic differentiation, with no expression in any of the BMSC 
samples. On the other hand, BMSCs exhibit higher upregulation of osteogenic and 
chondrogenic markers than ADSCs during differentiation. 
 
Expression of these markers at protein level was not investigated in the present 
study and as such, the results indicating expression at mRNA level need to be 
interpreted with caution. Although it has been reported that gene expression can 
carry through to protein level this is highly gene dependent and mixed results have 
been reported for the markers used in this study. 
 
3.7.9 GENE EXPRESSION AND DIFFERENTIATION STAINING 
The correlation between morphological differentiation and relevant gene 
expression was investigated. No correlation between gene expression and 
histological grade of differentiation could be found. However, this may be due to 
the day on which the mRNA was isolated for analysis.  
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CHAPTER 4: DISCUSSION  
Mesenchymal stem cells have been used in recent years for the treatment of 
various diseases and injuries in humans (Wilson et al., 2011), dogs (Guercio et al., 
2012) and horses (Richardson et al., 2007) due to their ability to self-renew and 
differentiate (Marfe et al., 2012). Multiple sources have been identified for the 
isolation of equine MSCs (Barry and Murphy, 2004). Adipose tissue and BM are 
two sources which have been used extensively for routine MSC harvest and 
therapeutic application (Schnabel et al., 2013; Vidal et al, 2008). Peripheral blood 
derived stem cells have been used to a lesser extent and has had mixed success 
reported in the literature in terms of culturing success (Giovannini et al., 2008; 
Koerner et al., 2006). What appears to be lacking in the literature is a standardised 
approach for identifying stem cells isolated from various sources. Although the 
ability to adhere to a culture vessel, differentiate into multiple lineages and 
express for markers of ‘stemness’ are the current requirements for MSC 
identification, some therapeutic approaches do not use a validated approach to 
determine whether the cells isolated from raw tissue are indeed MSCs (Schnabel 
et al., 2013). Due to the lack of verification, it is difficult for veterinary practitioners 
to confidently recommend the harvesting of a specific tissue to isolate MSCs for 
treatment. A comparison of MSCs isolated from AT, BM and pB, and their capacity 
into different cell fates in vitro, would therefore confirm whether the cells 
routinely harvested for stem cell therapy do indeed display the criteria to be 
characterised as MSCs. 
4.1 MAIN PROJECT 
4.1.1 ISOLATION OF MESENCHYMAL STEM CELLS FROM DIFFERENT TISSUES 
The isolation of AT, BM and pB required three specialised approaches for tissue 
harvesting. There were tissue specific advantages and disadvantages in terms of 
animal welfare and collection practicality.  
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Adipose tissue collection was an invasive procedure and had the highest perceived 
levels of surgical morbidity. Even so, the horses recovered well from the procedure 
and only one horse developed complications, a small abscess that resolved quickly 
with treatment. The scarring from the surgery was minimal and less obvious than 
expected. The use of an ultrasound to identify pockets of adipose tissue was 
particularly advantageous. The surgeons were able to make a small incision 
directly over a dense layer of fat, resulting in faster and more efficient tissue 
recovery. Of the six horses in the study, AT was collected from five individuals. The 
horse which did not have available adipose tissue was a thoroughbred of light 
build. This implies that adipose tissue collection may not be a viable option for 
owners of light or lean horses. Specialised breeds of horse, such as thoroughbreds 
and standardbreds, may have minimal fat deposits while in training due to 
rigorous exercise regimes. For horses with minimal fat deposits available, bone 
marrow collection may be a viable alternative for obtaining tissue for stem cell 
isolation.  
 
Three of the horses used for live tissue collection were euthanized later, for 
reasons unrelated to the project. The opportunity was taken to observe how the 
adipose tissue harvest site had healed. The tissue surrounding the incision was 
deeply mottled and purplish in colour indicating tissue necrosis. On consideration 
of the surgical procedure, the region of discoloured tissue reflected the inverted 
L-block pattern used by the veterinarians to inject local anaesthetic. Local 
anaesthetic is required to prevent the animal suffering during the procedure but 
is associated with tissue damage (B. Fraser, personal communication, March 18, 
2013). Therefore, AT harvesting is associated with unavoidable surgical morbidity.  
 
Human ADSCs are routinely isolated from lipoaspirate sampling (Dubois et al., 
2008). The use of liposuction may potentially be used for the collection of equine 
AT in an attempt to reduce surgical morbidity. It has been suggested by Dubois et 
al. (2008) that only minor modifications of human liposuction protocols are 
required to enable liposuction in other species.  An investigation into the use of a 
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modified liposuction technique for equine AT harvest would determine if this 
approach is a viable alternative to open surgery. 
 
Bone marrow aspiration from the sternum has associated risks due to the close 
proximity of the collection site to the heart. A biopsy needle inserted too deeply 
into the sternum could potentially have fatal consequences. No complications 
occurred during BM collection due to the experience of the veterinarian team. 
Indeed, this became the preferred method of tissue collection for the 
veterinarians involved with this project.  
 
Of the three tissue types collected, pB was the least invasive and caused little 
impact on animal welfare. Repeated samples can be taken from the same animal 
without unnecessary distress and, due to the large body mass of the horse, large 
volumes of blood can be isolated at one time without impacting negatively on the 
health of the animal.  
 
The number of MNCs isolated from raw tissue samples was compared. Bone 
marrow aspirate yielded the highest number of MNCs from 10ml of raw aspirate 
however, the MNC yield difference between the three tissue types was not 
significantly different. The number of MNCs isolated from AT, BM and pB is 
comparable to the isolation counts reported by Burk et al. (2013). Although the 
number of AT MNCs isolated in the present study was slightly lower than reported 
by Burk et al. (2013), the cells from both studies reached confluence at similar 
rates. This indicates that the proportion of MSCs per ml of raw tissue may indeed 
have been higher in the present study.  
 
Interestingly, the variability seen between donors and within donors for AT MNCs 
collected in the present study was similar. Bone marrow MNC and pB MNC counts 
showed high variability within and between horses, while AT MNC counts 
remained comparable. Mononucleated cells yielded from AT appeared to have a 
wider variability between horses in the literature (Burk et al., 2013) than seen in 
the present study. Cell count variability seen between repeated samples of BM 
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from the same horse may be due to uneven distribution of MNCs within the 
marrow. The variability reported in this project and in the literature suggests that 
each horse has wide variability of MNC concentrations within the sternum. 
Kasashima et al. (2011) reported an insertion site dependent yield of MSCs from 
BM aspirate. Additionally, Kasashima et al. (2011) also reported that the first 5ml 
of aspirate contained the densest concentration of MSCs. Variability of isolation 
counts may be due to where the biopsy needle is inserted and where the cell 
clusters are located in each horse. Bone marrow isolated in the present study was 
aspirated from either the 5th and 6th sternebrae. Isolation from either sternebrae 
appears to be suitable for equine BMSC harvesting. Although MSCs appear to be 
unevenly distributed within the marrow, this does not appear to impact on total 
MSC isolation success, as all of the BM samples collected from the six horses in 
this project reached P0 confluence.  
 
The jugular vein is an easily accessible source of pB for MNC isolation. The average 
yield of pB MNCs has been reported as approximately 12-24 x 105 cells/ml of pB 
(Dhar et al., 2012), however, a lower variability in MNCs per 10ml of pB was seen 
in the present study. Dhar et al. (2012) used a Ficoll method of cell isolation while 
the current study used a Lymphoprep method. Although the density of both 
gradients are the same, additional methodology was not reported by Dhar et al. 
(2012) and a more thorough comparison of culture techniques could not be 
carried out. The collection of pB for the isolation of MSCs is less well established. 
Generally, pB is processed in a similar manner to BM using Ficoll (Koerner et al., 
2006; Giovanini et al., 2008; Martinello et al., 2011) and Percoll gradients (Spaas 
et al, 2012) or lymphocyte separation media (Dhar et al, 2011).  The protocol used 
in this project consistently obtained a MNC fraction from 40ml of pB, however, the 
MSC component of the cell fraction was not able to attach and proliferate in any 
of the live samples.  
 
Overall, adipose tissue appears to be a stable source of MNCs, while BM and pB 
MNC yields can vary considerably between and within individuals. 
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Body condition can significantly impact on the volume of AT available for harvest. 
As previously mentioned, one of the horses used in this study was of light build 
and no AT could be found at the typical site of collection. Health status may affect 
the number of MSCs available in BM and pB, and potentially AT if weight loss has 
occurred due to illness. A previous study looking at MNC yield from BM aspirate in 
human leukaemia patients compared to healthy individuals showed a decreased 
yield of MNCs from compromised individuals (Jing et al., 2011). Interestingly, 
although the initial yield of MNCs was decreased, the proliferation rate of 
leukaemia patient MSCs was comparable to healthy patient MSC proliferation 
rates, indicating that donor health may not affect in-vitro behaviour of BMSCs. As 
all of the horses used for the present study were of good health, no comparison 
of health status on cell recovery was made. 
 
While performing the cell count at isolation, a viability assessment using trypan 
blue dye was carried out to determine the percentage of live cells within the 
freshly isolated cell population (Methodology: 2.3.4). The viability of freshly 
isolated cells was found to be significantly higher for BM MNCs and pB MNCs than 
for AT MNCs (P<0.05). This may be due to the more extensive processing that AT 
undergoes compared to BM and pB. Adipose tissue processing requires a number 
of washes before and after collagenase digestion which can be damaging to cells. 
The enzymatic digestion used for processing raw AT can also cause damage to the 
cells. Although the initial viability of AT MNCs was significantly lower than the 
viability of BM and pB MNCs, this did not appear to affect ADSC culture success. 
Indeed, the cells isolated from AT appeared to be considerably robust once in 
culture. Although the viability in AT MNCs was significantly lower than BM and pB 
MNCs, it still had a 93% viability, which indicates a high percentage of live cells.  
 
It appears that the count at isolation does not provide a definitive guide to how 
fast a sample may reach confluence. Indeed, the isolation count can only provide 
an indication of MNC concentrations and it is only at the first confluence count 
that we can begin to evaluate what proportion of those MNCs are indeed MSCs. 
Primary cell culture demonstrated that AT contains a significantly higher 
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proportion of MSCs than BM from the same size volume of raw tissue.  Across the 
literature, it appears that AT yields a higher quantity of adherent fibroblast-like 
cells (Ahern et al., 2011; Burk et al., 2013; Kern et al., 2006; Ranera et al., 2012) 
than BM. This observation complements the findings of the present study as 
ADSCs reached confluence on average 9.5 days faster than BMSCs and yielded a 
higher population of cells at confluence. This rapid proliferation rate of ADSCs is 
thought to be due to the higher density of MSCs found in raw AT (Ahern et al., 
2011). Indeed, the MNC fraction isolated from one ml of raw AT contained an 
estimated 53% of MSCs capable of adherence and expansion. The MNC fraction 
isolated from BM aspirate contained only 11% of MSCs per ml of raw BM.  
 
The pBSCs from two post-mortem blood samples were cultured and counted at 
confluence, however, it was observed that the cells had a tendency to clump 
during trypsinisation making it difficult to obtain an accurate count. This clumping 
may be linked to the unusual cluster-like growth pattern seen in both pBSC 
samples during culture. These cells adhered and displayed fibroblast-like 
morphology, although the mRNA from the samples did not express any markers 
of stemness. Therefore, the stem cells isolated from pB in this project may not 
necessarily be termed as mesenchymal without further validation.  
 
Interestingly, two different types of media were used to culture pBSCs, DMEM F12 
with 20% FBS and DMEM-high glucose with 20% FBS. Peripheral blood stem cells 
were able to be grown in both types of media however, differences were seen in 
the proliferation rate of the two cell samples. The sample cultured in DMEM F12 
reached confluence considerably faster than the sample cultured in DMEM HG. 
However, more work is required to determine whether DMEM F12 or DMEM HG 
is the superior medium for pBSC culture.  
 
Peripheral blood stem cell culture demonstrated initial cell attachment followed 
by progressive cell detachment.  The use of laminin as a matrix did not assist with 
cell attachment and the two samples which reached confluence were grown in 
Nunclon™ Delta treated flasks. Delta is a proprietary cell culture surface treatment 
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used to improve the adhesion ability of a range of cell types. Successful culturing 
of pBSCs may require a comparative study of various combinations of matrixes and 
reagents to determine the optimal culture conditions for pBSCs to efficiently reach 
confluence. A number of authors have demonstrated that pBSCs are capable of 
trilineage differentiation (Dhar et al., 2012; Giovannini et al., 2008) and express 
markers of pluripotent stem cells (Marfe et al., 2012). These findings suggest that 
pB can be used as a source of MSCs, and highlights the need for future research in 
pB cell culture to determine the optimal culture conditions for this easily 
accessible source of MSCs. However, whether this source of MSCs will ever be 
comparable to AT and BM is currently unknown.  
 
In comparison to ADSCs and BMSCS, the two post-mortem pBSC samples took an 
average of 26.5 days to reach confluence while ADSCs and BMSCs from live 
samples took an average of 5.5 and 15 days to confluence respectively. With this 
in mind, MSCs isolated from AT and BM may still prove to be a superior source of 
MSCs than pB due to the extensive time required for the blood derived samples to 
reach confluence. 
 
Of the two sources of live stem cells that reached confluence, raw AT contained a 
significantly higher percentage of MSCs than raw BM. In terms of using MSCs for 
therapeutic application, the tissue type with the highest proportion of MSCs at 
isolation would likely be the optimal cell source for immediate transfer. However, 
further research is required to verify the therapeutic benefit of injecting freshly 
isolated cells from raw tissue. 
 
The current stem cell treatment kits available on the market, Regeneus Adicell and 
Stem Vet NZ Ltd, use freshly isolated stem cells from adipose tissue for immediate 
transfer into animal patients. This suggests that ADSCs are of greater potential 
benefit than BMSCs or pBSCs when using primary cells for treatment. The higher 
concentration of MSCs in the AT MNC fraction is correlated to reduced time in 
culture as the isolated ADSCs reached confluence significantly faster than BMSCs. 
Therefore, not only are ADSCs potentially a more suitable candidate for immediate 
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transfer, they can also be amplified within five days of raw tissue extraction and 
used for cell therapy.  
 
Bone marrow derived stem cells are found in lower concentrations and require 
additional time to reach confluence, however, these cells can be amplified and 
used for cell therapy in approximately 15 days after raw tissue isolation. Currently, 
it is unknown at what point in time after an injury has occurred that cell therapy 
should be applied (Smith et al., 2003). It has been suggested that stem cell therapy 
should be carried out soon after an injury has occurred but a specific interval of 
time has not been established (Godwin et al., 2011 cited in Burk et al., 2013). Smith 
et al. (2003) injected cultured BMSCs into a five week old superficial digital flexor 
tendon injury and suggested that a delay between injury and cell therapy may be 
advantageous as angiogenesis and granulation tissue formation may assist MSCs 
by forming a ‘graft bed’. If further research indicates that there is a wide window 
of time where stem cell treatment is effective, then the differences seen between 
ADSC and BMSC culture would become less significant.  
 
The superiority of ADSCs in culture continued through to secondary culturing. 
Adipose derived stem cells yielded a significantly higher number of cells at 
confluence than BMSCs from the same seeding density. This finding is supported 
by the literature in which ADSCs are found to be superior to BMSCs for both the 
total number of cells and cell doubling time (Burk et al., 2013; Colleoni et al., 2009).  
 
Of the six BMSC samples cultured, only five reached passage one. One sample 
could be cultured to confluence but when replated, the cells failed to attach to the 
flask surface. Interestingly, the ADSC and BMSC samples reached confluence at 
similar rates, however, the number of cells counted at confluence was significantly 
different. This may be due to the subjective nature of assessing confluence, which 
is influenced by experience and personal judgement. Due to an increase in 
experience as the project progressed, my assessment of confluence became more 
accurate. Additionally, the size of the individual cells in culture may vary with 
tissue source. As there was a consistently lower count of BMSCs, these cells may 
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indeed have been larger than ADSCs and reached confluence at a similar day but 
with a lower number of larger cells. 
 
Mesenchymal stem cells can only be maintained in culture for a limited number of 
passages before the ability to self-replicate is lost and the population undergoes 
senescence. Culturing of MSCs therefore aims to expand the number of cells in 
culture through dividing the population, replating and expanding the cells to 
confluence through a minimal number of passages. When culturing for 
therapeutic application, cells can be passaged two or three times to retain a 
portion of the population for storage while being able to supply cells for 
treatment. The ADSC and BMSC samples used for differentiation in the present 
project were able to be passaged six times. For veterinary purposes, the 
amplification of cells to passage six would provide ample amounts of cells for 
treatment and storage. The duration of time in culture before senescence occurs 
is reportedly greater in ADSCs compared to BMSCs (Vidal et al., 2012). Burk et al. 
(2013) compared five sources of equine MSCs, including AT and BM. In this 
experiment, AT and BM cells were passaged eight times, with all of the ADSC 
samples reaching passage eight, while only three of the ten BMSC samples 
reached passage eight.  On the other hand, Braun et al. (2010) reported that only 
two of six ADSC samples could be cultured to passage nine which conflicts with 
the results reported by Burk et al. (2013). Although there are conflicting results 
reported in the literature, it would appear that BMSCs have a more limited number 
of passages in culture than ADSCs, however, the present study found that both 
ADSCs and BMSCs were able to be passaged six times without any detrimental 
effect on cell plasticity.  
 
Cryopreservation 
All of the ADSC, BMSC and pBSC samples that reached confluence were 
cryopreserved in 20% FBS and 5% DMSO. A slow freeze and rapid thaw protocol 
resulted in viable ADSCs, BMSCs and pBSCs. All samples reached confluence 
following thawing, demonstrating that cryopreservation can be used to store 
MSCs from AT, BM and pB for future use. Although cryopreservation impacts on 
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cell viability at thaw, the ADSCs and BMSCs recovered from liquid nitrogen storage 
demonstrated cell proliferation, fibroblast-like morphology and trilineage 
differentiation. Thawed pBSCs were able to be amplified after long term storage 
in liquid nitrogen and retained fibroblast-like morphology when placed back into 
culture. The effect of cryopreservation on pBSC differentiation capacity was not 
determined due to the small number of samples available.  
 
The ability to collect a single sample of raw tissue, either AT or BM, amplify the 
MSC population and store the cells for future use is a particularly advantageous 
aspect of MSC culture. Storage of cells for successive treatments negates the need 
to re-harvest tissue, thereby avoiding putting horses through repeated surgery 
and risk, while reducing the cost for the owner.  
 
The ability to cryopreserve MSCs for long term storage is supported by the 
literature. Preservation of MSC characteristics have been reported for ADSCs 
(Mambelli et al. 2009; Ranera et al., 2011; Vidal et al., 2008) BMSCs (Berg et al., 
2009; Ranera et al., 2011) and pBSCs (Martinello et al., 2010) after 
cryopreservation of approximately four weeks. As there are reports of DMSO 
causing adverse reactions in patients receiving thawed cells, a thorough washing 
protocol, or culturing the cells before transfer is recommended (Hunt, 2011).  
 
Adipose derived stem cells from post-mortem collections were used to investigate 
two different concentrations of cryopreservation medium (Appendix 1) on cell 
viability at thawing. A combination of 90% FBS with 5% DMSO and 20% FBS with 
5% DMSO was compared. No significant difference was found between the two 
media, however, a cryopreservation medium containing 20% FBS would be the 
most cost-effective storage approach.  
 
Overall, the cryopreservation phase of the project supports the possibility that 
equine MSCs from AT and BM can be frozen for future therapeutic use. 
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Differentiation 
The differentiation phase assessed the trilineage differentiation capacity of ADSCs 
and BMSCs. Peripheral blood derived stem cells were not assessed as there were 
not enough samples to carry out a statistically valid assay. The samples used for 
differentiation are displayed in Table 2.7. 
 
One of the main features of MSCs is their trilineage differentiation potential. 
Adipose derived stem cells and BMSCs were differentiated into adipocytes, 
chondrocytes and osteocytes to assess multipotency. Adipogenesis was confirmed 
by using the fluorescent stains BODIPY and by measuring the expression of the 
adipogenic marker, PPARγ2. Chondrogenic differentiation was confirmed by 
sectioning the pellets and staining with Alcian Blue to highlight deposits of GAGs. 
The mRNA isolated from pellets during differentiation was measured for 
expression of the chondrogenic marker SOX9. Osteogenic differentiation was 
confirmed by staining with Alizarin Red and measuring the expression of two 
osteogenic markers, RUNX2 and SPP1.  
 
Adipogenic differentiation 
In the present study, a superior adipogenic differentiation efficiency was seen in 
ADSCs when compared to BMSCs. Adipogenic differentiation occurred in all of the 
ADSC and BMSC samples although not all BMSC samples differentiated equally. 
The four ADSC samples showed a high proportion of adipogenic differentiation 
based on the number of adhered cells containing lipid vesicles and the size and 
distribution of lipid vesicles within the cells. The nuclei of the individual cells was 
visible and surrounded by lipid deposits. The five BMSC samples showed a lower 
efficiency for adipogenic differentiation than ADSCs with two samples showing 
poor lipid deposits. The triplicate design of the assay showed high variability in the 
distribution of cells across the surface of the wells for ADSCs and BMSCs. At the 
beginning of the assay, prior to differentiation, the cells had reached 80% 
confluence and were evenly distributed in the wells. However, by the end of the 
assay, many of the cells had lifted and only small patches of cells remained 
attached. 
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The gene expression for adipogenic differentiation was evaluated on day six 
following activation with adipogenic induction medium. Although PPARγ2 is 
expressed highest at the end of adipogenesis (Ranera et al., 2012), an increase in 
expression can reportedly be seen after six and seven days in adipogenic medium 
(Braun et al., 2010, Bracegirdle et al, submitted). Although mRNA collection was 
originally planned for day eight, due to the large amount of cells detaching from 
the well surfaces, mRNA collection was moved forward two days to ensure there 
would be an adequate amount of mRNA for analysis. The earlier mRNA extraction 
date may account for the lack of PPARγ2 expression in eight of the differentiated 
samples. Only one ADSC sample demonstrated an upregulation in PPARγ2 even 
though all of the ADSC samples differentiated efficiently. This particular sample 
also received the highest grade for adipogenic differentiation due to the high 
density of large lipids deposited within the cells. The early upregulation of PPARγ2 
in this sample may account for more extensive differentiation seen at the end of 
the adipogenic assay.  
 
The cell fraction isolated from raw adipose tissue contains a mixture of cells 
including fibroblasts and preadipocyte cells. Preadipocytes are capable of self-
replication and are thought to be in a committed state of adipogenic 
differentiation (Cawthorn et al., 2012). As higher numbers of these pre-committed 
cells are likely to be found in AT MNCs than in BM MNCs, the increased adipogenic 
differentiation capacity of ADSCs may be due to the presence of preadipocytes in 
the cell sample.  
 
Chondrogenic differentiation 
All of the ADSCs and BMSCs samples aggregated into hard pellets during the 
chondrogenic differentiation assay, indicative of chondrocyte development. A 
tertiary structure is required for chondrogenic differentiation to occur and cell 
clusters are created prior to differentiation stimulation by micromassing 
undifferentiated cells. The structure of chondrogenic pellets is used as a measure 
of differentiation (Vidal et al., 2008) and as such, this parameter is an important 
indicator of chondrogenic efficiency. The pellet structure of control and treated 
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pellets were compared. Treated pellets appeared to develop into defined 
aggregates of cells while control pellets displayed less uniform aggregates. It 
appears that the presence of TGF-β1 is an important supplement for tertiary 
structure development in chondrocytes. Ten pellets, including control and treated 
pellets, were sectioned to compare the extent of GAG deposits and lacunae 
formation in ADSCs and BMSCs. The pellets used for sectioning were from live 
horse three (BMSCs), live horse four (ADSCs and BMSCs) and live horse six (ADSCs 
and BMSCs). The sample from live horse three was sectioned due to the high level 
fold increase in SOX9 expression. The sectioned BMSC pellets showed greater 
chondrogenic differentiation efficiency than ADSC pellets. Alcian Blue staining was 
more intense in BMSC pellets and there was a greater proportion of lacunae. 
Adipose derived stem cell pellets stained positively for GAG deposits however, the 
stain was pale and the formation of lacunae was less obvious. Additionally, the 
chondrogenic marker SOX9 was expressed in two BMSC samples but no expression 
was detected in any of the ADSC samples. One BMSC sample (LH3) had a 28.83 
fold increase change in SOX9 expression during differentiation. This pellet was 
sectioned and compared to the other sectioned BMSC pellets, one of which 
expressed SOX9 but at a lower level (3.27). Interestingly, the high fold change in 
SOX9 expression did not correlate to higher chondrogenic differentiation 
efficiency. Indeed, the only BMSC sectioned sample that did not have any 
expression of SOX9 demonstrated more defined lacunae formation and more 
intense staining of GAG deposits than the two samples with SOX9 upregulation. It 
is important to remember that mRNA expression does not necessarily translate to 
protein level. This may account for the discrepancy between histological findings 
and mRNA gene expression.   
 
Previous studies looking at chondrogenic differentiation in ADSCs and BMSCs have 
produced conflicting results. Burk et al. (2013) found that BMSCs demonstrated 
the weakest chondrogenic potential compared to cells isolated from umbilical 
cord blood, umbilical cord tissue, AT and tendon tissue. However, in a study by 
Giovannini et al. (2008), BMSCs displayed intense chondrogenic differentiation 
and Vidal et al. (2008) reported that BMSC chondrogenic potential was greater 
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than ADSC chondrogenic potential. Expression of collagen type II (COL1A2) was 
found to be higher for BMSC chondrocytes than ADSC chondrocytes (Vidal et al., 
2008). Furthermore, positive staining for GAG deposits could be seen as early as 
day three after activation in BMSC chondrocytes while GAG deposits in ADSC 
chondrocytes could only be seen from day 14.    
 
An interesting observation was the positive staining of the BMSC control pellets 
for GAG deposits. Staining in the ADSC control pellets was not seen, however a 
small amount of blue stain could be seen in all three BMSC control pellets. The 
only difference between the control and treated pellets is the exposure to TGF-β1. 
This growth factor is from a family of cytokines which regulate cell proliferation 
and differentiation and is considered to be essential for the induction and 
maintenance of chondrogenic differentiation (Goessler et al., 2005). As the 
staining in the control pellets was restricted to BMSC samples only, it may be that 
BMSCs have greater potential for chondrogenic differentiation and may begin to 
deposit GAGs even when exposed to incomplete induction medium. Nevertheless, 
chondrogenic differentiation was greater in BMSC samples exposed to TGF-β1. 
 
Osteogenic differentiation 
Osteogenic differentiation was achieved in all ADSC and BMSC samples, however 
there were clear differences between some of the BMSC samples. Adipose derived 
stem cells displayed similar osteogenic differentiation capacities, as all four 
samples formed distinctive cell clusters which stained positively for calcium. The 
BMSCs displayed localised staining of cell clusters in four of the five osteogenic 
differentiated samples. In contrast to the samples forming cell clusters, one 
sample demonstrated generalised staining of individual cells. Variability between 
individual differentiation capacities was not found to be reported in the literature. 
The differentiation grades of ADSCs and BMSCs were not found to be significantly 
different (P= 0.358), indicating that the osteogenic differentiation efficiencies of 
ADSCs and BMSCs are comparable.  
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The expression of two osteogenic markers, Runt-related transcription factor two 
(RUNX2) and secreted phosphoprotein 1 (SPP1), were analysed on day seven after 
exposure to osteogenic medium.  While RUNX2 expression in BMSC samples 
ranged from 3.49-11.41, no increase in expression was seen in any of the ADSC 
samples. The osteogenic marker SPP1 was expressed in three BMSC samples and 
in one ADSC sample. The BMSC sample (LH3) with the highest RUNX2 expression 
increase did not form any clusters, however the individual cells along the well 
surface stained positively for calcium and covered a large surface area. This sample 
also demonstrated the highest fold change of SPP1 (28.34). As all of the ADSC 
samples stained positively for calcium, osteogenic differentiation can be 
confirmed for these cells, although gene expression of specific osteogenic markers 
did not complement the histological findings. Ranera et al. (2012) showed that not 
only is RUNX2 expressed in ADSC osteocytes, it is upregulated by day three in 
activation medium. These findings are in contrast to what was observed in the 
present study. The mRNA analysis was a snapshot approach as the mRNA was 
collected from day six only. The expression of RUNX2 and SPP1 on this day may 
differ between tissue types due to tissue specific upregulation or the amount of 
cells available for mRNA collection. The expression of either osteogenic marker did 
not appear to correlate with the histological findings, however, as previously 
mentioned, mRNA does not necessarily translate to protein level and the selected 
genes may indeed have been upregulated. Furthermore, ADSCs and BMSCs may 
differentiate at different rates and as such, gene expression evaluated on the same 
day would not necessary show the same pattern for both cell sources. 
 
There appears to be a range of osteogenic differentiation observations in the 
literature and it remains unclear whether ADSCs or BMSCs have superior 
osteogenic differentiation capacity. However, what can be reported from the 
current project is that both ADSCs and BMSCs are capable of osteogenic 
differentiation. Adipose derived stem cells demonstrated higher morphological 
differentiation than BMSCs, although this was not significantly different. As BMSCs 
demonstrated superior gene expression of markers for osteogenesis, this suggests 
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that the optimal day for collecting mRNA for assessing the two osteogenic markers 
may have already passed for ADSCs.   
 
Trilineage differentiation of ADSCs, BMSCs and pBSCs has been demonstrated by 
a number of authors (Bourzac et al., 2010; Braun et al., 2010; Burk et al., 2013; 
Dhar et al., 2012; Giovannini et al., 2008; Koerner et al., 2006; Ranera et al., 2012; 
Ranera et al., 2011; Spaas et al., 2013; Vidal et al., 2007), with adipogenic, 
osteogenic and chondrogenic lineages the most commonly used lineages to 
demonstrate multipotency in equine MSCs. Additionally, tenogenic differentiation 
capacity has been established in BMSCs (Violini et al., 2009) and myogenic 
differentiation capacity has been established in pBSCs (Martinello et al., 2010).  
 
The wide range of protocols used for trilineage differentiation may account for the 
variable results reported for MSC differentiation capacity. For example, the 
protocol used by Schwarz et al. (2012) for adipogenic differentiation of equine 
ADSC, differed to the protocol used in the present project as rabbit serum was 
used instead of autologous serum.  Additionally, the passage at which the cells are 
differentiated has been found to influence differentiation success (Braun et al., 
2010). The ADSCs and BMSCs used for differentiation in this study were passaged 
four to six times before being utilized in the trilineage assay. At these higher 
passages, both cell types retained their capacity for trilineage differentiation. 
Adipose tissue derived stem cells from passage two and passage four were 
compared by Braun et al. (2010) to determine if two additional passages can effect 
differentiation capacity. It was found that chondrogenic and osteogenic lineages 
differentiated better at passage two than differentiating at passage four, although 
differentiation did occur in both groups of cells. Additionally, gene expression of 
collagen type I, II, and X (COL1AI, COL1A2, COL1A10) for chondrogenic 
differentiation and osteopontin, COL1A1 and β-actin for osteogenic differentiation 
was increased in cells differentiated at passage two, but not four. Adipogenic 
differentiation demonstrated the opposite effect where passage four cells 
developed higher concentrations of lipid deposits within the cells and had 
increased expression of PPARγ2. As MSCs used in equine cell therapy are likely to 
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be treating joint or tendon injuries the use of early passage cells may be beneficial 
for treatment. However, the present study demonstrated that ADSCs and BMSCs 
retain osteogenic and chondrogenic differentiation when passaged up to six times.  
 
Cellular detachment of ADSCs and BMSCs during adipogenic and osteogenic 
differentiation was concerning. The protocols used for adipogenic and osteogenic 
differentiation were optimised for ovine stem cell differentiation and may account 
for cell loss during induction. Although cellular detachment occurred across all of 
the samples used for adipogenic differentiation there were limited reports of this 
phenomenon in the literature. Koerner et al. (2006) reported high cell detachment 
rates when pBSCs were exposed to adipogenic induction medium. The cells in the 
adipogenic assay in the present study were thoroughly assessed for bacterial 
contamination during culture and no bacterial growth was observed in any of the 
wells. Although cell loss during adipogenic differentiation has not been reported 
in the literature as a standard phenomenon, photographic evidence of 
differentiation in a number of papers clearly show distinct clusters of cells 
attached to the culture plate surface (Braun et al., 2010; Burk et al., 2013). This 
would suggest that cellular detachment is commonly seen with adipogenic 
differentiation with no detrimental effect on differentiation capacity. In the 
present project, one ADSC sample demonstrated particularly high rates of cell 
detachment. However, even with the loss of many cells, this sample differentiated 
well and scored highly for lipid development and percentage of differentiated 
cells. It appears that the number of cells that detach during differentiation is not 
an indication of the differentiation capacity of the individual cells in the sample. 
Due to the heterologous nature of the cell population used for differentiation, the 
loss of cells may be related to the portion of cells that do not possess 
multipotency.  
 
The type of matrix used during differentiation may influence the rate of cell 
detachment during adipogenic differentiation. In the post-mortem pilot trial two 
matrixes, Matrigel and Laminin, were compared for BMSC adipogenic 
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differentiation. Laminin appeared to be a superior matrix with less cellular 
detachment occurring than with Matrigel.  
 
Cell detachment also occurred during osteogenic differentiation in the present 
project. A human MSC osteogenic differentiation kit by R&D Systems states that 
cell detachment during differentiation can occur (R&D Systems, 2011). The 
osteogenic differentiation potential of equine MSCs and equine adult fibroblasts 
were compared by Colleoni et al. (2009). It was found that the fibroblast samples 
demonstrated extensive cell loss during differentiation and the few cells that 
remained attached did not stain positively for alkaline phosphatase or calcium. 
These findings suggest that the ADSCs and BMSCs seeded for osteogenic 
differentiation in the present study were a mixture of fibroblast and mesenchymal 
cells. As the population of cells used for differentiation are of heterologous nature 
this potentially explains the extensive cell loss seen during osteogenic and perhaps 
adipogenic differentiation of ADSCs and BMSCs.   
 
Stemness 
Stemness of MSCs isolated from AT, BM and pB was assessed through the 
expression of Oct4, Nanog and CD34.  The markers Oct4 and Nanog are key 
regulators in the formation and maintenance of pluripotent embryonic stem cells 
(Mohanty et al., 2014). Positive expression of Oct4 and Nanog and the negative 
expression of CD34 in equine MSCs has been reported by Raabe et al. (2011) (in 
ADSCs) and Violini et al. (2009) (in BMSCs). The expression of these pluripotent 
markers in multipotent MSCs is debated in the literature. Indeed, Guest et al. 
(2008) has reported that multipotent cells, such as MSCs, do not express Oct4 or 
Nanog, and that these two markers are only expressed in ESCs.  Irrespective of 
differing opinions, positive expression of Oct4 and Nanog has been found in 
equine ADSC, (Raabe et al., 2011) BMSC, (Violini et al., 2009) and UBC (Mohanty 
et al., 2014).  
 
Although Oct4 expression was tested in all undifferentiated and differentiated 
samples, no expression was detected. Nanog was expressed in one 
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undifferentiated ADSC sample however, the CT values for the sample was above 
35, indicating a low copy number for the mRNA. Interestingly, this ADSC sample 
demonstrated negative expression of Nanog once the cells underwent 
differentiation. The expression of Nanog in the ADSC samples prior to 
differentiation and subsequent loss of Nanog expression suggests that the 
‘stemness’ of the MSCs was lost once the cells committed to a specific lineage fate.  
The results of the present study indicate that Oct4 cannot be used as a reliable 
marker of stemness in equine MSCs. Similarly, Nanog was only weakly expressed 
in one sample and may not be suitable for routine confirmation of stemness in 
equine MSCs. These findings are supported by Guest et al. (2008) but conflict with 
Raabe et al. (2011) and Violini et al. (2009). 
 
There were two undifferentiated samples (ADSC PM13 and BMSC LH3) which 
expressed CD34. The CD34 gene is from a family of glycoproteins that can 
potentially influence cell adhesion, proliferation, migration, and differentiation. 
The expression of this gene has been seen on hematopoietic progenitor cells and 
is closely associated with this cell type (Cawthorn et al., 2012). No expression of 
CD34 has been reported in BMSCs but there are reports of ADSCs being positive 
for CD34, while maintaining trilineage differentiation capability (Dhar et al., 2012; 
Ranera et al., 2011). The expression of this marker is thought to decrease with 
time in culture although it is reportedly still present in ADSCs at passage three 
(Ranera et al., 2011). The ADSCs and BMSCs samples which expressed CD34 in this 
study had been passaged six times demonstrating that CD34 expression can 
continue for a number of passages. The ADSC and BMSCs samples which expressed 
for CD34 demonstrated trilineage differentiation, and the BMSCs from LH3 had 
the highest fold increase for chondrogenic and osteogenic differentiation markers. 
Therefore, the expression of CD34 does not appear to affect differentiation 
potential and may not be suitable as a negative marker of stemness for equine 
MSCs. As previously mentioned with the markers of differentiation and stemness, 
mRNA does not necessarily translate to protein level. As gene expression at 
protein levels were not tested, it cannot be determined whether there was a 
corresponding expression of CD34 in the post-translational protein level. 
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Antibacterial trial  
Primary tissue culture is particularly vulnerable to bacterial and fungal 
contamination. In this project, cell culture presented a significant challenge due to 
environmental contamination apparently connected with the 2013 drought. 
Seven AT samples became contaminated with various strains of bacteria from an 
unknown source. All potential sources of contaminations were considered and 
several steps were taken to rule out common sources of bacterial contamination. 
Alternative autoclaves were used, samples were transported to AgResearch Ltd 
for processing and sterile surgical gowns, including face masks and hairnets were 
used. These extra measures did not reduce the occurrence of bacterial 
contamination.  The samples were evaluated by Gribbles Veterinary Pathology and 
were found to consist of several different strains of bacteria. Due to this finding it 
was suggested that the primary source of contamination was from dust circulating 
in the environment when the tissue samples were collected. These 
contaminations coincided with the drought conditions during the summer of 2013, 
specifically during the months of January and March. It was decided to delay 
further collections until the drought conditions ended and the veterinarians and I 
then proceeded to collect AT from two horses.  
 
Prior to the re-commencement of live surgeries, two post-mortem AT samples 
were collected and processed to assess for contamination risk. These samples 
were collected after the drought had finished to determine whether the change in 
environmental conditions had an effect on contamination rate. Gribbles 
Veterinary Pathology ran a minimum inhibition concentration test of the various 
strains of bacteria found in the contaminated samples. It was found that the 
bacteria, namely Coryneform bacteria and Enterrococcus, were resistant to 
penicillin (P) but susceptible to vancomycin (V). This prompted an antibiotic trial 
to compare penicillin/streptomycin (P/S) with gentamycin/ vancomycin (G/V) 
containing medium on cell proliferation and viability in culture and to determine 
if G/V could be used for routine equine ADSC culture.  
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A combination of P/S is routinely used in cell culture as it prevents contamination 
from many strains of bacteria and has minimal effect on cellular viability (Parker 
et al., 2012). However, many forms of bacteria are resistant to penicillin and 
streptomycin resulting in bacterial growth if only P/S is used. The antibacterial 
combination of G/V is less commonly used than P/S in equine stem cell culture and 
is thought to be more detrimental to cell health, although low concentrations of 
gentamicin have been found to have minimal effect on cell viability (Parker et al., 
2012). Antibacterial action against a wide range of bacteria is provided by G/V, and 
this combination would be ideal in culture if there was no detrimental effect on 
cell proliferation or gene expression. It has been reported that if the 
concentrations of gentamicin are increased in culture, there is a corresponding 
decline in total RNA and expression of certain genes, although low concentrations 
are thought to be suitable for cell culture (Parker et al., 2012). Conversely, 
concentrations of penicillin as high as 500ug/ml do not result in any change to cell 
viability or RNA levels (Parker et al., 2012).  
 
The antibiotic trial in the present project compared the rate of growth and viability 
of cells grown in medium containing G/V at 40ug/ml to controls cultured in P/S at 
100U/100µg. There were no significant differences between growth rates and cell 
viability of any of the ADSC samples in the trial. There were no bacterial 
contaminations in any of the samples grown in either combination of antibiotics. 
However, as the antibiotic trial took place after the drought had ended, an 
improvement in environmental conditions appeared to have reduced the risk of 
bacterial contaminations.  
 
Bone marrow and pB appeared to be more sterile tissue types to harvest cells from 
compared to AT. There was a lower incidence of bacterial or fungal 
contaminations occurring on the BM and pB and the bacterial contamination that 
did occur was due to contaminated media.  
 
Post-mortem vs Live 
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An important point for discussion is the comparison of post-mortem (PM) and live 
samples for research purposes. All of the non-contaminated AT and BM samples 
collected PM yielded fibroblast-like cells which grew to confluence, and the 
samples selected for the differentiation trials demonstrated multipotency. Two of 
the PM pB samples yielded fibroblast-like cells, although these cannot be 
confirmed as MSCs as their trilineage capacity was not investigated. What can be 
inferred from the result obtained in the present study is that PM tissue, harvested 
soon after euthanasia, is a viable source for ADSCs, BMSCs and potentially pBSCs 
for research purposes.  
 
Live BM and post-mortem AT from the same horse has been used as a scientifically 
valid approach to compare multiple tissue types for MSC research (Burk et al., 
2013). To compare growth and differentiation characteristics of equine MSCs from 
different sources, Burk et al. (2013) collected tissue samples from umbilical cord 
blood and umbilical cord tissue of 12 foals and BM from 12 adult horses. Seven of 
the adult horses were euthanized to enable harvesting of post-mortem AT and 
tendon tissue. The post-mortem AT samples yielded the fastest growing MSCs 
with the highest yield of cells at confluence. Furthermore, all tissue types 
demonstrated multipotency (Burk et al., 2013). While compiling articles for the 
literature review, it was noticed that the vast majority of researchers used live 
tissue samples rather than harvesting from healthy horses being euthanized for 
reasons other than research. The present study showed that MSCs obtained from 
freshly euthanized animals displayed similar differentiation capacity to cells 
harvested from live animals. From an ethical point of view this is a valuable finding 
and should be considered for future equine stem cell research and indeed for 
many other species as well.  
 
4.2 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
The aim of the project was to compare the recovery and stemness of MSCs 
harvested from adipose tissue (AT), bone marrow (BM) and peripheral blood (pB). 
Tissue recovery practicality was considered and compared. The number and 
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viability of cells at isolation, and cell proliferation differences were evaluated and 
compared. Bone marrow derived stem cells and ADSCs were also evaluated for 
trilineage differentiation efficiency. Confirmation of stemness was investigated 
through gene expression using specific stem cell markers. 
 
Adipose tissue and bone marrow are two reliable sources of equine MSCs. 
Peripheral blood does not appear to be a reliable source and is not recommended 
for routine MSC isolation. In matched samples, AT appeared to be a superior 
source of MSCs than BM, particularly during primary culture. However, both tissue 
sources contained adherent cells capable of expansion in culture.  
 
Trilineage differentiation was achieved in ADSC and BMSC samples. Adipogenic 
differentiation efficiency was superior for ADSCs while BMSCs displayed higher 
efficiency for chondrogenic differentiation. Osteogenic differentiation efficiency 
appeared to be similar for both sources of cells. These findings imply that BMSCs 
are a more suitable candidate for treating lameness in horses due to their superior 
plasticity into relevant cell lineages. Whether these superior efficiencies translate 
into in vivo application requires investigation.  
 
Stemness of ADSCs, BMSCs and pBSCs could not be confirmed using pluripotent 
markers or the negative hematopoietic marker. Further research is required to 
establish which markers of stemness should be used for routine identification of 
stem cells. 
 
Although a single source of stem cells was not consistently superior throughout 
the project, when taking into account tissue collection practicality, differentiation 
efficiency and gene expression, BM appears to be a superior source of equine 
MSCs. This tissue source can be collected safely provided the veterinarian is 
experienced with sternal BM aspiration. Although BMSCs take longer initially to 
reach confluence than ADSCs, once in culture, confluence rate is comparable. The 
superior chondrogenic differentiation efficiency seen in BMSCs is of clinical 
relevance as joint injury is a leading cause of wastage in horses.  
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Currently, there is no available kit in New Zealand capable of processing BM 
aspirate for equine MSC isolation. The development of a BMSC kit for reinjection 
into equine patients would fulfil a vacant niche in the market. Although the 
findings of this project suggests that BMSCs are superior to ADSCs, the next step 
is to investigate how these two sources of cells assist in regenerative therapy using 
a controlled in vivo trial. Findings of an in vivo trial would be of particular value in 
recommending a specific tissue source for treating equine musculoskeletal 
injuries. 
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APPENDIX 1: MEDIA AND STAINS 
Media 
Media for ADSCs – (DMEM x 2, 10% FBS, 1% P/S, 0.1% fungizone) 
Ingredients Volume Source 
DMEM X 2 100ml Gibco (powder) 
HCO3 10.6ml AgResearch 
FBS 20ml Gibco 
P/S 2ml Sigma Aldrich 
Fungizone 200ul Sigma Aldrich 
Sterile MQ water To make total volume of 
200ml 
AgResearch 
Filter sterilised stock ingredients 
 
Media for BMSCs (DMEM F12, 10% FBS, 1% P/S, 0.1% fungizone) 
Filter sterilised stock ingredients 
F12: Gibco 
 
Media for pBSC (DMEM F12, 20% FBS, 1% P/S, 0.1% fungizone) 
Ingredients Volume 
DMEM X 2 50ml 
F12 X 2 50ml 
HCO3 10.6ml 
FBS 40ml 
P/S 2ml 
Fungizone 200ul 
Sterile MQ water To make total volume of 200ml 
Filter sterilised stock ingredients 
F12: Gibco 
 
PBS (% P/S, 0.1% fungizone) for adipose tissue processing 
Ingredients Volume Source 
PBS 100ml Thermofisher 
P/S 1ml Thermofisher 
Fungizone 100ul Thermofisher 
Autoclaved before adding fungizone 
 
Ingredients Volume 
DMEM X 2 50ml 
F12 X 2 50ml 
HCO3 10.6ml 
FBS 20ml 
P/S 2ml 
Fungizone 200ul 
Sterile MQ water To make total volume of 200ml 
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Media for tissue processing 
Media Quantity Source and contents 
DMEM x 2, F12, 10% FBS 200ml Thermofisher 
Vigro™ complete flush 
medium 
200ml Containing surfactant and 
antibiotic; Bioniche, Animal 
Health, USA -1000 ml 
Sterile stock 
 
Cryopreservation medium 
Ingredients Volume (20ml stock) Source 
75% DMEM  15ml Thermofisher 
20% FBS 4ml Life 
Technologies/Gibco 
5% DMSO 1ml Thermofisher 
Sterile stock 
 
Red blood cell lysis 
Ingredients Volume (10ml stock) Source 
NH4Cl (0.83% w/v in water) 9 ml Sigma Aldrich 
Tris (2.06% w/v in water) 1 ml Sigma Aldrich 
Filter sterilised 
 
Collagenase 
Ingredients Quantity/volume (10ml) Source 
Collagenase, Type 1A, 125 
CDU/mg solid 
0.02g Sigma Aldrich 
PBS 10ml Thermofisher 
Filter sterilised, used immediately. 
 
30% Sucrose solution 
Ingredients Quantity/volume 500ml Source 
Sucrose 150g Sigma Aldrich 
PBS 10x 50ml Thermofisher 
Sterile dH20 To 500ml Waikato University 
Filter sterilised and stored at 4°C 
 
Stains 
 
Trypan blue  
Ingredients Source 
Trypan blue solution 0.4% in PBS Thermofisher 100ml 
 
Alcian Blue – Provided by AgResearch, pH 1, 1% Alcian Blue in acetic acid. 
 
Alizarin Red – Provided by AgResearch, pH 4.1. (Sigma) 
 
BODIPY/DAPI stain 
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Ingredients Source 
10ul of 1mg/ml BODIPY Life Technologies 
10ul of 1mg/ml DAPI Life Technologies 
10ml 150mM NaCl  
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APPENDIX 2: INSTRUMENTS, MATERIALS, CHEMICALS, 
DRUGS 
Equipment/ materials Supplier Specifications 
Cell flasks Thermofisher Nunclon T75 
Cell flasks  Thermofisher Nunclon T50 
Cell strainer  Ray Lab 100um 
Cell strainer  Ray Lab 70um 
Centrifuge (AgResearch) 
50/15ml (no brake) Sorvall  H-2000B 
Centrifuge (AgResearch) 
50/15ml tubes (with brake) Eppendorf 5702 
Centrifuge (Equibreed) 15ml 
tubes MSE VWR 
Centrifuge (Equibreed) 50ml 
tubes Hettich Rotofix 32 
Centrifuge tubes  Interlab 50ml 
Centrifuge tubes  Interlab 15ml 
Collection containers Thermofisher 50ml 
Coverslips (rectangular) Sigma Aldrich 22x60 
Coverslips (round) Thermofisher Nunc 13mm 
Cryostat Leica CM1850UV-Cryostat 
Cryovial inserts Ray Lab Greiner 
Cryovials Ray Lab Greiner 2ml 
EDTA tubes SVS Vacutainer 10ml 
Fluorescent microscope Olympus BX50 U-ND25-2 
Fluorescent microscope Olympus  BX50 U-ND25-2  
Freezing medium 
Jung Tissue Freezing 
Medium  
Freezing spray 
Surgipath® Frostbite® 
Spray  
Inverted microscope Zeiss Axiovert 40 CFL 
Jamshidi™ needles Shoof 11g 
Microscope (EquiBreed NZ) Olympus CK2 ULWCD 0.30 
Needles 18G SVS 18G, 21G 
Parafilm Interlab 2 inch 
Pasteur pipettes Interlab 3ml 
Penrose drains Shoof 13mm, 46cm 
Pipette bulb Thermofisher  
Pipette tips  Interlab 10ul, 200ul, 1000ul 
Rocking platform Waikato university  
Shaking incubator 
(AgResearch) Ratek Orbital mixer incubator 
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Shaking incubator 
(Equibreed) Interlab 
S1-45 environmental 
shaker 
Slides Polysine  25x75x1mm 
Slides 
Surgipath Apex 
superior slides 25x75x1mm 
Stripette Interlab 5ml 
Stripette Interlab 10ml 
Stripette  Interlab 25ml 
Supramid Braun suture SVS 4met, 75m 
Syringe filter Interlab 0.22µm 
Syringe filter (AgResearch) Millipore 0.27µm Millex-GP 
Tissue tek cryomold FisherScientific 10x10x5mm 
Chemicals Supplier Specifications 
Ammonium chloride Thermo Fisher 500g 
Amphotericin B Thermo Fisher 20ml 250ul g/ml 
Antibiotics -P/S Thermo Fisher 50ml,  
CO2 BOC 
Carbon dioxide food 
fresh size G 
Collagenase Sigma Aldrich Type 1A 100g 
DMSO Thermo Fisher 100ml 
Lymphoprep Medica Ltd 1.077g/ml 
Mounting medium Dako   
Percoll 
Sigma Aldrich 
(AgResearch) 1.08g/ml 
Trypsin/EDTA Thermo Fisher 0.25% (1x) 100ml 
Drugs Supplier Specifications 
Depocillin SVS 100ml 
Dormosedan SVS 5ml 10mg/ml 
Phenylbute paste Caledonian Holdings 200mg/ml 
Torbugesic SVS 50ml 10mg/ml 
 
PCR equipment and enzymes 
Equipment/enzymes Supplier Specifications 
Ethidium bromide  10mg/ml 
100bp Ladder GenScript M102R 500ul 
Loading dye Solis BioDyne 6 x DNA Loading Dye 
Buffer 
Hot Start 
Thermostable DNA 
Polymerase 
Hot 
Firepol®(TAQ) 
Waikato University 
Nucleic acid stain Syto82 Orange 
Fluorescent  
Waikato University 
MgCl2 2M and 4M  
Electrophoresis unit Owl tank and 
power packs 
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Thermal cycler BioRad T100 
Real Time PCR 
machine 
Corbett Research Rotor-Gene 6000 
UV illuminator Gibco BRL UV-TFX-35M 
Spectrophotometer Nanodrop 2000  
PCR eppendorfs  200ul, 500ul 
Refrigerated 
centrifuge  
Eppendorf 5415R  
Vortex TALBOYS  
Thermo mixer Compact 
Eppendorf 
1.5ml tube tray 
 
1% Agarose gel 
Ingredients Quantity Source 
Agarose powder .33g  
1xTAE buffer 33ml Waikato University 
 
50x TAE stock 
Ingredients Quantity Source 
Tris 242g Sigma Aldrich 
glacial acetic acid 57.1ml Sigma Aldrich 
0.5M EDTA 100ml Sigma Aldrich 
dH20 To 1L Waikato University 
1 x TAE (20ml 50x TAE into 980 ml dH20) 
 
Myogenic staining reagents supplied by AgResearch Ltd 
Ingredients Quantity Source 
Triton  0.1% w/v in PBS Sigma Aldrich 
Tris buffered saline 1 x Sigma Aldrich 
Cג  Sigma Aldrich 
Mouse anti-MHC 1:200 Sigma Aldrich 
Normal sheep serum 5% Sigma Aldrich 
Biotinylated sheep anti- 
mouse 
1:300 Sigma Aldrich 
Streptavidin Alexa Fluor 
488 
1:400 Life Technologies 
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APPENDIX 3: DIFFERENTIATION MEDIA 
 
Adipogenic differentiation  
 
Induction medium 
Medium/reagents Concentration used (stock 
concentration) 
Source 
DMEM 10% NRS, 1% P/S, 
0.1% fungizone, buffer 
1ml per well NRS - Gibco 
IBMX 100x stock (500µM) Sigma Aldrich 
Dexamethasone 50x stock (50µM) Sigma Aldrich 
Indomethacin 200x stock (100µM) Sigma Aldrich 
Insulin – bovine 50 x stock (10mg/ml, 
25mM) 
Sigma Aldrich 
 
Maintenance medium 
Medium/reagents Concentration used (stock 
concentration) 
Source 
DMEM 10% NRS, 1% P/S, 
0.1% fungizone, buffer 
1ml per well  
Dexamethasone 50x stock (50µM) Sigma Aldrich 
Insulin – bovine  500x stock (10mg/ml) Sigma Aldrich 
 
Chondrogenic differentiation  
 
Incomplete medium (control medium) 
Medium/reagents Concentration used 
(stock concentration) 
Source 
DMEM, 1% FBS, 1% P/S, 
0.1% fungizone, buffer 
20µl/well for treated induction, 200ul/well for 
control pellets 
Ascorbic acid 2-phosphate 100x stock (100µM) Gibco 
Dexamethasone 500x stock (100µM) Sigma 
ITS+1 premix 1% BD Science 
 
Complete medium 
Medium/reagents Concentration used 
(stock concentration) 
Source 
DMEM, 1% FBS, 1% P/S, 0.1% 
fungizone, buffer 
20µl/well for treated induction, 200ul/well for 
control pellets 
Dexamethasone 500x stock (100µM) Sigma Aldrich 
ITS+1 1% BD Science 
TGF-β1 10ng/ml R & D Systems 
TGF-β1- R&D systems 
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Osteogenic differentiation 
 
Induction/maintenance medium 
Medium/reagents Concentration used 
(stock concentration) 
Source 
DMEM, 10% FBS, 1% P/S, 
0.1% fungizone 
1ml/well 
Ascorbate 2-phosphate 100x stock (100µM) Sigma Aldrich 
β-Glycerophosphate 100x stock (100µM) Sigma Aldrich 
Vitamin D 1000x stock Sigma Aldrich 
Dexamethasone 500x stock (100µM) Sigma Aldrich 
 
Myogenic differentiation 
 
Induction/maintenance medium 
Medium/reagents Concentration used 
(stock concentration) 
Source 
DMEM, 5% FBS, 2% horse 
serum (HS), 1% P/S, 0.1% 
fungizone 
1ml/well HS - Gibco 
Hydrocortisone 1000x stock (3.5µm per 
3.5ml medium) 
Sigma Aldrich 
 
